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Trauma deaths are a result of hemorrhage in 37% of civilians and 47% military
personnel and are the primary cause of death for individuals under 44 years of age.
Current techniques used to treat hemorrhage are inadequate for severe bleeding.
Preliminary research indicates that fibrin sealants (FS) alone or in combination with a
dressing may be more effective; however, it has not been economically feasible for
widespread use because of prohibitive costs related to procuring the proteins. To meet
future demands for hemostatic therapies, FS will likely include recombinant human
fibrinogen (rFI) and recombinant human Factor XIII (rFXIII).

The underlying

hypothesis of the research presented in this dissertation is that a liquid fibrin sealant
(LFS) composed of recombinant FI, FXIII and FIIa in optimized proportions can assist
hemostasis in the presence and absence of a bioresorbable bandage while using
considerably fewer biologics than commercial products currently available.

This

dissertation characterized rFI produced in the milk of transgenic cows, plasma-derived
thrombin (pdFIIa) activated by sodium citrate and rFXIIIa expressed in genetically
engineered Pichia pastoris with respect to their capacity to serve as components in a
LFS. The ratios of these factors were optimized to yield a LFS with a rapid clot
formation rate and high viscoelastic strength. This optimized LFS was preliminarily
tested ex vivo and in vivo.

The clotting kinetics and viscoelastic strength of our

optimized LFS was equivalent to those of a commercially available LFS; however, it
uses approximately 75% less fibrinogen and thrombin. Our optimal LFS successfully
achieved hemostasis in a significant number of the wounds that included extensive
tissue and vascular damage. LFS applied without the assistance of a dressing was able

to stop bleeding of oozing wounds or those with small vessels; however, a scaffold was
needed when wounds contained large vasculature.
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Chapter 1
Introduction

2
Hemostasis
Hemostasis is a delicate balance between pro- and anticoagulant forces which
require numerous proteins in the proper concentrations to activate, function and inactivate
correctly to stop bleeding after tissue injury and avert inappropriate clotting events.1,

2

Hemostasis has three phases: the primary and secondary phases occur quickly to stop
bleeding while the final stage breaks down the clot once the blood vessel is repaired.
Primary hemostasis is instigated by tissue injury which exposes collagen fibers from the
injured vascular endothelium to blood. When exposed to the collagen, platelets are
activated initiating the release of numerous signaling molecules and coagulation factors
which results in their adherence to each other and the vessel wall. Once activated,
negatively charged phospholipids are transported to the external membrane of platelets to
serve as a catalytic surface for binding of coagulation factors.1 During this initial phase,
the platelet plug minimizes blood loss1, 3 but only a miniscule amount of prothrombin (1
to 5 nM) is activated to thrombin (FIIa) by activated Factor X (FXa) attached to the
phospholipid membrane.4,

5

While the enzyme FXa can convert prothrombin, it has

insufficient catalytic efficiency to activate the necessary proteins to stop bleeding.6
Secondary hemostasis is initiated by the exposure of tissue factor (TF) to blood
resulting in a cascade of activation of numerous serine proteases and several
nonenzymatic cofactors (Figure 1.1).

3

Figure 1.1. Schematic of the cascade of protein activation reactions that occur to create a fibrin
clot. Red arrows indicate steps within the procoagulation pathway. Blue arrows are steps initiated
within the intrinsic pathway. Black arrows indicate inactivation of FVIIIa and FVa by APC (one of the
components of the anticoagulant pathway) resulting in the down-regulation of thrombin.

TF activates Factor VII (FVII) which activates Factor IX (FIX).

FIX can also be

activated without tissue injury by activated Factor XI (FXIa) through the intrinsic
coagulation pathway. In both pathways, activated Factor IX (FIXa) binds with activated
Factor VIII (FVIIIa), a nonenzymatic cofactor, and the negatively charged phospholipid
surface of platelets to form the tenase complex which activates Factor X (FX) to FXa.
FXa and thrombin proteolyze Factor V (FV) to activated Factor V (FVa), another
nonenzymatic cofactor that serves as a catalyst for FXa’s generation of thrombin.
Finally, thrombin cleaves fibrinogen into soluble fibrin fibers which polymerize into a
fibrin clot1,

3

which is subsequently cross-linked and made insoluble by thrombin

activated Factor XIII (FXIIIa).3, 7, 8 This fibrin clot is critical in the cessation of bleeding.

4
Fibrinogen
Fibrinogen (FI) is the penultimate protein in hemostasis. In addition to assisting
in the initial platelet aggregation following vascular injury,9, 10 during the last step of the
clotting cascade FI is activated to fibrin which aggregates and is crosslinked to form the
fibrin clot. In clot form, the fibrin stops bleeding and provides a scaffold for cellular
migration and proliferation required for tissue regeneration.11-14
FI, a 340,000 Da (450 Å) protein, is synthesized by hepatocytes and circulates in
plasma at 2-4 mg/ml (6-12 µM).5, 15 FI consists of two Aα (66 kDa), two Bβ (52 kDa)
and two γ-chains (46.5 kDa)16 held together by 29 disulfide bonds.5,

15

Each chain is

synthesized by hepatocytes and each undergoes posttranslational modifications: Aαchain phosphorylation17 (Ser3 and Ser345),18 Bβ- and γ-chain N-glycosylation19 and γ’chain tyrosine sulfation.20 Following modification, hexameric FI is assembled in the
endoplasmic reticulum (ER)21 creating a trinodal structure22 with a central “E” nodule,
containing the N-terminals of the six chains, and two “D” nodules linked by α-helical,
coiled-coil segments (Figure 1.2A).22
FI is activated into fibrin monomer by thrombin which binds to the E nodule and
cleaves the 16 residue N-terminal peptide of the Aα chain (fibrinopeptide A, FpA) at
Arg16-Gly17 and then the 14 residue N-terminal peptide of the Bβ chain (fibrinopeptide
B, FpB) at Arg14-Gly15 (Figure 1.2B). The release of FpA exposes the new N-terminal
sequence of the α-chain (“A” site) which is involved in noncovalent interactions with the
C-terminal γ-chain in the D nodule (“a” pocket, blue triangles in Figure 1.2) of an
adjacent FI molecule resulting in protofibril formation.5, 23 Subsequent release of FpB
yields a similar interaction between the newly formed N-terminal of the β-chain (“B”

5
site) with the D nodule β chain (“b” pocket, pink triangles in Figure 1.2) of another
molecule.5, 24 Activated fibrin molecules combine to make double-stranded protofibrils
(Figure 1.2C).

These

double-stranded protofibrils subsequently aggregate laterally

producing a soluble fibrin clot composed of thick fibers (Figure 1.3).25

A
fibrinogen

FIIa
FPA
FPB

B

C

fibrin monomer

fibrin protofibril

Figure 1.2. Schematic of the fibrinogen and fibrin molecules and protofibril formation.22, 25, 26
Fibrinogen consists of an E nodule (blue circles) and two D nodules (green and red ovals) connected by
coiled-coils. The αC-domains (orange ovals) extend out from the D nodule and curl around and bind to the
E nodule in fibrinogen (A). When activated by thrombin, fibrin monomer is formed when fibrinopeptide A
and B are released resulting in the freeing of the αC-domains (B). These activated fibrin monomers
aggregate into protofibrils (C).

6
fibrin protofibril

lateral fibril association

FXIIIa
γ-crosslinked fibrin clot

Figure 1.3. Schematic of aggregation and γ-γ crosslinking of fibrin.27-29 The αC-domains of the fibrin
protofibrils interact resulting in lateral association creating thicker fibrin polymers. FXIIIa creates a stiffer
clot by γ-γ crosslinking (represented by gray bars). Longitudinal (end-to-end) crosslinking occurs between
“D:D” sites located at the outside of the D nodule.27, 28 Transverse crosslinking occurs between γXL sites
located on γA and γ’ chains protruding out from the D nodule. 27, 28 γ chains can also be linked laterally.30

7
Factor XIII (FXIII) and its activated form (FXIIIa) crosslinks FI31 and fibrin
protofibrils by a calcium-dependent reaction32,

33

transforming the soluble clot to a

stiffer26, 34 insoluble clot35 with resistance to fibrinolysis.34 Once activated, FXIIIa binds
to residues 241 to 476 in the αC-domain of fibrin36 which brings fibrin protofibrils into
close proximity.

Aggregation of fibrin monomers aligns the proteins easing the

crosslinking process.37, 38 Crosslinks are constructed by FXIII’s catalytic triad (Cys314,
His373 and Asp396)39 which creates an intermolecular γ-glutamyl-ε-lysine bridge
between the side-chains of two aligned fibrin molecules (Figure 1.4).40-45

Fibrin B
Lys

Fibrin B
Lys

βCH2

βCH2
FXIIIa
SH
+
O

C NH2
γCH2

γCH2

γCH2

FXIIIa

δCH2

δCH2
S

Ca2+
O
NH3

C

εCH2
+

NH2

NH3

γCH2

βCH2

βCH2

Gln
Fibrin A

Gln
Fibrin A

εCH2

Ca2+

NH2
O

FXIIIa
SH

C
γCH2
βCH2

Gln
Fibrin A

Figure 1.4. Biochemistry of ε-(γ-glutamyl)lysine crosslinking of fibrin molecules by FXIIIa.32, 42, 45, 46
FXIIIa, a transglutaminase, forms a thioester bond to a specific glutamine residue of the bound molecule,
releasing ammonia.47 This thioester reacts with the primary amine of a lysine residue of another molecule
near the catalytic site creating an amide bond.43, 48

FXIIIa crosslinks antiparallel49 fibrin α- and γ-chains with the γ-γ formation proceeding
at a much faster rate than the α-α crosslinking.46, 50, 51 Gln398 or 399 on one fibrin γchain crosslinks to Lys406 on an adjacent fibrin γ-chain within 10 minutes.52,
addition to contributing to viscoelastic strength,54,

55

53

In

γ-γ crosslinking holds the fibrin

aggregates in the proper orientation allowing α-α crosslinking to occur.8

α-chain

8
crosslinking can take up to 24 hours to form56 but is important in resisting
plasminolysis57-60 because it yields high viscoelastic strength46, 50 and insolubility.50 αand γ-chains can also be crosslinked; however, this does not greatly affect clot strength.55

Hemorrhage treatment
Hemorrhage occurs when primary and secondary hemostasis fails to stop blood
loss. Trauma deaths are a result of hemorrhage in 37% of civilians61 and 47% military62
and is the primary cause of death for individuals under 44 years of age.63 For the past
2000 years, the same techniques have been used to stop hemorrhage: packing with
gauze, direct pressure and tourniquet.64 This method is inadequate for treating severe
hemorrhage. The Department of Defense Combat Casualty Care Research Program is
focused on developing more effective options for treating hemorrhage.65
Several hemostatic products are currently used or under development.
Cyanoacrylates are utilized as hemostatic aides in oral surgery but can cause
inflammation and necrosis.66 Gelatin-resorcinol-formaldehyde (GRF) glue is frequently
used as a sealant and yields excellent tensile strength but has less clotting ability,
inferior clots to other sealants and results in fibroblast infiltration.67 QuikClot speeds
clot formation by creating an exothermic reaction when absorbing water; however, it is
not biodegradable requiring its removal post-treatment.68,

69

Compared to other

treatment options, fibrin sealants (FS), also known as fibrin glues, are viewed as the
best sealant70 because they are biocompatible,66, 71, 72 biodegradable66 and safe71 and are
not linked to excessive inflammation, immune responses or necrosis.66, 72
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Fibrin sealants
Fibrin sealants (FS) which are composed of fibrinogen (FI), thrombin (FIIa),
calcium chloride and occasionally Factor XIII (FXIII) are designed to mimic the final
stage of the coagulation cascade by forming a fibrin clot. When applied to a wound,
these exogenous components can assist the same endogenous proteins in achieving
hemostasis. Because they mimic natural clotting mechanisms, FS are biocompatible,66,
71, 72

biodegradable66 and safe71 and are not linked to excessive inflammation, immune

responses or necrosis66,

72

and provide similar functions as endogenous plasma

components.73
FS is used as a hemostatic agent,74 matrix for wound healing,72, 74 adherence for
tissues74 and drug delivery74 in a variety of procedures. With respect to hemostasis, FS
can be used alone or in combination with a dressing to stop blood oozing from holes,
incisions and raw surfaces which cannot be stopped by suturing.67 The use of FS has
been shown to reduce blood loss,74, 75 fluid loss,74 transfusion occurrence,76 operative
time,75 mortality,75 hospital stay77 and treatment costs.74
Despite its usefulness, FS have drawbacks. Current FS are relatively expensive
making it economically infeasible for use as a dressing coating or for widespread uses
in the field. In addition, commercial sealants contain plasma-derived proteins which are
purified from limited blood sources and have associated risks of pathogen
contamination77 that can withstand current treatments.66,
proteins which can initiate immune responses.74,
abundant source of materials for FS is needed.

77

74

Some FS use bovine

Consequently, a safer, more

10
Recombinant alternatives for fibrin sealants
A hallmark of hypocoagulopathic states (disseminated intravascular coagulation
(DIC),78-81 liver disease,81,

82

surgery,79,

83, 84

haemodilution due to fluid resuscitation,79,

acute haemorrhagic injury79,

81, 83, 86

85

and

) is depletion of FI which plays a

primary role in the formation of blood clots. Consequently, FI may be helpful as topical
and systemic therapies for treatment of severe haemorrhagic injury.81, 87 Because of its
utility, fibrin(ogen) is the key and prominent protein in fibrin sealants (FS) which are
used for hemostasis in various surgical procedures and treatments for wound healing.
Both topical88,

89

and systemic administrations of FI may require gram dosings as

normal plasma concentrations range from 2 to 5 grams per liter.5, 32, 46, 71, 83 As a result,
the therapeutic use of fibrin(ogen) will continue to increase, requiring a source to
provide an abundant amount of medical-grade material.
Current products contain plasma-derived fibrinogen (pdFI) which is purified
from limited blood sources and has associated risks of pathogen contamination. These
risks and limitations could be minimized by producing a recombinant version of human
fibrinogen (rFI).

Recombinant versions of the α-, β- and γ-chains have been

individually expressed in Escherichia coli;90-92 however, they were not biologically
functional.20

Active recombinant human fibrinogen has been expressed by baby

hamster kidney (BHK),20 monkey kidney COS-1 cells93 and Chinese hamster ovary
(CHO) cells which closely mimics its plasma-derived counterpart.94 Unfortunately,
these systems produce less than 4 µg/ml and are therefore unable to meet therapeutic
demands.95
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Another option for producing an ample amount of rFI is production in transgenic
animals. Functional human fibrinogen has been expressed and assembled in the milk of
transgenic mice at expression levels up to 2 mg/ml.95 This proved the feasibility of
producing ample amounts of fibrinogen in transgenic animals.

The work in this

dissertation uses a rFI expressed in the milk of transgenic cows. Cows were chosen
because they can produce amounts necessary to meet therapeutic demands.

Each

transgenic cow can produce 25 liters of milk per day for 300 days per year allowing the
production of significant amounts of protein per transgenic animal.
Fibrinogen is a complex protein requiring multiple post-translational
modifications; therefore, to produce a functional protein, it must be produced by
mammalian cells. Unlike fibrinogen, an active A-chain of FXIII can be produced in
abundance by yeast.96-98

Hemophilia A
Hemophilia A is an X-linked, inherited disorder of blood coagulation primarily
caused by deficiency or dysfunction of factor VIII (FVIII) that affects approximately one
in every 5,000-10,000 males.99-101 Currently, hemophilic patients are treated with
intravenous infusion of highly purified FVIII concentrates derived from donor human
plasma or a variety of recombinantly-derived FVIII (rFVIII) produced by animal cells in
large scale bioreactors.102-104 Despite the clear benefits of prophylactic therapy in this
population, 80% of the world hemophilia population does not receive adequate access to
replacement therapy. Many factors contribute to this, but a lack of abundance and
associated costs of current production of plasma-derived FVIII and rFVIII concentrates
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preclude the application of universal prophylactic treatment of hemophilia A in even the
most economically developed countries and routine access in developing countries.99, 102,
103

Thus, another system must be developed that can economically produce an abundant

quantity of therapeutic-grade FVIII. FVIII is complex and requires numerous posttranslational modifications necessitating the production by mammalian cells. While cell
culture has thus far not been economically viable for unlimited production, expressing
therapeutic proteins in the milk of transgenic animals has yielded ample amounts more
economically.105

Dissertation objectives
The underlying hypothesis of the research presented in this dissertation is that a
LFS composed of recombinant FI, FXIII and FIIa in optimized proportions can assist
hemostasis in the presence and absence of a bioresorbable bandage while using
considerably less biologics than commercial products currently available. To test this
hypothesis, each of the components of the LFS need to be evaluated. This dissertation
has multiple specific aims:
1. Identify the mechanism of activation of pdFII by sodium citrate: Recombinant
thrombin was not available for initial LFS experiments; therefore, plasma-derived
thrombin (pdFIIa) was used. pdFIIa for these experiments was activated from
plasma-derived prothrombin (pdFII) by 35% sodium citrate.

The research

presented in this chapter was designed to identify the intermediates produced
when activating plasma-derived prothrombin (pdFII) with 35% sodium citrate.

13
The time course of intermediate formations was evaluated and a mechanism of
activation suggested.
2. Characterize rFXIII:

Recombinant Factor XIII (rFXIII) produced in Pichia

pastoris was evaluated with respect to the hypothesis that recombinant FXIII Achain expressed in Pichia pastoris has the same structure, function and activity as
its plasma-derived counterpart. It was evaluated as a future component of an
LFS.
3. Optimize LFS components: Research was designed to test the hypotheses that (1)
the addition of rFXIIIa will increase clot strength thereby reducing the amount of
FI need in FS; and (2) our LFS containing optimized ratios of rFI, rFXIIIa and
FIIa will yield equivalent clot kinetics and strengths as plasma-derived LFS.
4. Test optimal LFS ex vivo: Interactions of normal human blood, platelet rich
plasma and platelet poor plasma with each LFS component alone or in
combination with others were evaluated to anticipate in vivo success.
5. Evaluate efficacy of LFS in multiple surgical models: FS function is based on
complicated interactions between other pro- and anticoagulant proteins, blood
cells and vessel surface under flow and viscosity conditions;67 therefore, the
optimized LFS was tested in vivo in liver and femoral artery models.
6. Characterize partially B-domain deleted rFVIII:

rFVIII (226/N6-tg) was

produced in the milk of transgenic mice with both von Willebrand Factor (vWF)
and α1-antitrypsin (A1AT). The milk was evaluated for the presence of all three
recombinant proteins and was tested by several techniques to determine whether
the mammary gland could produce a functional FVIII molecule in abundance.
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Chapter 2
Sequence of Activation of Prothrombin by Sodium Citrate
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Abstract
Thrombin is the key serine protease in hemostasis because it is responsible for
activating both procoagulant proteins critical for creating fibrin clots and anticoagulant
proteins needed to return the system to balance. Prothrombin is converted to thrombin in
primary hemostasis by activated Factor X (FXa) attached to the phospholipid membrane
and secondary hemostasis by the prothrombinase complex which consists of FXa,
activated Factor V (FVa), calcium ions complexed on the phospholipid surface of
activated platelets.

In the laboratory, prothrombin can be activated to thrombin in

solutions containing high sodium citrate concentrations; however, the mechanism is not
well understood. The work presented in this chapter focuses on identifying intermediates
and fragments derived from prothrombin activation by sodium citrate using SDS-PAGE
and N-terminal sequencing analyses. The activity of the citrate activated thrombin was
analyzed by chromogenic assay and functionality evaluated by ability to cleave FXIIIa
and activate fibrinogen. This research found that prothrombin could be activated in the
absence of added activators. This activation was not due to autocatalytic degradation but
is due to contaminating FX which alone or activated to FXa proteolyzed prothrombin.
Incubating prothrombin in 25% or 35% sodium citrate also resulted in activation of
prothrombin. Activation by citrate may be autocatalytic or a result of FX; however, FXa
and thrombin did not play a role in citrate activation. Analysis of activation fragments
indicates that the sequence of activation does not follow the primary or secondary
hemostasis pathways; rather, it follows an alternative pathway with a prethrombin-1
intermediate that is subsequently proteolyzed into prethrombin-2, prethrombin-2a,
thrombin, α-thrombin and β-thrombin. The activity of citrate activated thrombin was 368
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± 173 U/mg (mean ± standard deviation) which is significantly lower than previous
reports probably due to the presence of less active thrombin forms. Thrombin formed by
35% sodium citrate appeared to release all of fibrinopeptide B but only a portion of
fibrinopeptide A; however, it was able to cleave FXIIIa in the same manner as
recombinant thrombin.

When evaluated by thromboelastography, citrate activated

thrombin created a fibrin clot at equivalent kinetics as the highly purified recombinant
thrombin.

Although activation of prothrombin by sodium citrate is different than

physiological mechanisms, the thrombin produced is functional.
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Introduction
Thrombin (FIIa) is the key serine protease in hemostasis because it is responsible
for activating both procoagulant proteins critical for creating fibrin clots and
anticoagulant proteins needed to return the system to balance.1

With regard to

procoagulation, FIIa activates many of the proteins in the clotting cascade including
fibrinogen (FI), factor V (FV), factor VIII (FVIII), factor XI (FXI), factor XIII (FXIII),
and can convert additional prothrombin to FIIa.1,

2

FIIa also activates platelets and

vascular endothelial cells3 and is integral in initiating cellular responses including
production and secretion of cytokines, growth factors and cellular adhesion molecules.1, 2
With regard to its anticoagulant function, FIIa activates anti-fibrinolytic components such
as protein C and FIIa-activated fibrinolysis inhibitor (TAFI).4
Thrombin’s precursor, prepro-prothrombin (Figure 2.1), is synthesized in
hepatocytes where it undergoes posttranslational modifications.

After entering the

endoplasmic reticulum (ER), the signal peptide is removed and 10 glutamate residues
adjacent to the propeptide are converted to γ-carboxyglutamate (Gla) residues.5-7 This
Gla domain interacts with calcium ions and is critical for creating the conformation
required to bind to negatively-charged phospholipid surfaces of injured vascular tissue
and activated platelets1 which concentrates this key enzyme at the injury site. Following
alteration of the Gla residues, the propeptide is removed followed by the attachment of
three N-linked oligosaccharide chains, two in the first kringle domain and the last in the
B-domain. Thrombin’s zymogen, prothrombin (70 kDa), is then secreted into blood at a
concentration of 1.2 μM.1
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Prothrombin is converted to FIIa during primary and secondary hemostasis by
slightly different mechanisms (Figure 2.2). During primary hemostasis (the formation of
a platelet plug) a miniscule amount of prothrombin (1 to 5 nM) is activated by activated
Factor X (FXa) attached to the phospholipid membrane (Figure 2.2, left side).8 FXa
activates prothrombin by cleaving Arg273-Thr274 creating the intermediate prethrombin2 consisting of combined A- and B-chains and releasing fragment 1.2.9 This intermediate
is subsequently converted to FIIa by cleavage at Arg322-Ile323 to separate the A- and Bchains9 which remain attached by a disulfide bridge.10 While the enzyme FXa can
convert prothrombin, it has insufficient catalytic efficiency to activate the necessary
proteins to stop bleeding.11

Formation by FXa alone is significantly slower than

conversion during secondary hemostasis.8,

9, 12

During secondary hemostasis, exposed

tissue factor (TF) initiates a cascade of activation of numerous serine proteases and
several nonenzymatic cofactors. Once the coagulation cascade is activated, prothrombin
is converted to FIIa by the prothrombinase complex which consists of FXa, activated
Factor V (FVa), and calcium ions complexed on the phospholipid surface of activated
platelets.9,

13, 14

This complex converts prothrombin to meizothrombin by cleaving

Arg322-Ile3239, 15 resulting in the B-chain held to the rest of the molecule by a disulfide
bridge (Figure 2.2, right side). Subsequent cleavage at Arg273-Thr274 results in FIIa and
the release of fragment 1.2.9, 12 During this second, critical phase, the prothrombinase
complex activates prothrombin to FIIa five-fold faster than FXa alone15 propagating the
formation of FIIa (700 to 900 nM)10 by FXa and its cofactor FVa in close proximity.16
FXa17 or FIIa9 can then cleave Arg155-Ser156 to separate the kringle domains into
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Fragments 1 and 2 from fragment 1.2. FIIa can also cleave Arg286-Thr287 creating
prothrombin-2a from prethrombin-2 and α-thrombin from meizothrombin or FIIa.9

Figure 2.1. Schematic of the amino acid sequence of prepro-prothrombin. Preproprothrombin contains a signal peptide, propeptide, Gla domain, two Kringle domains and a light
(A-chain) and heavy (B-chain) chain.1 The N-terminal sequence of prothrombin is indicated by
an orange arrow. Gla residues are in the sequence as γ and the three ◊ indicated N-linked
carbohydrates. FXa cuts that occur during activation are marked with red arrows and blue
arrows indicate sites cleaved by FIIa. The serine protease catalytic triad (His, Asp and Ser) are
circled in red. This figure minus a few additions is adapted from Davie and Kulman.1
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Prothrombin (72 kDa)

Primary
Hemostasis

Secondary Hemostasis

Prothrombinase Complex:
FVa, FXa, PL, Ca2+

Fragment 1.2 (30 kDa)
FXa

Meizothrombin (72 kDa)

Fragment 1.2 (30 kDa)
Prethrombin-2 (42 kDa)

FXa

Thrombin (42 kDa)

FIIa

α-thrombin (40 kDa)

Figure 2.2. Activation of prothrombin. Prothrombin is activated by two mechanisms in vivo during
primary and secondary hemostasis. This figure modifies the prothrombin schematic published by Davie
and Kulman.1 Note: Prethrombin-2a is equivalent to prethrombin-2 minus the 13 amino acid N-terminal of
the A-chain.
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The serine protease, FIIa, consists of the 49 residue A-chain linked to the 259
residue B-chain by a disulfide bond (Figure 2.2). α-thrombin is formed when FIIa is
cleaved after Arg284 releasing a 13 residue peptide (Figure 2.3). Both FIIa and αthrombin (α-FIIa) are active serine proteases; however, which species acts at the injury
site in vivo is unknown.1 FIIa is homologous to and has the same catalytic triad as other
serine proteases. The catalytic triad consists of His43, Asp99 and Ser205 which is
located in a cleft within the B-domain18,

19

and brought into close proximity by salt

bridges following activation.19 The active site is surrounded by three surface loops19-21
and two charged surface areas (exosites)11 that create specificity for certain substrates.
FIIa is removed quickly from the blood stream in vivo; however, in vitro, FIIa can
be degraded into less active products: β- and γ-thrombin (Figure 2.3).1 These degraded
species result from proteolysis of the B-chain by plasmin, trypsin,22 FXa23 or FIIa itself.22
β-thrombin is formed when FIIa cleaves the B-chain after Arg380 and Arg391
(prothrombin numbering, Arg62 and Arg73 in FIIa numbering) releasing a small 11
residue peptide important for recognizing fibrinogen thereby creating the B1 and B2
fragments.22 γ-thrombin is subsequently formed with the cleavage after Arg442 and
Lys472 (prothrombin numbering, Arg123 and Arg154 in FIIa numbering) resulting in the
creation of the B3 and B4 fragments.1,

22

The B-chain in β- and γ-thrombin are held

together by noncovalent interactions22 and because they still contain the catalytic triad
they retain some activity.23
In the laboratory, prothrombin is frequently activated to FIIa by venom. Ecarin,
the venom from Indian saw-scale vipers (Echis carinatus), activates prothrombin to FIIa
with the meizothrombin intermediate.24, 25 Other venoms, like that from the Taipan snake
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(Oxyuranus scutellatus), activates prothrombin with both meizothrombin and
prethrombin-1 intermediates.26 Prothrombin can also be activated to FIIa in solutions
containing high sodium citrate concentrations;27-31 however, the mechanism is not well
understood.32

Prothrombin was initially thought to auto-activate under high citrate

conditions;29, 30 however, other researchers assert that impurities, such as FX, play key
roles in the activation.28,

32

While low concentrations of sodium citrate yield minimal

activation of prothrombin, concentrations of 25% (weight/volume) is much more
effective.30
Like Lanchantin, Friedmann and Hart (1965),28 this work focuses on identifying
species derived from prothrombin activation and evaluating the functionality of the
resulting FIIa with respect to fibrinogen and Factor XIII (FXIII) activation and fibrin clot
formation. To our knowledge, this work is the first detailed analysis of the time course of
activation of prothrombin by sodium citrate and first attempt at identifying the
intermediates and fragments created during the process. This information was used to
suggest a sequence of activation.
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α-thrombin

B1 (9 kDa)

β-thrombin

B2 (21 kDa)

B1 (9 kDa)

γ-thrombin
B3 (6 kDa)
B4 (12 kDa)
Figure 2.3. Autolytic inactivation of thrombin. α-thrombin can be autolytically
degraded to β- and γ-thrombin.22 This figure modifies the prothrombin schematic
published by Davie and Kulman.1

Materials and Methods
Materials
Purified, plasma-derived prothrombin was bought from Enzyme Research
Laboratories (South Bend, IN) with a specific activity of 11.11 U/mg. Recombinant
thrombin (Recothrom®) (rFIIa) was purchased from Zymogenetics. Purified recombinant
fibrinogen, expressed in the milk of transgenic cows, was obtained from Pharming Group
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NV (Leiden, Netherlands). Phe-Pro-Arg-chloromethylketone (PPACK) and Glu-GlyArg-chloromethylketone (GGACK), specific and irreversible inhibitors of FIIa33, 34 and
FXa,33, 35 respectively, were purchased from Haematologic Technologies (Essex Junction,
VT). Materials for the thromboelastograph were purchased from Haemoscope (Niles,
IL). Ecarin, sodium citrate and all other reagents were purchased from Sigma (St. Louis,
MO) unless otherwise specified.
Vector construction, expression and purification of FXIIIA in Pichia pastoris
The human Ultimate ORF clone containing the human coagulation factor
FXIIIA1 cDNA in the pENTRTM221 vector was purchased from Invitrogen (Carlsbad
CA). The following primers were used to obtain FXIIIa gene to subclone in pPICZA
intracellular

Pichia

expression

vector.

(Forward,

5'-

CCAATTGATGCATCATCATCATCATCATTCAGAAACTTCCAGGACCGC-3';
Reverse, 5'-GCGGCCGCTCACATGGAAGGTCGTCTTTGAATC-3').

The forward

primer introduced a methionine and 6 histidine amino acids at the N-terminus of mature
FXIIIa peptide. The PCR product was digested with MfeI and NotI and subcloned into
pPICZA which was digested with the same enzymes. The DNA sequence of the FXIIIA
was confirmed by sequencing the insert fragment. One of the confirming plasmid
pPICZAFXIIIa was linearized with PmeI and transformed into P. pastoris X-33 host
strain and copy number of the clones was determined as described.36 Varying copy
number clones were screened in shake flask culture to confirm intracellular production of
FXIIIa protein. The highest producing clone was scaled up to 5 L bench scale. A fedbatch fermentation protocol was followed to optimize FXIIIa production as described by
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Zhang et al., (2007).37 At the end of fermentation process the cells were separated by
centrifugation (6,000g) and pellet was stored at -80oC.
Frozen cell paste was processed in 300 gram batches. Cells were lysed in three
sets of 100 gram batches. 100 grams of cell paste was resuspended in 100 ml of cold
lysis buffer (50 mM Tris-HCL, 10 mM MgSO4, 1 mM EDTA, 10 mM potassium acetate,
1 mM DTT (DL-Dithiothreitol), 2 mM PMSF (phenylmethanesulphonylfluoride) in
methanol, pH 9.5). 100 ml (250 g) of 0.5 mm glass beads (Biospec, Bartlesville, OK)
were added to the cells. Surrounded by an ice bath, cells were lysed using a BeadBeater
Blender (Biospec, Bartlesville, OK) with twenty 20 second on/off cycles. The cell lysate
mixture was then centrifuged to remove cellular debris. The lysate from 300 grams of
cell paste was combined and purified using the HisBind Purification Kit (EMD
Chemicals, Inc., San Diego, CA) with 40 ml of resin slurry. Following purification,
rFXIII was dialyzed in 10 mM Tris-HCl, 0.1 mM EDTA, 60 µM polysorbate-20, pH 8.0
in snake-like dialysis membranes and the protein samples were filter-sterilized and
concentrated using the Amicon tubes (Millipore, Billerica, MA). The purity of the
sample was tested by SDS-PAGE (NuPAGE 12% Bis-Tris) (Invitrogen, Carlsbad, CA)
and immunoblot. The concentration of rFXIII was determined by standard Bicinconic
Acid (BCA) methods.
Prothrombin activation by ecarin, rFIIa, FXa and sodium citrate
Plasma-derived human prothrombin (Enzyme Research Laboratories, South Bend,
IN) was treated with PPACK (final concentration: 60 µM) and GGACK (final
concentration: 60 µM) (Haemotologic Technologies, Essex Junction, VT) to eliminate
FIIa and FXa activity, respectively. Following a 24 hour incubation period at 37oC on a
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rotating mixer, the PPACK and GGACK was removed by ultracentrifugation with
Amicon tubes with a 10,000 Da molecular weight cut-off membrane (Millipore, Billerica,
MA). Prothrombin was subsequently activated by several methods: rFIIa, FXa, ecarin
and sodium citrate in the presence and absence of 60 µM GGACK.
Prothrombin (final concentration: 1 mg/ml) was incubated at 37oC with 0.2%
rFIIa (0.002 mg/ml, 4.65 U/ml) (Zymogenetics, Seattle, WA) or 2% FXa (0.02 mg/ml)
(Enzyme Research Laboratories, South Bend, IN), 20 U/ml of ecarin (Echis carinatus)
(Sigma, St. Louis, MO), or 25% or 35% (weight/volume) sodium citrate (0.25 or 0.35
grams of sodium citrate per milliliter of solution). Ecarin samples were incubated for 0,
5, 15, 30, 60, 120, 180, 240, 360 and 480 minutes. Sodium citrate treated samples were
incubated for 0, 6, 12, 18, 24, 36 and 48 hours while samples activated by FIIa and/or
FXa were incubated for 0, 24, 48 and 72 hours.

Control samples were also run:

prothrombin in the presence and absence of PPACK and GGACK were incubated for 0,
24, 48 and 72 hours under the same conditions as the activated samples. At the proper
time periods, 10 µl of unactivated samples and those activated by ecarin, rFIIa and FXa
were removed and the reaction stopped by adding it to 8.75 µl NuPage® LDS sample
buffer (Invitrogen, Carlsbad, CA) and storing it at -20oC. Sodium citrate samples were
removed and stored at -80oC. Sodium citrate was removed with PD-10 desalting columns
(GE Healthcare, Giles, United Kingdom).
For identifying the role FIIa plays during citrate activation and to determine the
efficacy of the FXa inhibitor under harsh conditions created by 35% sodium citrate,
prothrombin (final concentration: 1 mg/ml) was incubated at 37oC with 35% sodium
citrate (0.35 grams of sodium citrate per milliliter of solution) alone or with 0.2% rFIIa
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(0.0002 mg/ml) or 0.2% FXa (0.0002 mg/ml) (Enzyme Research Laboratories, South
Bend, IN) in the presence of 60 µM GGACK. Samples were incubated for 6, 24 and 72
hours horizontally on a shaker maintained at 37oC.

Sodium citrate samples were

removed and stored at -80oC. Sodium citrate was removed with PD-10 desalting columns
(GE Healthcare, Giles, United Kingdom).
Activation of prothrombin was evaluated by SDS-PAGE on 12% NuPage® BisTris gels (Invitrogen, Carlsbad, CA) under nonreducing conditions with 2-(Nmorpholino)ethanesulfonic acid (MES) running buffer and NuPage® LDS sample buffer
which were purchased from Invitrogen (Carlsbad, CA). Samples were incubated at 74 oC
for 10 minutes before loading on the gels which were run at 200 volts for one hour. Gels
were stained with Colloidal Blue (Invitrogen).
N-terminal sequencing of activated samples
Fragments produced by rFIIa, FXa, ecarin and 35% sodium citrate activation of
prothrombin (see above) were evaluated by N-terminal sequencing.

Bands were

separated by sodium dodecylsulfate-polyacrylamide (SDS-PAGE) gel electrophoresis on
4-12% NuPage® Bis-Tris gels with 2-(N-morpholino)ethanesulfonic acid (MES) running
buffer, NuPage® LDS sample buffer (Invitrogen, Carlsbad, CA).

Samples were

incubated at 74oC for 10 minutes before loading on the gels and then electroblotted onto
polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA) by applying 30
volts for one hour. The blot was stained with Colloidal Blue (Invitrogen, Carlsbad, CA).
Each band was excised and the first ten amino acids in the N-terminal were sequenced by
Edman degradation with an Applied Biosystems 494 Procise automated sequencer. N-
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terminal N-terminal sequencing was performed by the University of Nebraska Medical
Center’s Protein Structure Core Facility.
Thrombin activity by chromogenic assay
The specific activity of the FIIa produced by FXa and 35% sodium citrate
activation was determined by a chromogenic assay. 50 µl of standard and samples were
added in triplicate to wells of a 96-well plate. Recothrom® was used to create an eightinterval standard curve ranging from 1.8 mU to 293.6 mU. Based on BCA concentration
results, rFIIa was diluted so that wells would contain 1, 20 and 80 ng. The plate was
incubated at 37oC for two minutes. 50 µl Tris-buffered saline (TBS) were added to each
well followed by three minute incubation at 37oC.

50 µl Chromogenix S-2238

(DiaPharma Group, West Chester, OH) were added to each well followed by two minute
incubation at 37oC.

50 µl 20% acetic acid was added to stop the reaction.

The

absorbance was then read on a Beckman Coulter AD340 Microplate Reader (Brea, CA)
at 405 and 495 nm wavelengths. Data was imported into Microsoft Excel and the 495 nm
absorbance was subtracted from that at 405 nm. The standard curve was established and
the sample activity calculated.
Thrombin activity by SDS-PAGE
The ability of the activated prothrombin samples were evaluated by monitoring
the activation of fibrinogen to fibrin and FXIII to FXIIIa by SDS-PAGE. rFI or rFXIII
(final concentrations: 0.4 mg/ml) were incubated with FIIa (0.10 mg/ml) in Ringers
solution (155 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2) for 60 minutes at 37oC.
The activation reactions were halted by the addition of NuPage® LDS sample buffer and
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NuPage® Sample Reducing buffer (β-mercaptoethanol) (Invitrogen, Carlsbad, CA).
Samples were evaluated by sodium dodecylsulfate-polyacrylamide (SDS-PAGE) gel
electrophoresis on 4-12% NuPage® Bis-Tris gels with 2-(N-morpholino)ethanesulfonic
acid (MES) running buffer. Samples were incubated at 74oC for 10 minutes before
loading on the gels which were run at 200 volts for one hour and were stained with
Colloidal Blue (Invitrogen, Carlsbad, CA).
Thrombin activity by thromboelastography
The kinetics of the FIIa initiation of a fibrin clot was determined by
thromboelastography (TEG) which was performed on solutions containing purified rFI
and rFXIII with a Thromboelastograph® (TEG®) Hemostasis System 5000 series
(Haemoscope Corp., Niles, IL). rFI (final concentration: 8.56 mg/ml) was transferred to
a single-use TEG cup maintained at 37oC by the instrument. rFXIII (final concentration:
0.35 mg/ml) was added. CaCl2 (final concentration: 11 mM) and Ringers solution (155
mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, was added to standardize the
volumes in the cups) was added followed quickly by FIIa (final concentration: 52.8 U/ml)
to initiate clot formation. Data was collected every five seconds for 30 minutes by the
TEG interfaced with a computer.

The TEG Analytical Software (version 4.2.2,

Haemoscope, Niles, IL) collected the time to clot initiation (R), the time to achieve a clot
firmness of 20mm (K) and the maximal clot strength (MA).

The instrument was

calibrated each day of use. Each sample was run in triplicate so means and standard
deviations could be calculated. The data was exported and analyzed in Microsoft® Excel.

36
Results
rFXIIIa characterization
SDS-PAGE and N-terminal sequencing indicated that the purified protein from
the yeast was rFXIIIa rather than rFXIII. These and immunoblots indicated rFXIIIa had
a purity of greater than 98% (data not shown). The Pefakit® Factor XIII Incorporation
Assay (Pentapharm, CT) yielded a specific activity of almost 7,000 U/mg for rFXIII
compared to the theoretical specific activity of approximately 100 U/mg of plasmaderived FXIII.
Prothrombin activation by ecarin, rFIIa, FXa and sodium citrate
Plasma-derived prothrombin was incubated at 37oC in the presence and absence
of FXa (GGACK) and FIIa (PPACK) inhibitors (Figure 2.4). Over a 72 hour incubation
period, there was a gradual decrease in the main 72 kDa band which corresponded to a
gradual increase in bands at approximately 50 and 22 kDa. When GGACK and PPACK
were added, prothrombin consists of a main band at approximately 72 kDa and a minor
band at 50 kDa at all time periods (Figure 2.4B). If incubated for a month at 37oC,
prothrombin was gradually activated even in the presence of FXa and FIIa inhibitors
(Figure 2.5). The starting material for this experiment started with a major band at
approximately 72 kDa and minor bands at 50 and 30 kDa (Figure 2.5, lane 2). The bands
were not significantly changed at 26 hours of incubation; however, over the next month,
the 72 and 50 kDa bands gradually decreased while the band at approximately 42
increases.
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Figure 2.4. Evaluation of the activation of prothrombin without added
activators in the presence and absence of FIIa and FXa inhibitors by nonreduced
SDS-PAGE. Prothrombin was incubated at 37oC in the absence (A) and presence of
60 µM FIIa and 60 µM FXa inhibitors, PPACK and GGACK respectively (B). Lane
1: molecular weight marker. Lane 2: starting prothrombin. Lanes 3 through 6:
prothrombin incubated for 0, 24, 48 and 72 hours. Lane 7 of each contains rFIIa.
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Figure 2.5. Evaluation of prothrombin activation over 28 days after being
treated with FIIa and FXa inhibitors by nonreduced SDS-PAGE. Prothrombin
was incubated at 37oC in the presence of 60 µM FIIa and 60 µM FXa inhibitors for 28
days. Lane 1: molecular weight marker. Lane 2: starting prothrombin. Lanes 3
through 7: prothrombin incubated for 1.1, 7, 14, 21 and 28 days.

Prothrombin was activated by several methods in order to compare and
characterize the mechanism employed by sodium citrate. Activation was evaluated by
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nonreduced SDS-PAGE. When treated with 0.2% rFIIa, prothrombin (~72 kDa) was
gradually activated resulting in the appearance of bands at approximately 50 kDa, 38 kDa
(doublet), 25 kDa and 13 kDa (Figure 2.6A). As the 72 kDa band faded, the bands at 50
kDa, 38 kDa and 28 kDa darken. After 72 hours incubation, most of the prothrombin
was degraded; however, there is still a significant band at 50 kDa. If added FIIa was
increased or the reaction was allowed to incubate longer, all of the prothrombin was
degraded into FIIa and other fragments. If incubated too long, FIIa was degraded (data
not shown). If GGACK was added prior to rFIIa addition, the band at ~72 kDa is
maintained over the 72 hour incubation period (Figure 2.6B).
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Figure 2.6. Evaluation of the activation of prothrombin by rFIIa in the presence
and absence of FXa inhibitor by nonreduced SDS-PAGE. Prothrombin was
activated by 0.2% rFIIa in the absence (A) and presence of 60 µM GGACK (B). Lane
1: molecular weight marker. Lane 2: starting prothrombin. Lanes 3 through 6:
prothrombin with rFIIa incubated for 0, 24, 48 and 72 hours. Lane 7: rFIIa.

Activation by FX resulted in gradual proteolysis of the band at approximately 72
kDa (Figure 2.7A). At the initial time point, prothrombin remained at 72 kDa. At 24
hours, there were minor bands at 72 and 46 kDa with heavier bands at approximately 36,
22 and 10 kDa (Figure 2.7A, lane 4). At 48 and 72 hours, the same bands were present;
however, the 72 kDa band density decreased with increases in low molecular weight
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degradation bands. When incubated with 2% FXa, prothrombin (~72 kDa) immediately
started degrading. Just after addition, FXa had formed a light band at approximately 40
kDa (Figure 2.7B, lane 3). Within 24 hours, the 72 kDa band was gone leaving bands at
approximately 40, 26, and 13 kDa (Figure 2.7B, lane 4). Incubation for an additional 24
or 48 hours did not result in further activation or degradation (Figure 2.7B, lanes 5 and 6,
respectively).
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Figure 2.7. Evaluation of the activation of prothrombin by FX and FXa by
nonreduced SDS-PAGE. pdFII was activated by 10% FX (A) and 2% FXa (B).
Lane 1: molecular weight marker. Lane 2: starting prothrombin. Lanes 3 through 6:
prothrombin with rFIIa incubated for 0, 24, 48 and 72 hours. Lane 7 of the FX and
FXa activation gels contains FX and FXa, respectively. Lane 8: rFIIa.

Prothrombin was also activated by ecarin (Figure 2.8). Within 5 minutes, the
addition of ecarin resulted in the reduction of the prothrombin band (~72 kDa) and the
formation of bands at approximately 50 and 26 kDa (Figure 2.8A, lane 4). After 15
minutes, most of the 72 kDa band had disappeared resulting in the darkening of the 50
kDa band and the appearance of a doublet band at approximately 40 kDa (Figure 2.8A,
lane 5). After 30 minutes, most of the 50 kDa band had disappeared resulting in the
darkening of the 40 kDa band and the appearance of a band at approximately 13 kDa
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(Figure 2.8A, lane 6).

Incubation for 60 minutes, yielded only three bands at

approximately 40, 26 and 13 kDa (Figure 2.8A, lane 7). Incubation for 240 or 480
minutes did not result in further activation or degradation (Figure 2.8A, lanes 8 and 9,
respectively). If GGACK is added prior to the addition of ecarin, the band at ~72 kDa
gradually disappeared with the appearance and darkening of bands at approximately 50
and 26 kDa. By 30 minutes, the entirety of the 72 kDa band was gone replaced by
primarily the band at 50 kDa and 26 kDa with a doublet at ~40 kDa. The following 60
minutes of incubation did not significantly alter the band ratio (Figure 2.8B).
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Figure 2.8. Evaluation of the activation of prothrombin by ecarin by nonreduced SDS-PAGE. pdFII
was activated by 20 U/ml ecarin in the absence (A) and presence of 60 µM GGACK (B). Lane 1:
molecular weight marker. Lane 2: starting prothrombin. For the gel in the absence of GGACK (A), lanes 3
through 9: prothrombin incubated with ecarin for 0, 5, 15, 30, 60, 240 and 480 minutes. For the gel in the
presence of GGACK (B), lanes 3 through 9: prothrombin incubated with ecarin for 0, 5, 10, 15, 30, 45 and
60 minutes. Lane 10 of each gel contains rFIIa.

Activation by 25% sodium citrate resulted in a slow lightening of the 72 kDa band
and gradual appearance of bands at approximately 50 and 26 kDa starting after
incubation for 24 hours (Figure 2.9A). If the reaction was allowed to incubate longer, all
of the prothrombin was degraded into FIIa and other fragments. If incubated too long,
FIIa was degraded (data not shown). Increasing sodium citrate to 35% resulted in the
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appearance of the 50 and 26 kDa bands within 12 hours (Figure 2.9B, lane 5). At 36
hours, the 72 kDa band was almost gone; however, the 50 kDa band has not darkened.
Bands have appeared at approximately 40, 26, 24, 13 and 10 kDa (Figure 2.9B, lane 7).
After 72 hours incubation, only a light band was visible at 40 kDa (Figure 2.9B, lane 9).
35% sodium citrate activation follows the same activation time course and sequence in
the presence or absence of 60 µM GGACK (Figure 2.10).
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Figure 2.9. Evaluation of the activation of prothrombin by 25% and 35% sodium citrate
by nonreduced SDS-PAGE. Prothrombin was activated by 25% (A) and 35% (B) sodium
citrate. Lane 1: molecular weight marker. Lane 2: starting prothrombin. Lanes 3 through 9:
samples incubated for 0, 6, 12, 24, 36, 48 and 72 hours. Lane 10 contains rFIIa.
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Figure 2.10. Evaluation of the activation of prothrombin by 35%
sodium citrate in the presence and absence of FXa inhibitor by
nonreduced SDS-PAGE. Prothrombin was activated by 35% sodium
citrate in the absence (A) and presence (B) of 60 µM GGACK. Lane 1:
molecular weight marker. Lane 2: starting prothrombin. Lanes 3 through
5: samples incubated for 24, 48 and 72 hours. Lane 6: rFIIa.

Prothrombin was incubated with 35% sodium citrate alone, with FXa or with FIIa
in the presence of FXa inhibitor (Figure 2.11). All three samples showed equivalent
activation rates and fragments.
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Figure 2.11. Evaluation of the activation of prothrombin by 35% sodium citrate in combination with
FXa or FIIa in the presence of FXa inhibitor by nonreduced SDS-PAGE. Prothrombin was activated
by 35% sodium citrate alone or in combination with rFIIa or FXa. Samples were incubated for 8 (A), 24
(B) and 72 (C) hours. Lane 1: molecular weight marker. Lane 2: starting prothrombin. Lanes 3:
prothrombin incubated with 35% citrate alone. Lane 4: prothrombin incubated with 35% citrate and 0.02%
FXa. Lane 5: prothrombin incubated with 35% citrate and 0.02% rFIIa. Lane 6: rFIIa. Lane 7: FXa.

Prothrombin was also activated by a combination of 0.2% FIIa and 35% sodium
citrate (Figure 2.12). At 0 and 1 minutes, the major band is at approximately 72 kDa.
Over the following hour, the band at 72 kDa decreased with an increase in the bands at
50, 42, 28 and 14 kDa.
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Figure 2.12. Evaluation of the activation of prothrombin by FIIa and sodium
citrate by nonreduced SDS-PAGE. Prothrombin was activated by 0.2% plasmaderived FIIa and 35% sodium citrate. Lane 1: molecular weight marker. Lane 2:
starting prothrombin. Lane 3: plasma-derived FIIa used for activation. Lanes 4
through 9: samples incubated for 0, 1, 5, 15, 30 and 60 minutes.

N-terminal sequencing of activated samples
The first five to ten amino acids of the N-terminal were determined for each of the
main fragments resulting from activation by 2% FXa and 35% sodium citrate (Table 2.1).
Activation by FXa resulted in fragments with molecular weights of ~45 kDa (FXa), ~40
kDa (IVESGEADIG), ~22 kDa (ANTFLEAVVK) and ~13 kDa (SEGNXVA). Several
prothrombin fragments activated by 35% sodium citrate alone or with 0.2% FIIa were
analyzed by N-terminal sequencing. These fragments included bands at ~50 kDa (Nterminal sequence: ANTFLXLVVX), ~42 kDa (N-terminal sequence: TATSEYQTFF),
~40 kDa (N-terminal sequence:

TFGSGEADIG), ~26 kDa (N-terminal sequence:

ANTFLXXVXK), ~25 kDa (N-terminal sequence:
terminal sequence:

TFGSGEADIG), ~22 kDa (N-

IVEGSDAEIG), ~13 kDa (N-terminal sequence:

TFXXX) and

various degradation bands with lower molecular weights. Based on these sequences,
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molecular weights and presence or absence of other bands at certain time points, each
sequenced band was identified as a particular prothrombin/thrombin species (Table 2.1,
Figure 2.13).

Table 2.1. N-terminal amino acid sequences of prothrombin and its fragments following activation
by FXa (2%) and sodium citrate (35%).
Approximate
Activation Enzyme
Molecular Weight
Amino Acid Sequence
Identity
(kDa)
None (starting material)
72
ANTFLXLVVX
Prothrombin

Activated Factor X (FXa)

40

IVESGEADIG

B-chain

22

ANTFLEAVVK

Fragment 1

13

SEGNXVA

Fragment 2

50

SEGSSVNLSP

Prethrombin-1

42

TATSEYQTFF

Prethrombina-2 or FIIa

40

TFGSGEADIG

Prethrombina-2a or
αFIIa

26

ANTFLXXVXK

Fragment 1

25

TFGSGEADIG

βFIIa

22

IVEGSDAEIG

B-chain from βFIIa

35% Sodium Citrate

13
TFXXX
Fragment 2
Notations: Prethrombin-1 (PreFIIa-1), Prethrombin-2 (PreFIIa-2), Prethrombin-2a (PreFIIa-2a), Thrombin
(FIIa), α-thrombin (αFIIa), β-thrombin (βFIIa), γ-thrombin (γFIIa).
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Figure 2.13. Identification of the fragments of prothrombin activated by 35%
sodium citrate suggested by N-terminal sequencing. Results from several Nterminal sequencing analyses of multiple prothrombin samples activated by 35%
sodium citrate with or without thrombin were compiled and shown overlaying an
equivalent time course activation by citrate. Lane 1: molecular weight marker. Lane
2: starting prothrombin. Lanes 3 through 9: samples incubated for 0, 6, 12, 24, 36, 48
and 72 hours. Lane 10: rFIIa.

Thrombin activity by chromogenic assay
The activity of plasma-derived thrombin (pdFIIa) prepared by FXa and citrate
activation were determined by chromogenic assay. Positive and negative controls yielded
specific activities similar to those reported by the manufacturer (Table 2.2). The specific
activity of the FXa activated prothrombin sample was 293 U/mg. The mean specific
activity of citrate activated prothrombin was 368 ± 173 U/mg (mean and standard
deviation of four samples activated by 35% sodium citrate).
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Table 2.2. Specific activity of activated prothrombin by chromogenic assay.
Specific Activity,
Estimated
as per
Specific Activity
manufacturer
(U/mg)
(U/mg)
Prothrombin (Enzyme Research)
0
11
Prothrombin (Enzyme Research)

2,805

3,230

rFIIa (Zymogenetics)

2,618

2,370

Prothrombin activated by 2% FXa

293

Prothrombin activated by 35% sodium citrate
368 ± 173
Note: Each sample was measured in triplicate at three dilutions. Intra-sample standard
deviations were 0 for prothrombin, 874 for plasma-derived FIIa (Enzyme Research), 625 for
rFIIa (Zymogenetics), 1 for FXa activated and between 12 and 38 for citrate activated
samples. Four samples from different 35% sodium citrate activations were measured in three
assays to yield a mean ± standard deviation.

Thrombin activity by SDS-PAGE
The functions of the samples activated by 0.2% rFIIa (72 hours), 2% FXa (72
hours), 20 U/ml ecarin (480 minutes), 35% sodium citrate (48 hours) were evaluated by a
60 minute incubation with rFI (Figure 2.14A) and rFXIII (Figure 2.14B). rFI incubated
with a commercial recombinant thrombin (rFIIa) is activated into fibrin with the release
of fibrinopeptide A (FpA) and fibrinopeptide B (FpB) as seen by the decrease in
molecular weight of the 66 and 52 kDa bands (Figure 2.14A, lane 3). Prothrombin
samples activated to pdFIIa by 2% FXa (Figure 2.14A, lane 5) and 20 U/ml ecarin
(Figure 2.14A, lane 6) resulted in identical shifts. Prothrombin samples activated to
pdFIIa by 0.2% rFIIa resulted in a shift of the 52 kDa band but not the 66 kDa band
(Figure 2.14A, lane 4). The sample activated by 35% sodium citrate resulted in a partial
shift in the 66 kDa band and full shift in the 52 kDa band (Figure 2.14A, lane 7).
When incubated with a commercial thrombin (rFIIa), the molecular weight of
rFXIIIa shifted down slightly from ~84 kDa to ~80 kDa (Figure 2.14B, lane 3). The
molecular weight shift of rFXIIIa was fully achieved by pdFIIa activated by 2% FXa
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(Figure 2.14B, lane 5) and 20 U/ml ecarin (Figure 2.14B, lane 6). pdFIIa activated by
0.2% rFIIa and 35% sodium citrate shifted most of the rFXIIIa; however, a minor band at
the original molecular weight was visible (Figure 2.14B, lanes 4 and 7, respectively).
The proper thrombin-mediated FXIIIa inactivation fragments (~25 and ~54 kDa) were
also seen for rFIIa, FXa and ecarin activated pdFIIa.
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Figure 2.14. Fibrinopeptide release and Factor XIIIa molecular weight shift by prothrombin
samples activated by rFIIa, FXa, ecarin and 35% sodium citrate. Prothrombin (0.10 mg/ml) activated
by rFIIa, FXa, ecarin and 35% sodium citrate were evaluated by incubation with 0.4 mg/ml rFI (A) or 0.4
mg/ml rFXIII (B). Lane 1: molecular weight marker. Lane 2: rFI (A) or rFXIII (B) alone. The remaining
lanes contain rFI (A) or rFXIII (B) incubated for 60 minutes rFIIa (lane 3) or with prothrombin activated by
0.2% rFIIa (lane 4), 2% FXa (lane 5), 20 U/ml ecarin (lane 6) or 35% sodium citrate (lane 7).

Thrombin activity by thromboelastography
The kinetics and strength of clots formed by 8.56 mg/ml rFI, 0.35 mg/ml rFXIII
and 52.8 U/ml rFIIa or prothrombin activated by 35% sodium citrate (pdFIIa) were
evaluated by thromboelastography (TEG) (Figure 2.15). The time to clot initiation (R)
and clotting kinetics (K) catalyzed by pdFIIa (11.86 ± 2.89 and 50.0 ± 0 seconds,
respectively) were equivalent to that catalyzed by rFIIa (10.00 ± 0 and 50.0 ± 0 seconds,
respectively). Maximal clot strengths for the pdFIIa catalyzed reaction (10,585.97 ±
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1,670.88 dynes/sec) were comparable to that created by rFIIa (12,865.60 ± 1,688.44
dynes/sec).
80
70

Amplitude (mm)

60
50
40
30
20
pdFIIa
10

rFIIa

0
0

200

400

600

800
1000
Time (sec)

1200

1400

1600

1800

Figure 2.15: Comparison of clotting activity of rFIIa and citrate activated pdFIIa clotting
analysis by thromboelastography. TEG monitored the initiation of clot formation, clotting kinetics
and change in clot strength over time of rFI (8.56 mg/ml) and rFXIII (0.35 mg/ml) activated by pdFIIa
(red) or rFIIa (blue) (52.8 U/ml).

Discussion
Detailed analysis of the activation of prothrombin by sodium citrate has not
previously been accomplished and only limited evaluations have been completed on the
fragments produced. The mechanism of activation by citrate is unknown. The research
presented in this chapter focused on identifying the sequence of activation of prothrombin
by sodium citrate. This was accomplished by analyzing molecular weight changes by
SDS-PAGE, N-terminal sequencing and comparison to activations with known
sequences.
determined.

The activity of the subsequently activated thrombin samples was also
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Research has been complicated by the presence of trace amounts of other plasma
proteins in purified prothrombin samples which can activate it into thrombin.32 These
results support that assertion.

When purified prothrombin with a >95% purity is

incubated over 72 hours, a portion of prothrombin is activated into prethrombin-1 (Figure
2.4A). If the same prothrombin sample is pre-treated with FXa and FIIa inhibitors which
are subsequently removed, prothrombin is not activated over a 72 hour incubation period
(Figure 2.4B).

These results indicate that trace amounts of FXa and/or FIIa are

responsible for activating prothrombin.

Even if pretreated, prothrombin is slowly

activated when incubated at 37oC for 28 days (Figure 2.5). If incubated for over five and
a half months, most of the prothrombin is proteolyzed into small molecular weight pieces
(data not shown). The activation of prothrombin after pre-treatment with FIIa and FXa
inhibitors indicates that some component in the sample is activating the zymogen. Some
researchers believe prothrombin can autoactivate27 while others assert that FX is
responsible for activating prothrombin.32
Research presented in this chapter indicates that trace amounts of FIIa in the
prothrombin sample are not responsible for activation of prothrombin. When thrombin
was added to prothrombin pretreated with FXa and FIIa inhibitors, prothrombin was
activated within 24 hours (Figure 2.6A); however, when FXa inhibitor was added with
the FIIa, prothrombin was not activated (Figure 2.6B). Thus, rather than activating
prothrombin, FIIa is activating the trace amount of FX into FXa which is subsequently
activating prothrombin.
When FX is added to prothrombin, FX (~59 kDa) is activated into FXa (~46 kDa)
and prothrombin is activated into thrombin and other fragments within 24 hours (Figure
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2.7A). Activating with FXa similarly transformed all of the prothrombin to thrombin
within 24 hours (Figure 2.7B). This activation of FX occurs in the absence of thrombin;
therefore, this research supports assertions that FX can be autocatalytically activated or
activated by prothrombin.32 It is still unclear whether FX can activate prothrombin or
whether prothrombin is activated once FXa is created.
Research has been mixed with regard to the success of citrate activation. Early
research indicated that prothrombin could auto-activate to thrombin in the presence of
25% sodium citrate;29,

30

however, Teng and Seegers (1981) found that prothrombin,

prethrombin-1 nor prethrombin-2 were activated by 25% sodium citrate with or without
activated thrombin.32

Teng and Seegers asserted that contaminating traces of other

plasma proteins are necessary to activate prothrombin to thrombin.32 They stated that
citrate activation of prothrombin was a result of “reciprocal proenzyme activation” where
FX and prothrombin activate each other; however, while FX can auto-activate,
prothrombin requires the presence of FX.32
While we know our prothrombin sample is contaminated with other plasma
proteins, pretreatment with FXa and FIIa inhibitors cease activation over 72 hours;
however, the addition of sodium citrate initiates prothrombin activation and as seen
previously27 activation proceeded at a faster rate at the higher citrate level. We have
shown that FIIa is not responsible for this activation. It is unclear whether trace amounts
of FX are responsible but FXa is not. Incubation with 35% citrate alone or with added
FXa inhibitor yielded equivalent activation profiles (Figure 2.10); therefore, FXa does
not appear to play a role in this activation. When FXa was added to prothrombin in
combination with FXa inhibitor and 35% sodium citrate, activation rates and fragments
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were equivalent indicating that the FXa inhibitor is still functional in the harsh sodium
citrate environment. Activation by sodium citrate could be due to FX, autocatalytic or
non-enzymatic activation. Autolytic degradation of thrombin has been reported in the
literature. α-thrombin in the presence of 0.4 M NaCl will autolytically degrade into βand γ-thrombin.22 Future research needs to include studies designed answer this question.
Whatever the activator, previous research found that in the presence of 25%
citrate, thrombin was formed within five hours as measured by thrombin activity.27, 28, 32
In our studies, it typically took more than 72 hours and between 24 and 36 hours for
prothrombin to be activated to FIIa by 25% and 35% sodium citrate, respectively (Figure
2.9); however, activation times were occasionally more than 72 hours (Figure 2.10). Our
erratic activation times in the presence of citrate have been previously observed in
prothrombin samples that are not highly pure; however, the causes for these
inconsistencies are unknown.27
In 1950, Seegers, McClaughry and Fahey, using electrophoretic mobility and
activity assays, tentatively asserted that a minimum of three different molecular weight
species were derived following activation by 25% sodium citrate.27

Lanchantin,

Friedmann and Hart (1965), using sedimentation velocity techniques, identified a
molecular weight decrease from approximately 70 kDa to 35 kDa with subsequent
fragments with approximate weights of 25 and 10 kDa after incubation with 25% sodium
citrate.28 This work identifies several more intermediates and fragments produced by
citrate activation of prothrombin. Both 25% and 35% sodium citrate followed identical
pathways with 25% citrate activating at a slower rate (Figure 2.9 and other data not
shown).
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Initially, prothrombin is activated into two species at approximately 50 and 26
kDa (Figure 2.9B, lane 5 and 6). N-terminal sequencing indicates that the band at ~26
kDa has the same amino terminal as prothrombin; therefore, the band is either fragment 1
or fragment 1.2. The molecular weight is more consistent with fragment 1.2 which
should be approximately 30 kDa which would indicate a meizothrombin intermediate.
However, if it were fragment 1.2, a band should also exist at approximately 42 kDa for
FIIa which is the other fragment formed with meizothrombin.

Since there is no

corresponding band at 42 kDa but only bands at 72 and 50, then the 26 kDa band must be
fragment 1. This conclusion is supported by the N-terminal sequencing of the 50 kDa
band which indicates it is prethrombin-1 indicating that the 26 kDa band is the released
of fragment 1.
After further incubation, prothrombin and prethrombin-1 are activated into a band
at approximately 42 and 40 kDa (Figure 2.9B, lane 7). N-terminal sequencing indicates
that the 42 kDa band corresponds to thrombin and/or prethrombin-2 and the 40 kDa band
is α-thrombin and/or prethrombin-2a. A proteolyzed thrombin, β-thrombin (~25 kDa), is
also formed. This proteolysis results in fragments at 13 kDa which is α-thrombin or
prethrombin-2a degraded on the C-terminal and multiple lower molecular weight
degradation bands.

It is possible that prethrombin-2a is directly activated from

prethrombin-1; however, after all of the prothrombin and most of the prethrombin-1 has
been proteolyzed, the band at 42 kDa is no longer present replaced by only the 40 kDa
band corresponding to prethrombin-2a and/or α-thrombin. Therefore, it appears that
prethrombin-2 is converted to prethrombin-2a. Under reducing conditions, the 40 kDa
band splits into a doublet of bands at approximately 40 and 36 kDa exist which N-
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terminal sequencing indicates as prethrombin-2a and the B-chain, respectively. These
results indicate that under nonreducing conditions, the band at 40 kDa includes both αthrombin and prethrombin-2a.
This sequence of activation by sodium citrate does not follow the primary or
secondary hemostasis pathways (Figure 2.1); rather, it follows an alternative pathway
similar to that of primary hemostasis (Figure 2.16). Activation with prethrombin-1 as an
intermediate has been reported for bovine and human prothrombin when treated with
thrombin.38

It is interesting to note that activation by ecarin resulted in a similar

sequence of activation with a prethrombin-1 intermediate although it should have yielded
a fragment 1.2 intermediate instead.
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Prothrombin (72 kDa)

Fragment 1
(~26 kDa)

Prethrombin-1 (55 kDa)

Fragment 2
(~13 or 15 kDa)

Prethrombin-2
(42 kDa)

Thrombin (42 kDa)

Prethrombin-2a
(40 kDa)

α-thrombin (40 kDa)
Figure 2.16. Suggested primary pathway of activation of prothrombin by sodium citrate. When
activated by sodium citrate, prothrombin is proteolyzed into prethrombin-1 then to prethrombin-2, FIIa,
prethrombin-2a or αFIIa. The order of activation after formation of prethrombin-1 is uncertain. This figure
modifies the prothrombin schematic published by Davie and Kulman. 1
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The activity of four thrombin solutions, activated by 35% sodium citrate and 0.2%
FIIa, containing primarily prethrombin-2a and α-thrombin but also β-thrombin (Figure
2.12, lane 3) was determined by chromogenic assay. The activity was 368 ± 173 U/mg
(mean ± standard deviation) which is significantly lower than earlier specific activity
reports of 1,40027 to 4,000 U/mg.28 Our activities are probably lower than other reports
and purchased thrombin references because it contains thrombin, α-thrombin, and the less
active β-thrombin rather than a pure thrombin as is in Recothrom.
The activity of citrate activated thrombin was also measured by SDS-PAGE and
thromboelastography. Activity was evaluated with regard to the ability of the citrate
activated thrombin sample to activate fibrinogen to fibrin and factor XIIIa to its lower
molecular weight form. Thrombin formed by 35% sodium citrate appeared to release all
of fibrinopeptide B but only a portion of fibrinopeptide A (Figure 2.14A). However, it
was able to cleave FXIIIa in the same manner as recombinant thrombin (Figure 2.14B).
The lower efficiency of citrate activated thrombin in releasing fibrinopeptide A compared
to recombinant thrombin may be due to high number of degradation bands. When
evaluated by thromboelastography, citrate activated thrombin created a fibrin clot at
equivalent kinetics as the highly purified recombinant thrombin (Figure 2.15). For the
SDS-PAGE analysis, thrombin was added by mass; therefore, the recombinant thrombin
reactions contained approximately 7-fold more units per ml than the citrate activated
thrombin reactions.

When dosed at equivalent activity levels as rFIIa in the

thromboelastographic analysis, pdFIIa activated by sodium citrate yielded equivalent
clotting kinetics and clot strength.
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This research examined the activation of prothrombin in the presence and absence
of sodium citrate. Thrombin is not responsible for activation of prothrombin in the
absence of high salts; rather, thrombin activates trace amount of FX to FXa which
subsequently activates prothrombin. FX did result in prothrombin proteolysis; however,
it is unclear whether FX directly proteolyzed prothrombin or autocatalytically produced
FXa which subsequently activated prothrombin. Despite remaining questions regarding
the activation of prothrombin in the absence of sodium citrate, prothrombin activation in
the presence of citrate does not appear to be related to FXa. The sequence of activation
of prothrombin by sodium citrate did not follow the primary or secondary hemostasis
pathways; rather, it followed an alternative pathway with prethrombin-1 as an
intermediate. Although activation of prothrombin by sodium citrate is different than
physiological mechanisms, the thrombin produced is functional. Further research with a
recombinant prothrombin will eliminate contamination of other plasma proteins and
thereby allow further elucidation of activation sequences and intermediates.
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Chapter 3
Characterization of Recombinant Factor XIII Expressed in Pichia pastoris
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Abstract
Factor XIII A-chain (FXIII), also known as fibrin-stabilizing factor, is important
in establishing hemostasis because it crosslinks fibrin during clot formation imparting
viscoelastic strength and resistance to lysis. Consequently, FXIII deficiency results in a
hemophilia characterized by recurrent bleeding. Its importance in producing a resilient
clot indicates that it would be a valuable component in liquid fibrin sealants; therefore,
FXIII was produced in Pichia pastoris.

Rather than producing FXIII, N-terminal

sequencing indicated that the yeast expressed FXIIIa which is the active form of the
enzyme. This recombinant protein was produced at approximately 0.24 mg per gram of
cell mass and purified by His-tag affinity chromatography. While SDS-PAGE and size
exclusion chromatography indicate that FXIIIa primarily exists in monomer form with
small amounts of aggregates, dynamic light scattering and analytical ultracentrifuge
suggest that FXIIIa exists as a trimer in solution. The expressed FXIIIa had a molecular
weight of approximately 82 kDa but was rapidly cleaved by thrombin to the 79 kDa.
After further incubation, thrombin proteolyzed the expressed FXIIIa into two bands at
approximately 25 and 54 kDa which is equivalent to degradation products of plasmaderived material. The recombinant FXIIIa (rFXIIIa) had a specific activity of almost
7,000 U/mg and successfully crosslinked fibrin(ogen) in the presence and absence of
thrombin and α2-antiplasmin (A2AP) to fibrinogen. Thromboelastography showed that
the addition of rFXIIIa to fibrinogen and thrombin significantly increased clot strength.
These results indicate that rFXIIIa expressed in Pichia pastoris successfully functions as
a transglutaminase closely mimicking plasma-derived FXIII and may be a good
alternative for therapeutic uses.
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Introduction
Factor XIII (FXIII) is a coagulation protein located in plasma and on platelets at a
ratio between 1:11 and 5:1;2 however, FXIII activity is split evenly between plasma and
platelets.3, 4 Platelet FXIII is a 166 kDa homodimer consisting of two A-chains3 linked
by strong noncovalent bonding.5

Plasma FXIII is a 326 kDa noncovalently-bound

heterogeneous tetramer consisting of two A-chains (82 kDa) and two B-chains (76 kDa)68

held together by strong noncovalent bonds.5 The A- and B-chains of FXIII are different

in structure and function (Table 3.1).

Table 3.1. Structure, function and genetic differences between the A- and B-chains of FXIII.
A-chain
B-chain
Molecular weight (kDa)6-8
82
76.5
Amino acids9, 10
731
641
Location8
Plasma, platelets, placenta
Plasma
Structure11
Globular
Kinked, thin, flexible strand
Carbohydrate12-14
None
~8.5% total weight
Disulfide Bridges7, 10, 14
None
20
hepatocytes, monocytes,
4, 15-17
Synthesized by
hepatocytes
megakaryocytes
5, 18
Function
Enzyme: transglutaminase
Stabilization and transport
β-sandwich, catalytic core and two
14, 19-21
Domains
Ten β glycoprotein-1
barrels
22, 23
Chromosome location
6p24-p25
1q32-q32.1
Kilobases (kb)9, 10
160
28
Exons9, 10
15
12

Plasma and platelet FXIII A-chains are identical in structure and function.2,

24, 25

Although the A-chain has six possible asparagine-linked glycosylation sites, none contain
carbohydrates.12, 13 Synthesized by hepatocytes, monocytes and megakaryocytes,15-17 the
A-chain contains four domains: a β-sandwich, catalytic core and two barrels.20, 21 The Bchain is secreted as a single chain into plasma by hepatocytes where some form
complexes with the A-chain17 and others circulate freely.5 FXIII tetramer circulates in
plasma at approximately 0.07 µM18 while the B-chain circulates at a concentration
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between 14 and 0.24 µM.26, 27 The A-chain is the catalytic component of the enzyme;15-17
while the B-chain surrounds the hydrophobic A-chain and is thought to stabilize the
enzyme during transport.5, 18 While A-chain is intertwined into the fibrin clot during its
formation,18 the B-chain is absent.28
When plasma FXIII is in the tetramer form, the 36 amino acid29 activation peptide
of one A-chain protects the cysteine in the active site of the other A-chain.

This

conformation is secured by hydrogen bonds and salt bridges.20 Plasma and platelet FXIII
can be activated by trypsin,24 papain,24 platelet acid protease30 or calpain;31 however, it is
primarily activated into active FXIII (FXIIIa) by thrombin which binds to the A-chains’
4.5 kDa activation peptide32 and cleaves at Arg37-Gly38 by hydrolysis.29 During this
cleavage, the activation peptide is released.33 Fibrin and calcium ions then initiate the
dissociation of the B-chain to form FXIIIa (Figure 3.1).

HS
HS
A

HS

Thrombin

A

A
SH

B

B

A
A
SH

A
SH

Fibrin
+ CaCl2

B

B
+
Activation
Peptides

B

B

Figure 3.1. Schematic representation of thrombin activation of plasma FXIII. Plasma FXIII is a
heterogeneous tetramer of two A- and two B-chains. The activation peptide of each A-chain covers
the active site of the other A-chain. Thrombin cleaves the activation peptide exposing the enzymes’
active sites. Calcium and fibrin initiate dissociation of the B-chains leaving activated FXIII
(FXIIIa).18

The presence of calcium greater than 10 mM is critical for activation of FXIII after
cleavage by thrombin34,

35

because it initiates conformational changes resulting in

65
dissociation of the B-chains19 and exposure of the active site.34, 36, 37 The activation to
FXIIIa by thrombin is hastened by the presence of fibrin polymers24,

33, 38-41

which

apparently changes its conformation, altering the calcium binding site42 lowering the
calcium requirement to 1.5 mM which is the calcium content in plasma37,

41

and

promoting the dissociation of the B-chain.40, 43 Both the B-chain of the heterotetramer
plasma FXIII44 and thrombin45 bind to the γ-chain of fibrinogen which localizes the three
integral proteins required to form a fibrin clot in close proximity and disperses FXIII
throughout the forming clot.18 Unlike the fast thrombin activation of platelet FXIII,46
plasma FXIII activation is significantly slower because the rate is limited by B-chain
dissociation.40, 46-49 This is thought to regulate the activation of FXIII in plasma.42
FXIII also known as fibrin-stabilizing factor, is important in establishing
hemostasis because it plays a key role in the final stage of coagulation. During this stage,
thrombin cleaves fibrinogen into fibrin which polymerizes into a soluble fibrin clot.
Thrombin activated Factor XIII (FXIIIa) creates an insoluble clot by crosslinking fibrin
polymers.50 The manner in which FXIIIa recognizes its substrate is unknown;18 however,
once activated, FXIIIa binds to residues 241 to 476 in the αC-domain of fibrin.51 Fibrin
polymers in close proximity are crosslinked by the catalytic triad (Cys314, His373 and
Asp396)21 of FXIIIa which creates an intermolecular γ-glutamyl-ε-lysine bridge between
the side-chains of two aligned fibrin molecules (Figure 3.2).25, 52-56
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Figure 3.2. Biochemistry of ε-(γ-glutamyl)lysine crosslinking of fibrin molecules by FXIIIa.18, 25, 37, 54
FXIIIa forms a thioester bond to a specific glutamine residue of the bound molecule, releasing ammonia. 57
This thioester reacts with the primary amine of a lysine residue of another molecule near the catalytic site
creating an amide bond.55, 58

Aggregation of fibrin monomers aligns the proteins easing the crosslinking
process.59, 60 FXIIIa crosslinks antiparallel61 fibrin α- and γ-chains with the γ-γ formation
proceeding at a much faster rate than the α-α crosslinking.18, 62, 63 Gln398 or 399 on one
fibrin γ-chain crosslinks to Lys406 on an adjacent fibrin γ-chain within 10 minutes64, 65
which significantly increases clot stiffness.”66, 67 One of four glutamine residues68-70 and
one of 15 lysine residues71, 72 can be involved in α-chain crosslinking which can take up
to 24 hours to form73 but is important in resisting plasminolysis74-77 because it yields high
viscoelastic strength18,
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and insolubility.62 α- and γ-chains can also be crosslinked;

however, this does not greatly affect clot strength.67 FXIIIa can also crosslink the same
sites of fibrinogen but at a slower rate.24, 78
In addition to fibrin and fibrinogen, FXIIIa is important in crosslinking α2antiplasmin,79 fibronectin,80, 81 collagen,80, 82 von Willebrand factor,83, 84 Factor V85, 86 and
numerous other substrates necessary for clot stabilization, adhering clot to vessel wall,42
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resistance to lysis and wound healing (Table 3.2).18

FXIIIa also binds directly to

platelets.87 Platelet FXIII appears to play the key role with respect to creating resistance
to lysis.88
Table 3.2. FXIII substrates, crosslinking sites, crosslinking molecules and function.18
Substrate
Cross-linking Site
Crosslinked with
Function
Gln398, Gln399 and
64, 65, 89
Fibrin(ogen) γ-chain
Itself and α-chain
Clot stabilization
Lys406
Gln221, Gln237, Gln328,
Gln366 and 15 potential
68-72
Fibrin(ogen) α-chain
Itself and α-chain
Clot stabilization
lysines from Lys208 to
Lys606
Fibrin α-chain
Resistance to
α2-Antiplasmin79
Gln2
Lys303
fibrinolysis
Resistance to
79
TAFI
Gln2, Gln5, Gln292
Fibrin, itself
fibrinolysis
Fibrin α-chain
Resistance to
PAI-290, 91
Lys148, Lys230,
fibrinolysis
Lys413
Migration of cells
Itself, fibrin,
Fibronectin80, 81
Gln3
into the clot; wound
collagen
healing
Stabilization of
80, 82
Collagen
Fibronectin, fibrin
extracellular matrix
Platelet adhesion to
83, 84
Von Willebrand factor
Fibrin, collagen
clot
Vitronectin92, 93
Gln93
Thrombospondin94
Fibrin
Increased thrombin
Factor V85, 86
Fibrin, platelets
generation at the clot
surface
Clot retraction,
Actin95, 96
Fibrin
stabilization of
platelet cytoskeleton
Myosin97
Itself
Vinculin98
Fibrin
Stabilization of
αIIbβ399
Fibrin
platelet and fibrin
clot

The depletion of calcium is the only known inhibitor of FXIIIa in physiology; 100
however, there are synthetic inhibitors.101 FXIIIa is inactivated by thrombin cleaving the
A-chain at Lys513 or Arg51542 resulting in two fragments of 25 and 54 kDa.8
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The importance of FXIII in the formation of a blood clot is best characterized by
the description of issues seen with individuals with FXIII deficiency. Individuals with
this disease typically show normal clot formation; however, the fibrin polymers are not
crosslinked and are consequently still soluble resulting in short-lived clots in which
bleeding recurs 24 to 48 hours after injury.37, 42, 102 This bleeding and clotting cycle may
recur for months.102 These patients also suffer from other related issues including death
from intracranial hemorrhage and atypical wound healing.42 FXIIIa appears to have
several functions:
1. Crosslink the fibrin clot to yield a clot with high viscoelastic strength.18, 103
2. Reduce the rate of clot lysis74-77 by forming the strong clot and crosslinking lysis
inhibitors into the clot. Clot lysis is directly and inversely related to the amount
of fibrin α-α crosslinking.24
3. Weave cell signaling molecules into the clot to encourage wound healing.104
4. Crosslink the clot to the vessel wall.80, 82
Thromboelastography indicates that FXIIIa prolongs fibrinolysis,105 reduces time to clot
initiation, speeds clotting kinetics and increases viscoelastic strength.106,

107

Platelets

dispersed throughout the clot probably hasten108 and further stabilize the clot109 by
releasing additional FXIII. Research indicates that FXIII in the platelets is necessary to
obtain optimal crosslinking.110
A recombinant version of FXIII’s A-chain (rFXIIIA) has been expressed in
Saccharomyces cerevisiae111-113 as a nonglycosylated homodimer114 that functions in the
same manner as platelet FXIII.46 This rFXIIIA has been used to examine the kinetic
details of fibrin γ-chain crosslinking113 and evaluated as a drug for treating FXIII
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deficiency.115-117 In clinical trials, the rFXIIIA produced in Saccharomyces cerevisiae
did not result in serious adverse events or have immunological repercussions after
single115,

116

or multiple117 intravenous doses. Clinical studies indicate that rFXIIIA

infusion into patients with FXIII deficiency restores clot strength and lysis resistance.116
Preclinical studies also indicate that rFXIII infusion is a beneficial treatment to combat
depletion of coagulation proteins following cardiopulmonary bypass surgery.118

In

addition to functioning like native FXIII, after injection, rFXIIIA appears to bind to freecirculating plasma-derived FXIII (pdFXIII) B-chain and circulates as A2B2 like native
pdFXIII.115-117
The research presented in this chapter was designed to test the hypothesis that
recombinant FXIII A-chain expressed in Pichia pastoris has the same structure, function
and activity as its plasma-derived counterpart and rFXIIIA expressed by Saccharomyces
cerevisiae. Rather than producing FXIII, N-terminal sequencing indicated that the yeast
expressed FXIIIa which successfully crosslinked fibrin(ogen) yielding a clot with
increased viscoelastic strength.

Materials and Methods
Materials
Purified, plasma-derived prothrombin and plasma-derived FXIII was bought from
Enzyme Research Laboratories (South Bend, IN). Recombinant thrombin (Recothrom ®)
was purchased from Zymogenetics.

Materials for the thromboelastograph were

purchased from Haemoscope (Niles, IL). Purified recombinant fibrinogen, expressed in
the milk of transgenic cows, was obtained from Pharming Group NV (Leiden,
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Netherlands). PPACK was purchased from Haematologic Technologies (Essex Junction,
VT). Unless otherwise specified, reagents were purchased from Sigma (St. Louis, MO).
Vector construction, expression and purification of FXIIIA in Pichia pastoris
The human Ultimate ORF clone containing the human coagulation factor
FXIIIA1 cDNA in the pENTRTM221 vector was purchased from Invitrogen (Clone ID:
IOH11901, Carlsbad CA). The following primers were used to obtain FXIIIA gene to
subclone

in

pPICZA

intracellular

Pichia

expression

vector.

(Forward,

5'-

CCAATTGATGCATCATCATCATCATCATTCAGAAACTTCCAGGACCGC-3';
Reverse, 5'-GCGGCCGCTCACATGGAAGGTCGTCTTTGAATC-3').

The forward

primer introduced a methionine and six histidine amino acids at the N-terminal of mature
FXIIIA peptide. The PCR product was digested with MfeI and NotI and subcloned into
pPICZA which was digested with the same enzymes. The DNA sequence of the FXIIIA
was confirmed by sequencing the insert fragment. One of the confirming plasmid
pPICZA-FXIIIA was linearized with PmeI and transformed into Pichia pastoris X-33
host strain and copy number of the clones was determined as described.119 Varying copy
number clones were screened in shake flask culture to confirm intracellular production of
FXIIIA protein. The highest producing clone was scaled up to 5 L bench scale. A fedbatch fermentation protocol was followed to optimize FXIIIa production as described by
Zhang et al., (2007).120 At the end of fermentation process the cells were separated by
centrifugation (6,000xg) and pellet was stored at -80oC.
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AOX1

NotI

FXIIIA gene
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Tag
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TT
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Figure 3.3. Schematic of vector pPICZA-FXIIIA. FXIIIA cDNA (2199 bases)
with a six histidine tag (17 bases) on the N-terminal was inserted into the pPICZA
vector containing a 5’ AOX1 promoter (941 bases), multiple cloning site (79
bases), c-myc epitope (32 bases), six histidine tag (17 bases) and 3’ AOX1
transcription termination region (341 bases). The restriction enzyme sites utilized
are shown with orange arrows.

Frozen cell paste was processed in 300 gram batches. Cells were lysed in three
sets of 100 gram batches. 100 grams of cell paste was resuspended in 100 ml of cold
lysis buffer (50 mM Tris-HCL, 10 mM MgSO4, 1 mM EDTA, 10 mM potassium acetate,
1 mM DTT (DL-Dithiothreitol), 2 mM PMSF (phenylmethanesulphonylfluoride) in
methanol, pH 9.5). 100 ml (250 g) of 0.5 mm glass beads (Biospec, Bartlesville, OK)
were added and the cells. Surrounded by an ice bath, cells were lysed using a BeadBeater
Blender (Biospec, Bartlesville, OK) with twenty 20 second on/off cycles. The cell lysate
mixture was then centrifuged to remove cellular debris. The lysate from 300 grams of
cell paste was combined and purified using the HisBind Purification Kit (EMD
Chemicals, Inc., San Diego, CA) with 40 ml of resin slurry. Following purification,
rFXIII was dialyzed in 10 mM Tris-HCl, 0.1 mM EDTA, 60 µM polysorbate-20, pH 8.0
in snake-like dialysis membranes and the protein samples were filter-sterilized and
concentrated using the Amicon tubes (Millipore, Billerica, MA). The purity of the
sample was tested by SDS-PAGE (NuPAGE 12% Bis-Tris) (Invitrogen, Carlsbad, CA)
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and immunoblot. The concentration of rFXIII was determined by standard Bicinconic
Acid (BCA) methods. The molecular weights of the rFXIII expressed by the yeast and
the activated rFXIIIa were calculated based on the amino acid sequence8 and molecular
weights of the amino acids (Table 3.3).
Plasma-derived thrombin preparation
Plasma-derived human prothrombin (Enzyme Research Laboratories, South Bend,
IN), was thawed at 37oC. Plasma-derived thrombin (Enzyme Research Laboratories,
South Bend, IN) was added at a 1/10 mass to mass thrombin/prothrombin ratio. 0.35
grams of sodium citrate per milliliter of solution was added and then incubated at 37oC
on a rotating mixer for five hours. Sodium citrate was removed with PD-10 desalting
columns (GE Healthcare, Giles, United Kingdom).

Activation of prothrombin to

thrombin was confirmed by reducing and nonreducing SDS-PAGE (12% Bis-Tris
NuPAGE) (Invitrogen, Carlsbad, CA) stained with Colloidal Blue (Invitrogen, Carlsbad,
CA) and Western blot analysis.

The concentration of the thrombin solution was

determined by standard Bicinconic Acid (BCA) methods. The specific activity was
determined by aPTT analysis.
Comparison of pdFXIII and rFXIII by SDS-PAGE and Western blot
Reduced FXIII samples were evaluated by sodium dodecylsulfate-polyacrylamide
(SDS-PAGE) gel electrophoresis on 4-12% NuPage® Bis-Tris gels with 2-(Nmorpholino)ethanesulfonic acid (MES) running buffer and NuPage® LDS sample buffer
which were purchased from Invitrogen (Carlsbad, CA). Reduced samples were treated
with NuPage® Sample Reducing buffer (β-mercaptoethanol) (Invitrogen). Samples were

73
incubated at 74oC for 10 minutes before loading on the gels which were run at 200 volts
for one hour. Gels were stained with Colloidal Blue (Invitrogen) or electroblotted onto
polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA).

Blots were

subsequently developed with an anti-human factor XIII subunit A polyclonal antibody
made in sheep (US Biologicals, Swampscott, MA) and then an anti-sheep IgG peroxidase
conjugate antibody (Sigma, St. Louis, MO).
Dynamic light scattering
Dynamic light scattering was used to identify the radius of gyration of the
recombinant FXIII and estimate polydispersity of molecular weights in solution. pdFXIII
and rFXIII samples were diluted with 10 mM Tris-HCl, 0.1 mM EDTA, 60 µM
polysorbate-20, pH 8.0 to various dilutions. Data were collected at 24oC by a DynaProTM
(Protein SolutionsTM) Titan (Wyatt Technologies, Santa Barbara, CA) dynamic light
scattering instrument and analyzed by DYNAMICS software (Wyatt Technologies, Santa
Barbara, CA) which provided data regarding radius of gyrations and estimated molecular
weights of the particles in solution. Four measurements were collected for each sample.
Analytical ultracentrifuge
Sedimentation velocity experiments were performed using a ProteomeLab XL-I
analytical ultracentrifuge (Beckman Coulter, Brea, CA) to estimate molecular weights
and evaluate aggregation of rFXIII in solution. rFXIII sample, in 10 mM Tris-HCl, 50
mM NaCl, 60 µM polysorbate-20, pH 8.0, was tested at 0.1, 0.3 and 0.5 mg/ml and three
speeds (8,000, 10,000 and 12,000 rpm) and three wave lengths (275, 280 and 285 nm) at
20oC. 110 µl rFXIII and 125 µl of the corresponding buffer were loaded in triplicate into
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cells with sapphire windows and a 6-channel equilibrium centerpiece. Cells were spun in
an An-50 Ti 8-hole rotor and run for 22 hours at each speed collecting data at 20 and 22
hours. The partial specific volume of 0.73 ml/g was calculated for the A subunit of FXIII
was calculated from the amino acid sequence as described by Perkins (1986).121 Data
was analyzed using Microcal Origin 6.0 software.
Size exclusion chromatography
Size exclusion chromatography (SEC) was also utilized to estimate molecular
weight and possible aggregation of rFXIII. Bovine serum albumin (Sigma, St. Louis,
MO), immunoglobulin A (IgA) (Sigma, St. Louis, MO) and immunoglobulin G (IgG)
(Green Mountain Antibodies, Burlington, VT) were exchanged into 20 mM Tris-HCl,
200 mM NaCl, 60 μM Tween 20, pH 7.0 and rendered 1.94 mg/ml by ultracentrifugation.
After being passed through a 0.20 µm nylon filter (Millipore, Billerica, MA), 0.5 ml of
each sample were sequentially passed through a TSK-G3000SWxL (Tosoh Biosciences,
South San Francisco, CA) column (14 ml, 30 cm length, 7.8 mm ID) attached to a Knauer
HPLC System at 0.5 ml/min for 45 minutes and data were collected by a photodiode
array (PDA) with a 1 mm flow cell and analyzed by EZChrom Elite software. rFXIII
(0.5 ml at 1.94 mg/ml) in 20 mM Tris-HCl, 200 mM NaCl, 60 μM Tween 20, pH 7.0 was
also subsequently passed through the column using the same method. The EZChrom
Elite software was used to overlay the tracings and match the heights of the primary
peaks. Retention times of the primary peaks of the known samples were obtained from
the EZChrom Elite software and plotted in Excel. A linear trend line was fit and rFXIII
molecular weights estimated from resultant retention times. Purification products were
analyzed by SDS/PAGE and Western blot with an anti-FXIII antibody (US Biologicals,
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Swampscott, MA).

The percentage of rFXIII at different molecular weights was

estimated by determining the mass of rFXIII in each peak by SDS-PAGE.
Activation and inactivation of rFXIII by rFIIa
The ability of the recombinant FXIII to be activated and inactivated by rFIIa was
evaluated by SDS-PAGE by a similar procedure previously described.111 rFXIII (final
concentration: 0.67 mg/ml) was incubated with rFIIa (60 U/ml) in Ringers solution (155
mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2) for 0, 5, 15, 30, 60, 120, 180, 240
and 360 minutes at 37oC. The activation/inactivation reaction was halted by the addition
of PPACK (final concentration: 5 µM). For the zero time point, rFIIa and PPACK were
added at the same time.

Samples were evaluated by sodium dodecylsulfate-

polyacrylamide (SDS-PAGE) gel electrophoresis on 4-12% NuPage® Bis-Tris gels with
2-(N-morpholino)ethanesulfonic acid (MES) running buffer, NuPage® LDS sample
buffer and NuPage® Sample Reducing buffer (β-mercaptoethanol) (Invitrogen, Carlsbad,
CA). Samples were incubated at 74oC for 10 minutes before loading on the gels which
were run at 200 volts for one hour and stained with Colloidal Blue (Invitrogen, Carlsbad,
CA) or electroblotted onto polyvinylidene fluoride (PVDF) membrane (Millipore,
Billerica, MA) by applying 30 volts for one hour and stained with Colloidal Blue. Each
band was excised and the first ten amino acids in the N-terminal were sequenced by
Edman degradation with an Applied Biosystems 494 Procise automated sequencer. Nterminal sequencing was performed by the University of Nebraska Medical Center’s
Protein Structure Core Facility.
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Chromogenic activity assay
The activity of rFXIII was determined using a Pefakit® Factor XIII Incorporation
Assay (Pentapharm, CT) by comparing rFXIII to a plasma-derived reference FXIII
(Enzyme Research Laboratories, South Bend, IN). rFXIII was diluted to 0.055, 0.55, 5.5,
55 and 550 ng/ml with Tris buffered saline included in the kit. FXIII is activated to
FXIIIa by thrombin in wells coated with fibrinogen in the presence of 5biotinamidopentylamin (BAPA).

FXIIIa crosslinks BAPA to fibrin(ogen) which is

subsequently bound by streptavidine-alkaline phosphatase conjugate (Strept-AP).
Finally, addition of alkaline phosphatase produces p-nitrophenol and phosphate from pnitro phenyl phosphate (pNPP) which can be detected at 405 nm.
FXIIIa crosslinking ability
The ability of the recombinant FXIII to catalyze γ-γ crosslinking of fibrinogen
and fibrin was analyzed by a similar procedure previously described.122 Briefly, rFI
(final concentration: 0.38 mg/ml) was incubated with pdFXIII or rFXIII (final
concentration: 0.01 mg/ml) and pdFIIa (5 U/ml) in Ringers solution (155 mM NaCl, 5
mM KCl, 2 mM CaCl2, 1 mM MgCl2) for 0, 5, 15, 30 and 60 minutes at 37oC. rFI was
also incubated with pdFIIa without FXIII. Crosslinking of fibrinogen was also tested by
incubating rFI (0.38 mg/ml) and rFXIIIa (0.014 mg/ml) in Ringers solution for 0, 5, 15,
30, 60, 120 and 240 minutes. The reactions were halted by the addition of NuPage®
Sample Reducing Buffer (β-mercaptoethanol) (Invitrogen, Carlsbad, CA) and NuPage®
LDS buffer and incubation at 74oC for 10 minutes. For the zero time point, the reaction
buffers were added immediately after the addition of thrombin. Crosslinking was studied
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by reducing SDS-PAGE (12% Bis-Tris NuPAGE) which were run at 200 volts for one
hour and stained with Colloidal Blue (Invitrogen, Carlsbad, CA).
The ability of FXIIIa to covalently crosslink α2-antiplasmin (A2AP) to rFI was
analyzed by SDS-PAGE and immunoblot. rFI (0.38 mg/ml) was incubated with rFXIIIa
(98 U/ml, 0.014 mg/ml) in the presence and absence of A2AP (0.51 mg/ml, 1 mol A2AP
per mol rFI) in Ringers solution (155 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2)
for 90 minutes at 37oC. The crosslinking reaction was halted by the addition of NuPage®
Sample Reducing Buffer (β-mercaptoethanol) (Invitrogen, Carlsbad, CA) and NuPage®
LDS buffer and incubation at 74oC for 10 minutes. Crosslinking was studied by reducing
SDS-PAGE (4-12% Bis-Tris NuPAGE) stained with Colloidal Blue (Invitrogen,
Carlsbad, CA) and immunoblot with an anti-A2AP antibody (US Biologicals,
Swampscott, MA).
Clot formation by thromboelastography
The ability of the recombinant FXIII to catalyze crosslinks and thereby increasing
clot stiffness was evaluated by thromboelastography (TEG) which was performed on
solutions containing purified rFXIII, rFI and pdFIIa with a Thromboelastograph® (TEG®)
Hemostasis System 5000 series (Haemoscope Corp., Niles, IL). Clotting strength and
kinetics of purified rFXIII with rFI and pdFIIa were evaluated. rFI (final concentration:
8.56 mg/ml) was transferred to a single-use TEG cup maintained at 37oC by the
instrument. rFXIII (final concentration: 2,429 U/ml, 0.35 mg/ml) was added. CaCl2
(final concentration: 11 mM) and Ringers solution (155 mM NaCl, 5 mM KCl, 2 mM
CaCl2, 1 mM MgCl2, added to standardize volume in cup) was added followed quickly by
pdFIIa (final concentration: 52.8 U/ml) to initiate clot formation. Data were collected
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every five seconds for 30 minutes by the TEG interfaced with a computer. The TEG
Analytical Software (version 4.2.2, Haemoscope, Niles, IL) collected the time to clot
initiation (R), the time to achieve a clot firmness of 20mm (K) and the maximal clot
strength (MA). The instrument was calibrated each day of use. Each sample was run in
triplicate so means and standard deviations could be calculated. The data was exported
and analyzed in Microsoft® Excel.

Results
rFI and pdFIIa characterization
SDS-PAGE and immunoblots indicated rFI had a purity of greater than 98% (data
not shown). The pdFIIa prepared by citrate activation was comprised of α-thrombin and
fragments as per SDS-PAGE. Chromogenic assay yielded a specific activity of 528 U
per mg.
Expression and purification of rFXIII
DNA sequencing indicated that the gene of the FXIII A-chain was successfully
inserted into the cassette prior to transformation into Pichia pastoris.

Clones had

between one and five gene copies. rFXIII was produced at greater than 0.24 mg per gram
of cell mass by clones with four gene copies. rFXIII was located in the cell inclusion
body and could be successfully extracted and purified by His-tag with affinity
chromatography. Typical purification products are shown in Figure 3.4. When grown in
a flask, the yeast produced a 36 kDa protein that is also purified (Figure 3.4, lane 9);
however, this protein did not alter rFXIII’s activity and could be removed by size
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exclusion chromatography. This protein was not present when the yeast was grown in a
fermentor (data not shown) yielding a greater than 98% purity. The final yield following
purification, dialysis and concentration steps were approximately 0.24 mg rFXIII per
gram cell paste.
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Figure 3.4. Purification of rFXIII as analyzed by reducing SDS-PAGE and immunoblot. SDSPAGE (A) and immunoblot (B) under reducing conditions. Lane 1: molecular weight marker. Lanes
2, 3 and 4: 0.5, 1, and 2 µg purified rFXIII. Lane 5: cell lysate. Lane 6: loading flow through. Lanes 7
and 8: wash 1 and 2. Lane 9: elution. Lane 10: bovine serum albumin.

Comparison of pdFXIII and rFXIII by SDS-PAGE and western blot
The rFXIII A-chain is almost identical to the A-chain of plasma-derived FXIII
(pdFXIIIA) by SDS-PAGE analysis. Under nonreducing (Figure 3.5A) and reducing
(Figure 3.5B) conditions, rFXIII is at the same molecular weight (~82,000 Da) as
pdFXIIIA.

pdFXIII also has a B-chain that is visible at a molecular weight of

approximately 60 kDa under nonreducing conditions but is approximately 80 kDa under
reducing conditions due to the numerous disulfide bridges.
expressed in the yeast.

Only the A-chain is
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Figure 3.5. Plasma-derived and recombinant Factor XIII by SDSPAGE. SDS-PAGE gels under nonreducing (A) and reducing (B)
conditions. Lane 1: molecular weight marker. Lane 2: pdFXIII. Lanes 3:
rFXIII.

Molecular weight estimates of expressed protein
The recombinant protein expressed by the yeast should be FXIII with the His-tag
designed into the gene and the myc epitope and His-tag from the yeast vector (Figure
3.3). When the activation peptide of FXIII is cleaved by thrombin, the resulting protein
should contain FXIIIa with the myc epitope and His-tag from the yeast vector. The
molecular weights of these two products were calculated based on the amino acid
sequence8 and molecular weights of the amino acids (Table 3.3). The expressed rFXIII
should have an approximate molecular weight of 85 kDa. The pPICZA vector does not
contain any known thrombin cleavage sites; therefore, once cleaved by thrombin, the
molecular weight should drop to 82 kDa.
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Table 3.3. Molecular weight estimations of expressed rFXIII and rFXIIIa.
Molar
rFXIIIa without
myc epitope
Amino Acids
Mass
rFXIII*
rFXIIIa*
myc epitope +
+ His-tag
(g/mol)
His-tag
Alanine
71.08
38
34
1
33
Arginine
156.19
45
41
0
41
Asparagine
114.10
41
38
1
37
Aspartic Acid
115.09
49
47
2
45
Cysteine
103.14
9
9
0
9
Glutamic Acid
129.12
52
49
3
46
Glutamine
128.13
27
26
1
25
Glycine
57.05
50
47
0
47
Histidine
137.14
20
20
6
14
Isoleucine
113.16
39
39
1
38
Leucine
113.16
50
48
2
46
Lysine
128.17
39
39
1
38
Methionine
131.20
18
18
0
18
Phenylalanine
147.18
32
31
0
31
Proline
97.12
33
29
0
29
Serine
87.08
48
45
2
43
Threonine
101.11
45
42
0
42
Tryptophan
186.21
15
15
0
15
Tyrosine
163.18
29
29
0
29
Valine
99.13
72
68
1
67
Estimated Molecular
85,483
81,591
2,495
79,097
Weights (Da)
* The expressed rFXIII should contain two His-tags and the myc epitope. rFXIIIa should contain one Histag and the myc epitope.

Aggregation/molecular weight analysis (SDS-PAGE, DLS, AUC, SEC)
SDS-PAGE, dynamic light scattering (DLS), analytical ultracentrifuge (AUC)
sedimentation equilibrium and size exclusion chromatography were utilized to identify
different molecular weight species of rFXIII in solution (Table 3.3). Dynamic light
scattering indicated that rFXIII existed in solution as a single molecular weight species
with a mean molecular weight estimate of 228.75 ± 18.39 kDa for rFXIII compared to
381.20 ± 110.63 for pdFXIII. Analytical ultracentrifuge estimated FXIII in solution at
241.0 ± 48.6 kDa. SDS-PAGE and SEC suggested rFXIII exists primarily as a monomer
with some aggregates (Table 3.4). SDS-PAGE shows rFXIII with a molecular weight of
approximately 80 and 160 kDa (Figure 3.4B, Lanes 2, 3 and 4).
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Table 3.4. Molecular weight estimates of rFXIII in solution by multiple techniques.
Estimated MW
Mean ± Standard
Technique
Primary Species
Secondary Species
Deviation
(kDa)
SDS-PAGE
~80 and ~160
Monomer
Dimer
Dynamic Light Scattering

229 ± 18

Trimer

Analytical Ultracentrifuge

241 ± 49

Trimer

58, 183, 255, 365

Monomer

Size Exclusion Chromatography

Trimer, Tetramer,
Hexamer

The retention time of rFXIII in a size exclusion column was compared to
retention times of three proteins with known molecular weights:

BSA (~66 kDa

monomer), IgG (~150 kDa) and IgA (~300 kDa) (Figure 3.6). IgA (blue) yielded a single
peak while IgG (green) yielded one primary peak and two small peaks. BSA (black)
yielded a primary monomer peak and a secondary peak which appears to be aggregation
of two molecules. The retention times of the primary peaks of BSA, IgG and IgA were
plotted against their molecular weights and a linear trend line (R2 = 0.9992) was fit.
rFXIII molecular weights estimated from resultant retention times of peaks seen in the
SEC tracing (Figure 3.6 inset) were calculated using the equation for the trend line. SEC
suggests multiple molecular weights. 61.0% of the rFXIII exited the column at 18.10
minutes (~58 kDa), 36.6% at 15.28 minutes (~183 kDa), 1.7% at 13.68 minutes (~255
kDa) and 0.7% at 11.22 minutes (~365 kDa).
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~252 kDa
~180 kDa

mAU

~363 kDa

~53 kDa

minutes
Figure 3.6. Overlaid tracing of proteins analyzed by size exclusion chromatography and
individual tracing of rFXIII (insert). BSA (~66 kDa monomer, black), IgG (~150 kDa, green)
and IgA (~300 kDa, blue) were passed through an SEC column to yield tracings of known
molecular weights. rFXIII was then passed through the column (red) and estimated molecular
weights calculated from a linear trend line (R2 = 0.9992) produced with results from the known
samples.

Activation and inactivation of rFXIII by thrombin
The activation and inactivation of rFXIII by thrombin was evaluated by SDSPAGE by a similar procedure previously described and yielded similar results (Figure
3.7).111

Before being treated with rFIIa, rFXIII consisted of a single band at

approximately 82 kDa. Within five minutes of incubation with thrombin, a second band
appears with a molecular weight approximately 3 kDa lower than the original band. By
15 minutes, a majority of the protein is approximately 79 kDa; however, very little has
been inactivated. Between 30 and 360 minutes incubation, the protein is degraded into
two fragments visible at approximately 25 and 54 kDa.
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Figure 3.7. Recombinant Factor XIII cleavage by thrombin.
SDS-PAGE gel analysis of rFXIII (0.67 mg/ml) and rFIIa (60
IU/ml) under reducing conditions. Lane 1: molecular weight
marker; Lanes 2 through 9: Time periods 0, 5, 15, 30, 60, 120, 240
and 360 minutes. Lane 10: rFIIa.

The N-terminal amino acids of the bands at ~82, ~79, ~54 and ~25 kDa were sequenced
(Table 3.5 and Figure 3.8). The first 10 residues of the bands at approximately 54 and 79
kDa are consistent with the primary FIIa cleavage site that yields FXIIIa and the first
fragment. The first 10 residues of the 25 kDa band is consistent with the second FIIa
cleavage site. N-terminal amino acid sequence analysis of the 82 kDa band, however,
indicates the presence of multiple proteins. The most abundant protein in that band has a
10 residue sequence consistent with FXIIIa. The other possible sequences do not match
the zymogen or any other expected sequence.
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Table 3.5. N-terminal amino acid sequences of purified FXIII expressed by yeast.
Approximate Molecular
Amino Acid
Weight by SDS-PAGE
Identity
Sequence
(kDa)
~82
GVNLQEFLNVTI
FXIIIa + c-myc epitope and His tag?
~79

GVNLQEFLNV

FXIIIa

~54

GVNLQEFLNV

FXIIIa N-terminal after FIIa clip (K513-S514)

~25

SPSNVDMXFE

FXIIIa C-terminal after FIIa clip (K513-S514)

A
4 kDa

~79 kDa

B
~79 kDa

C
~54 kDa

~25 kDa

Figure 3.8. Linear model of the expected and actual molecules expressed by
yeast and the subsequent degradation products. Schematic of the expected
FXIII expressed by yeast (A), FXIIIa molecule purified from yeast (B), and
degradation products of FXIIIa (C). FXIII is composed of an activation peptide
(green) and the remainder of the molecule (blue) which is designated FXIIIa in the
absence of the activation peptide. His-tags are designated in yellow and the c-myc
epitope in grey. The known thrombin cleavage sites are indicated by red arrows
and the suspected site by a black arrow.

Chromogenic activity assay
The activity of rFXIIIa was determined using a Pefakit® Factor XIII Incorporation
Assay. The activity of rFXIIIa purified within two months of the activity test yielded a
specific activity of 6,940 ± 2,272 U/mg.
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γ-γ crosslinking of fibrin(ogen) by FXIIIa
γ-γ crosslinking of fibrinogen by FXIIIa was analyzed by SDS-PAGE as
previously described.122 γ-chain dimers begin forming within a couple of seconds when
catalyzed by either pdFXIII (Figure 3.9A) or rFXIIIa (Figure 3.9B). After 5 minutes, a
majority of the γ-chains were crosslinked and the remaining chains were slowly
converted to γ-γ dimers over the next 55 minutes. pdFXIII and rFXIIIa catalyze the
formation of γ-γ dimers at similar rates as seen by the disappearance of the monomer and
appearance of the dimer. The α-chain monomer is also disappearing for both samples
resulting in higher molecular weight bands. γ-γ dimers were not formed when pdFXIII or
rFXIIIa were added (Figure 3.9A and B, lane 8). When rFI and rFXIIIa are incubated in
the absence of thrombin, γ-γ crosslinking is visible within seconds (Figure 3.9C, lane 3).
Over the following 60 minutes, the α- (~67 kDa) and γ-chains (~47 kDa) gradually
decrease while the band at ~94 kDa and smearing at the top of the wells darken.
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Figure 3.9. Ability of rFXIIIa to crosslink fibrin and fibrinogen γ-chain by reducing SDS-PAGE.
Formation of fibrin γ-chain crosslinks was analyzed by SDS-PAGE gels under reducing conditions for
clots created with rFI, pdFIIa and pdFXIII (A), rFI, pdFIIa and rFXIIIa (B), and rFI and rFXIIIa in the
absence of thrombin (C). Lane 1: molecular weight marker. Lane 2: rFI sample prior to incubation
with FXIII and pdFIIa. For panels A and B, Lanes 3 through 7: rFI, FXIII and pdFIIa incubated for 2
seconds, 5, 15, 30 and 60 minutes. Lane 8: rFI incubated with pdFIIa for 60 minutes. Lane 9: FXIII
sample prior to incubation with rFI and pdFIIa. Lane 10: pdFIIa sample prior to incubation with FXIII
and rFI. For panel C, Lanes 3 through 9: rFI and rFXIIIa incubated for 2 seconds, 5, 15, 30, 60, 120
and 240 minutes. Lane 10: FXIII sample prior to incubation with rFI and pdFIIa.

The ability of rFXIIIa to covalently crosslink α2-antiplasmin (A2AP) to rFI was
analyzed by SDS-PAGE and immunoblot (Figure 3.10). rFI incubated with A2AP in the
absence of rFXIIIa have multiple bands all below approximately 70 kDa (Figure 3.10A,
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lane 7) with the A2AP band at ~62 kDa (Figure 3.10B, lane 7). When rFI is incubated
with rFXIIIa in the presence or absence of A2AP, bands appear above 70 kDa (Figure
3.10A, lanes 8 and 9, respectively). Incubation of rFI with rFXIIIa and A2AP results in
multiple A2AP bands (Figure 3.10A, lane 9). The largest band is at approximately 62
kDa followed by bands at ~130 and ~200 kDa indicating A2AP crosslinking to
fibrinogen’s α-chain and α-α crosslinking.
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Figure 3.10. Ability of rFXIIIa to covalently crosslink A2AP to rFI by SDS-PAGE and immunoblot.
The ability of A2AP to covalently bind to rFI was analyzed by SDS-PAGE (A) and an anti-A2AP
immunoblot (B). Lane 1: molecular weight marker. Lanes 2, 3 and 4: 0.5, 1.0 and 1.5 µg A2AP,
respectively. Lane 5: rFI. Lane 6: rFXIIIa. Lane 7: rFI incubated with A2AP. Lane 8: rFI incubated with
rFXIIIa. Lane 9: rFI incubated with rFXIIIa and A2AP.

Clot formation by thromboelastography
The role FXIII plays in clot formation was evaluated by thromboelastography
(TEG) (Figure 3.11). The kinetics and strength of polymerized fibrin formed by rFI and
rFIIa were measured when in the presence or absence of rFXIII. The time to clot
initiation of rFI treated with rFIIa in the absence of rFXIII was 21.7 ± 2.9 seconds
compared to 18.3 ± 5.8 seconds in the presence of rFXIII.

Maximal clot strength

increased from 1,345.2 ± 298.2 to 8,637.3 ± 867.2 dynes/sec when rFXIII is added.
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Figure 3.11. Analysis of the effect of rFXIIIa on clot strength by thromboelastography. TEG
monitored the change in clot strength over time of recombinant fibrinogen (8.56 mg/ml) activated by
recombinant thrombin (52.8 U/ml) with (blue) and without (red) rFXIII (0.35 mg/ml). Data are
expressed as mean +/- standard deviation.

Discussion
Pichia pastoris is widely used to produce recombinant proteins for research and
medical purposes because it can be cultivated to high density and efficiently secrete
protein.123, 124 The FXIII A-chain does not exhibit glycosylation; therefore, differences in
glycosylation between mammalian cells and yeast is not a concern.125 Consequently, this
production system was selected as a possibility to produce abundant quantities of FXIII
for use as therapeutics.
Initially, the gene to the A-chain of FXIII (FXIIIA) was inserted into yeast in a
vector designed to secrete the recombinant protein into the culture medium. Numerous
researchers have successfully used the same α-factor secretion signal from
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Saccharomyces cerevisiae to secrete recombinant proteins from Pichia pastoris.126-128
FXIII was expressed by the yeast but not secreted. This may indicate that the protein was
not folded properly by the endoplasmic reticulum (ER).127, 129, 130 Consequently, FXIIIA
gene was inserted into a vector for intracellular expression. The PCR amplified DNA
indicated that the full and unmutated FXIIIA gene was present when inserted into the
yeast.
Initial analyses of the expressed and purified protein were consistent with
naturally occurring inactivate FXIII. The molecular weight of the expressed protein was
approximately 82 kDa; however, N-terminal sequencing identified this band as the
activated enzyme: FXIIIa. Molecular weight estimates of the protein that should have
been expressed and its active form support the identification of the purified protein as
FXIIIa. The yeast should have expressed rFXIII at a molecular weight of approximately
85 kDa because of the inclusion of the myc epitope and His-tag attached by the yeast
vector (Table 3.3). 82 kDa is consistent with the estimate of rFXIIIa with the added
peptides. When activated by thrombin, the 85 kDa protein should have become ~82 kDa.
Instead, the yeast expressed an 82 kDa which dropped to 79 kDa when cleaved by
thrombin. 79 kDa is consistent with rFXIIIa after the removal of the myc epitope and
His-tag.

N-terminal sequencing identified both bands as FXIIIa.

This was further

supported by rFXIIIa’s rapid crosslinking of fibrinogen’s γ-chains (Figure 3.9C). While
FXIII and FXIIIa both yield γ-γ and α-α crosslinks, FXIIIa crosslinks at a faster rate131
more consistent with our results. The high specific activity of rFXIIIa of almost 7,000
U/mg compared to the activity of pdFXIII of approximately 50 U/mg also supports the
data indicating that the active form of rFXIII is the protein purified from the yeast.
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The yeast most likely expresses FXIII which is cleaved by a protease in the cell to
FXIIIa. The protease is extremely efficient. Although multiple proteins were detected
during N-terminal sequencing of the 82 kDa band, the primary sequence was FXIIIa.
The tentative secondary sequence did not correspond to FXIII or any other expected
sequence. The cleavage site to remove the activation peptide from FXIII to produce
FXIIIa is a thrombin site as is the degradation site at K513-S514. While the activation
peptide appears to be removed from a vast majority of the FXIII molecules, none have
been degraded into the 54 and 25 kDa fragments. The protein purified from yeast cell
lysate has a molecular weight of approximately 82 kDa which consists of the 79 kDa
FXIIIa, the 1 kDa His-tag and the 1.2 kDa c-myc epitope. Since N-terminal sequencing
indicates that the band at 79 kDa is the same as that of the 82 kDa band, it appears that
the His-tag and c-myc epitope are cleaved very rapidly when incubated with thrombin
leaving only FXIIIa; however, there is no known thrombin cleavage site. Despite the
presence of the extra peptide region on the C-terminal, FXIIIa is active and functional
when not treated with thrombin.
While pdFXIII exists as a heterotetramer in plasma and homodimer in platelets,24
rFXIII produced in Saccharomyces cerevisiae was secreted and maintained as a dimer.111
While SDS-PAGE and size exclusion chromatography indicate that rFXIIIa expressed in
Pichia pastoris primarily exists as a monomer with small amounts of aggregates,
dynamic light scattering and analytical ultracentrifuge indicate the existence of a trimer
(Table 3.4).

The harsh conditions of SDS and mechanical stress of size exclusion

chromatography appears to disrupt rFXIIIa aggregation; therefore, dynamic light
scattering and analytical ultracentrifuge, which analyze aggregation without significant

92
disturbance of the solution, may provide more accurate estimates of molecular weight
species. Dynamic light scattering yielded a molecular weight estimate of approximately
381 kDa for pdFXIII which is consistent with the heterotetramer in plasma from which
the reference material was derived. rFXIIIa purified from yeast does not appear to exist
as a homodimer as is seen under natural conditions. This could be related to the buffer
composition or improper folding which has been shown to result in abnormal aggregation
due to hydrophobic interactions.132
When incubated with thrombin, rFXIIIa expressed and purified from Pichia
pastoris was cleaved at K513-S514 yielding fragments of approximately 25 and 54 kDa.
N-terminal sequences of these two degradation bands is consistent with the second
thrombin cleavage site observed for plasma-derived FXIIIa.8 These results were similar
to those seen with a rFXIII produced in Saccharomyces cerevisiae that is currently in
clinical trials.115, 117
rFXIIIa expressed by yeast was functionally active.

rFXIIIa successfully

catalyzed γ-dimer formation when incubated with rFI (Figure 3.9C) or fibrin (Figure
3.9B). It was also able to covalently bind A2AP to rFI (Figure 3.10). Previous research
has shown that FXIII is critical for the formation of a strong, elastic clot in whole blood,
platelet rich and platelet poor plasma by thromboelastography.4, 116 rFXIIIa produced in
the yeast significantly increased clot strength compared to rFI and rFIIa alone.
The production of rFXIIIa rather than FXIII may be beneficial for therapeutic
uses. Expression of the A-chain alone is beneficial because it significantly increases its
rate of activation by eliminating the rate limiting dissociation of the B-chain.40,

46-49

Unlike the rFXIII produced in Saccharomyces cerevisiae, our rFXIIIa is already in active
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form with a high specific activity of 6,940 ± 2,272 U/mg. Consequently, it does not need
to be activated by thrombin before achieving optimal crosslinking potential. This could
be beneficial for certain therapies such as a component for fibrin sealants because FXIIIa
immediately begins crosslinking fibrin.
This research characterized rFXIII expressed in Pichia pastoris. Rather than
producing FXIII, N-terminal sequencing indicated that the yeast expressed the active
FXIIIa. This recombinant protein was produced at approximately 0.24 mg per gram of
cell mass and purified by His-tag affinity chromatography. While SDS-PAGE and size
exclusion chromatography indicate that FXIIIa primarily exists in monomer form with
small amounts of aggregates, dynamic light scattering and analytical ultracentrifuge point
toward FXIIIa in trimer form in solution. The expressed FXIIIa had a molecular weight
of approximately 82 kDa but is rapidly cleaved by thrombin to the expected 79 kDa.
After further incubation, thrombin proteolyzed the expressed FXIIIa into two bands at 25
and 54 kDa which is identical to degradation products of plasma-derived material. The
recombinant FXIIIa had a specific activity of almost 7,000 U/mg and successfully
crosslinked γ-chains of fibrin(ogen) and A2AP to fibrinogen.

rFXIIIa significantly

increased clot strength. These results indicate that rFXIIIa expressed in Pichia pastoris
closely mimic plasma-derived FXIII and may be a good alternative for therapeutic uses;
however, further research will further elucidate the efficacy of rFXIIIa as a therapeutic.
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Abstract
To meet future demands for hemostatic therapies, liquid fibrin sealants (LFS) will
likely include recombinant human fibrinogen (rFI) and recombinant human Factor XIII
(rFXIII). The research described here optimizes the components of a LFS containing rFI
produced in the milk of transgenic cows, active rFXIII (rFXIIIa) expressed in genetically
engineered Pichia pastoris, plasma-derived thrombin (pdFIIa) and CaCl2.

Each

component was optimized individually while maintaining the levels of other ingredients.
The optimal concentration of rFXIIIa and CaCl2 were selected to provide the highest
viscoelastic strength. The optimal level of thrombin was selected to provide the fastest
initiation of clot formation and clotting kinetics. rFI concentrations were selected to
provide the necessary clot strength while minimizing material used. The molecular
behavior of rFI with rFXIIIa catalyzed by FIIa was similar to the respective human
plasma analogues as judged by molecular weight changes by SDS-PAGE, polymerization
kinetics by turbidity, and formation of γ-γ chain crosslinked fibrin. rFXIIIa to rFI ratios
greater than 0.15 yield maximal clot strength. FIIa to rFI ratios greater than 0.09 yield
the fastest clot onset time and 0.14 ratio yields the greatest clot strength. rFXIIIa and
FIIa ratios to FI of 0.16 and 0.18, respectively, were selected for the optimal LFS for
future research. Fibrin clots made with rFI, rFXIII and FIIa yielded 5.0-fold greater shear
elastic modulus strength than clots formed from NHB alone. The addition of rFXIIIa
significantly increased clot strength thereby reducing the amount of FI need in the LFS.
The clotting kinetics and viscoelastic strength of our optimized LFS was equivalent to
those of a commercially available LFS; however, it uses approximately 75% less
fibrinogen and thrombin. These results suggest that rFI and rFXIII in combination with
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FIIa can be combined to create a LFS with equivalent or better kinetic and viscoelastic
properties as currently available products.
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Introduction
Trauma deaths are a result of hemorrhage in 37% of civilians1 and 47% military
personnel2 and are the primary cause of death for individuals under 44 years of age.3
For the past 2000 years, the same techniques have been used to stop hemorrhage:
packing with gauze, direct pressure and tourniquet.4 This method is inadequate for
treating severe hemorrhage.

The Department of Defense Combat Casualty Care

Research Program is focused on developing more effective options for treating
hemorrhage.5
Several hemostatic products are currently used or under development.
Cyanoacrylates are utilized as hemostatic aides in oral surgery but can cause
inflammation and necrosis.6 Gelatin-resorcinol-formaldehyde (GRF) glue is frequently
used as a sealant and yields excellent tensile strength but has less clotting ability,
inferior clots to other sealants and results in fibroblast infiltration.7 QuikClot speeds
clot formation by creating an exothermic reaction when absorbing water; however, it is
not biodegradable requiring its removal post-treatment.8, 9 Compared to other treatment
options, fibrin sealants (FS), also known as fibrin glues, are viewed as the best sealant10
because they are biocompatible,6, 11, 12 biodegradable6 and safe11 and are not linked to
excessive inflammation, immune responses or necrosis.6, 12 Because they mimic natural
clotting mechanisms, FS provide similar functions as endogenous components: creating
hemostatic clots13 and providing a scaffold for cellular infiltration needed to regenerate
tissue13, 14 and dissolve the clot.13
FS reproduce the final stage of the clotting cascade to assist in hemostasis.
Fibrin sealants contain fibrinogen (FI), thrombin (FIIa) and calcium chloride and on
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occasion Factor XIII (FXIII) which are the elements in the last step of the cascade
required to produce a fibrin clot.

When applied to a wound, these exogenous

components can assist the same endogenous proteins in achieving hemostasis. FIIa
catalyzes the conversion of FI to soluble fibrin monomer and FXIII to activated FXIII
(FXIIIa).15-18 FXIIIa then catalyzes the formation of the cross-linked, insoluble fibrin
clot that is melded with the platelet-based, primary hemostatic plug.17, 19-21 In addition
to binding other fibrin molecules and creating the fibrin clot, fibrin adheres the clot to
the wound by binding to collagen exposed at the site of tissue injury in addition to
platelets, endothelial and other cells.11
Fibrin has been utilized for 100 years for numerous biomedical therapies but
was first used as an adhesive with addition of bovine thrombin11 in the early 1940s for
skin grafts for burn patients.22 Unfortunately, the fibrin glue was a source of infection22
and failed to provide the necessary strength required to maintain its function until tissue
repair11 resulting in a loss of interest in FS as treatment options for hemorrhage. In the
early 1970s, researchers again began refining FS.11

Today, multiple products are

commercially available in the United States and Europe.11 The first FS approved by the
FDA was Baxter’s Tisseel® in 1998.23 Vitagel (Orthovita) and Crosseal (Johnson &
Johnson) were subsequently approved in 2000 and 2003, respectively.23 All of these
products use plasma-derived proteins. Tisseel,® like most FS,11 is a two-component
system: one containing FI and plasminolysis inhibitor and the second containing human
thrombin and calcium chloride.
FS are used as hemostatic agents,23 matrices for wound healing,12, 23 adherents
for tissues23 and drug deliveries23 in a variety of settings (Figure 4.1). With respect to
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hemostasis, FS can be used alone or in combination with a dressing to stop blood
oozing from holes, incisions and raw surfaces which cannot be stopped by suturing.7
Research indicates that liquid fibrin sealants (LFS) can be used as a drug delivery
device for high doses of antibiotics and growth factors.11,

24

Historically, FS were

primarily used in trauma situations24 and during cardiac7, 24 and vascular surgeries24 but
are now frequently used in general surgery.11,

25

FS has been shown to be useful in

various surgical settings including cardiovascular,11,
plastic,11,

30

26

vascular,27 thoracic,28,

reconstructive,31 oncologic,23 ophthalmologic,23 dental,23 orthopedic,11,

29

23

hepatic7 and urologic surgeries,32, 33 microsurgical procedures11 and neurosurgery.11, 34,
35

The use of FS has been shown to reduce blood loss,23,

36

fluid loss,23 transfusion

occurrence,37 operative time,36 mortality,36 hospital stay24 and treatment costs.23

Fibrin Sealant

Hemostasic
Agent

Trauma, cardiovascular

surgery, vascular
surgery ...

Tissue
Engineering

Scaffold for
wound/bone
repair

Tissue
Adherence

Suture support,
anastomotic sealing,
endothelialization,
pneumostasis, fluid
reduction ...

Drug Delivery

Antibiotics, growth
factors,
chemotherapeutic agents,
local anesthetics

Figure 4.1. Uses for fibrin sealant. Based on the schematic published by Spotnitz and Prabhu. 23

Despite its usefulness, FS have drawbacks. Current FS are relatively expensive.
For example, Tisseel® is over $130 per ml FI36 which makes it economically infeasible
for use as a dressing coating or for widespread use in the field. In addition, commercial
sealants use plasma-derived materials. In 1978, the Food and Drug Administration
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(FDA) suspended the use of fibrin sealants due to contamination with hepatitis.38
Treatments have been developed to minimized viral contaminants;24 however, there is
still some concern of contamination with viruses or prions able to withstand current
treatments.6,

23

For example, human parovirus B19 is not killed by current

pasteurization processes.23 Tisseel, Crosseal and Vitagel, the three FDA approved
fibrin sealants, and frequently used “home-made” fibrin sealants each have their own
issues. Vitagel23 and the home-made FS prepared by some medical centers use bovine
thrombin.24
responses.23,

Although relatively rare, bovine proteins in FS can initiate immune
24

While Crosseal contains only human proteins, it contains tranexamic

acid which has been linked to severe reactions that contraindicate its use when it may
come in contact with dura matter or cerebral spinal fluid.23, 39 Consequently, a safer,
more abundant source of material for FS is needed.
The objective of this chapter is three-fold: (1) characterize the importance of
FXIII in LFS; (2) optimize the concentrations of each LFS component to create the
strongest clot in the fastest time; and (3) compare recombinant human fibrinogen-based
to commercially available plasma-derived human fibrinogen-based LFS.

Due to

limitations in the availability of cost effective, safe supplies from human plasma, future
FS will be more often derived from recombinant technology which can produce
products more economically and in abundance.40-45 This study utilizes recombinant
human fibrinogen (rFI) purified from the milk of cloned, transgenic cows and
recombinant human activate factor XIII (rFXIIIa) expressed in yeast. Initial studies
used pdFIIa; however, final experiments utilized rFIIa from CHO cells. Experiments
were designed to evaluate the role of FXIII in FS. Most FS on the market contain FI
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and FIIa in similar amounts; however, FXIII content ranges.46 The ratio of FXIII to FI
in human plasma is approximately 0.4 U/mg; however, some commercial products
contain no FXIII or 0.1 U/mg except for Beriplast P which contains approximately 0.44
to 0.89 U/mg.46 We vary FXIII activity from 0 to 274 U rFXIIIa per mg FI. In addition
to testing the efficacy of our recombinant proteins and importance of FXIII in FS, the
ratios of components have never been optimized with the availability of highly active
FXIIIa. This research was designed to test the hypotheses that (1) the addition of
rFXIIIa will increase clot strength thereby reducing the amount of FI need in FS; and
(2) our LFS containing optimized ratios of rFI, rFXIIIa and FIIa will yield equivalent
clot kinetics and strengths as plasma-derived LFS.

Materials and Methods
Materials
Purified, plasma-derived prothrombin was bought from Enzyme Research
Laboratories (South Bend, IN). Recombinant thrombin (Recothrom®) was purchased
from Zymogenetics. Purified recombinant fibrinogen, expressed in the milk of transgenic
Swiss Brown cows, was obtained from Pharming Group NV (Leiden, Netherlands).
Materials for the thromboelastograph were purchased from Haemoscope (Niles, IL).
Unless otherwise specified, reagents were purchased from Sigma (St. Louis, MO).
Vector construction, expression and purification of FXIIIA in Pichia pastoris
The human Ultimate ORF clone containing the human coagulation factor
FXIIIA1 cDNA in the pENTRTM221 vector was purchased from Invitrogen (Carlsbad
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CA). The following primers were used to obtain FXIIIa gene to subclone in pPICZA
intracellular

Pichia

expression

vector.

(Forward,

5'-

CCAATTGATGCATCATCATCATCATCATTCAGAAACTTCCAGGACCGC-3';
Reverse, 5'-GCGGCCGCTCACATGGAAGGTCGTCTTTGAATC-3').

The forward

primer introduced a methionine and 6 histidine amino acids at the N-terminus of mature
FXIIIa peptide. The PCR product was digested with MfeI and NotI and subcloned into
pPICZA which was digested with the same enzymes. The DNA sequence of the FXIIIA
was confirmed by sequencing the insert fragment. One of the confirming plasmid
pPICZAFXIIIa was linearized with PmeI and transformed into P. pastoris X-33 host
strain and copy number of the clones was determined as described.47 Varying copy
number clones were screened in shake flask culture to confirm intracellular production of
FXIIIa protein. The highest producing clone was scaled up to 5 L bench scale. A fedbatch fermentation protocol was followed to optimize FXIIIa production as described by
Zhang et al., (2007).48 At the end of fermentation process the cells were separated by
centrifugation (6,000g) and pellet was stored at -80oC.
Frozen cell paste was processed in 300 gram batches. Cells were lysed in three
sets of 100 gram batches. 100 grams of cell paste was resuspended in 100 ml of cold
lysis buffer (50 mM Tris-HCL, 10 mM MgSO4, 1 mM EDTA, 10 mM potassium acetate,
1 mM DTT (DL-Dithiothreitol), 2 mM PMSF (phenylmethanesulphonylfluoride) in
methanol, pH 9.5). 100 ml (250 g) of 0.5 mm glass beads (Biospec, Bartlesville, OK)
were added and the cells. Surrounded by an ice bath, cells were lysed using a BeadBeater
Blender (Biospec, Bartlesville, OK) with twenty 20 second on/off cycles. The cell lysate
mixture was then centrifuged to remove cellular debris. The lysate from 300 grams of
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cell paste was combined and purified using the HisBind Purification Kit (EMD
Chemicals, Inc., San Diego, CA) with 40 ml of resin slurry. Following purification,
rFXIII was dialyzed in 10 mM Tris-HCl, 0.1 mM EDTA, 60 µM polysorbate-20, pH 8.0
in snake-like dialysis membranes and the protein samples were filter-sterilized and
concentrated using the Amicon tubes (Millipore, Billerica, MA). The purity of the
sample was tested by SDS-PAGE (NuPAGE 12% Bis-Tris) (Invitrogen, Carlsbad, CA)
and immunoblot. The concentration of rFXIII was determined by standard Bicinconic
Acid (BCA) methods.
FIIa preparation
Frozen, plasma-derived human prothrombin (Enzyme Research Laboratories,
South Bend, IN), was thawed at 37oC. Plasma-derived thrombin (Enzyme Research
Laboratories, South Bend, IN) was added at a 1/10 mass to mass thrombin/prothrombin
ratio. 0.35 grams of sodium citrate per milliliter of solution was added (Lanchantin
1965). This solution was incubated at 37oC on a rotating mixer for five hours. Sodium
citrate was removed using PD-10 desalting columns (GE Healthcare, Giles, United
Kingdom).

Activation of prothrombin to thrombin was confirmed by reducing and

nonreducing SDS-PAGE (12% Bis-Tris NuPAGE) (Invitrogen, Carlsbad, CA) stained
with Colloidal Blue (Invitrogen, Carlsbad, CA). The concentration of the thrombin
solution was determined by standard Bicinconic Acid (BCA) methods. The specific
activity was determined by aPTT analysis.
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γ-γ crosslinking of FI by FXIIIa
γ-γ crosslinking of FI by FXIIIa was analyzed by a similar procedure previously
described.49 Briefly, rFI (final concentration: 0.38 mg/ml) was incubated with rFXIII
(final concentration: 0.01 mg/ml), pdFIIa or rFIIa (5 U/ml) in Ringer’s solution (155 mM
NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2) for 0, 5, 15, 30 and 60 minutes at 37oC.
rFI was also incubated with pdFIIa or rFIIa without rFXIII. The reactions were halted by
the addition of NuPage® Sample Reducing Buffer (β-mercaptoethanol) (Invitrogen,
Carlsbad, CA) and NuPage® LDS buffer and incubation at 74oC for 10 minutes. For the
zero time point, the reaction buffers were added immediately after the addition of
thrombin. Crosslinking was studied by reducing SDS-PAGE (12% Bis-Tris NuPAGE)
run at 200 volts for one hour and stained with Colloidal Blue (Invitrogen, Carlsbad, CA).
Thromboelastography analysis of fibrin clot formation
Clotting strength and kinetics of various tri-component mixtures of purified rFI or
plasma-derived human fibrinogen (pdFI), rFXIII and pdFIIa or rFIIa were evaluated by
thromboelastography (TEG) (Thromboelastograph® Hemostasis System 5000 series,
Haemoscope Corp., Niles, IL).

The effect of FI on clot strength and kinetics was

evaluated by maintaining rFXIII (0.35 mg/ml, 2408 U/ml) and pdFIIa (0.10 mg/ml, 52.8
U/ml) levels while varying rFI concentrations (0, 3, 6, 9, 12 and 15 mg/ml). The effect of
rFXIII on clot strength and kinetics was evaluated by maintaining FI (8.56 mg/ml) and
pdFIIa (0.10 mg/ml, 52.8 U/ml) levels while varying rFXIII concentrations (0, 0.03, 0.13,
0.23, 0.28, 0.35 and 0.42 mg/ml). The effect of pdFIIa on clot strength and kinetics was
also evaluated by maintaining FI (8.56 mg/ml) and rFXIII (0.35 mg/ml, 2408 U/ml)
levels while varying pdFIIa concentrations (0, 0.03, 0.05, 0.10, 0.15, 0.20 and 0.25
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mg/ml). For all experiments, FI then FXIII was transferred to a single-use TEG cup and
warmed to 37oC by the TEG instrument. Calcium chloride (Sigma, St. Louis, MO) was
then added to the cups and clot formation was initiated by adding pdFIIa.
Using the same method, stoichiometric molar ratio based experiments were
performed. Once the optimal ratio was established, experiments were also performed that
maintained stoichiometric molar ratios of rFXIII/rFI (0.16) and pdFIIa/rFI (0.18) while
increasing rFI concentrations (9, 12, 12.5 and 15 mg/ml) to determine the effect of
increasing FI. To determine whether the rFXIII/rFI ratio of 0.16 was optimal at a higher
rFI concentration (12.5 mg/ml), experiments were performed that maintained rFI and FIIa
(FIIa/FI = 0.18) while increasing rFXIII/FI (0.16, 0.18 and 0.20).
Clotting parameters of several tri-component solutions consisting of different
levels of rFI, pdFI (Enzyme Research, Laboratories, South Bend, IN) or pdFI (Tisseel®,
Baxter, Deerfield, IL) and rFXIII were compared to human blood. Tisseel’s sealant and
thrombin solutions were reconstituted as per manufacturer’s instructions.

Tisseel’s

overall protein concentration was determined by standard Bicinconic Acid (BCA)
methods. FI (2.9 or 8.6 mg/ml) were combined with rFXIII (0.03 or 0.35 mg/ml), pdFIIa
(52.8 U/ml) and 11 mM CaCl2 and analyzed by TEG. Fresh, normal whole human blood
(NHB) from 22 healthy, medication-free individuals, collected in tubes containing 3.2%
citrate, was obtained from Research Blood Components (Brighton, MA). 340 µl of blood
was transferred to a single-use TEG cup and warmed to 37oC by the TEG instrument. 20
µl of 200 mM CaCl2 solution was then added to the cups to initiate clotting.
The optimized rLFS was compared to the commercially available Tisseel® which
was reconstituted as per manufacturer’s instructions used as intended by mixing the
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sealant and thrombin solutions in equal proportions. 180 µl of Tisseel’s sealant, which
consists of between 67 and 106 mg/ml pdFI and 2,250 and 3,750 KIU/ml inhibitor, was
transferred to a single-use TEG cup and warmed to 37oC by the TEG instrument. 180 µl
of Tisseel’s thrombin solution, which contains 400 to 625 U/ml pdFIIa and 36 to 44 mM
CaCl2, was then added to the cups containing sealant. These results were compared to
clotting parameters obtained with combining rFI (15 mg/ml), rFXIII (0.59 mg/ml, 4,095
U/ml, rFXIII/rFI = 0.16), rFIIa (0.33 mg/ml, 176.7 U/ml, rFIIa/rFI = 0.18) and 12 mM
CaCl2 in a TEG cup as described above.
The TEG Analytical Software (version 4.2.2, Haemoscope, Niles, IL) collected
time to clot initiation (R), time to achieve a clot firmness of 20mm (K) and maximal clot
strength (MA). Results were compared by ANOVA and t test with an α of 0.05. The
instrument was calibrated each day of use. All tests described above include a minimum
of three replicate samples in each treatment group. All NHB samples were tested within
36 hours of the blood draw of each individual donor.
Clot lysis by thromboelastography
Percent lysis by added plasmin was determined by thromboelastography which
was performed on solutions containing purified rFI or pdFI, rFXIII and rFIIa with a
Thromboelastograph® (TEG®) Hemostasis System 5000 series (Haemoscope Corp.,
Niles, IL). Clotting strength and kinetics of purified rFI or pdFI with rFXIIIa and rFIIa
with added plasmin was evaluated. rFI or pdFI (final concentration: 9 mg/ml) transferred
to a single-use TEG cup maintained at 37oC by the instrument.

rFXIIIa (final

concentration: 2,429 U/ml, 0.35 mg/ml rFXIIIa/FI = 0.16) and various amounts of
plasmin (final concentrations: 0, 8.4, 17, 84 and 842 mU/ml, 0.002 to 0.216 mg/ml) were
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added. CaCl2 (final concentration: 12 mM) and Ringers solution (155 mM NaCl, 5 mM
KCl, 2 mM CaCl2, 1 mM MgCl2, added to standardize volume in cup) was added
followed quickly by pdFIIa (final concentration: 105.6 U/ml, FIIa/FI = 0.18) to initiate
clot formation. Data was collected every five seconds for 30 minutes by the TEG
interfaced with a computer. Each sample was run in triplicate so means and standard
deviations could be calculated. The data was exported and analyzed in Microsoft® Excel.

Results
rFXIIIa and pdFIIa characterization
SDS-PAGE and N-terminal sequencing indicated that the purified protein from
the yeast was rFXIIIa rather than rFXIII. These and immunoblots indicated rFXIIIa had
a purity of greater than 98% (data not shown). The Pefakit® Factor XIII Incorporation
Assay (Pentapharm, CT) yielded a specific activity of almost 7,000 U/mg for rFXIIIa.
The pdFIIa prepared by citrate activation was comprised of α-thrombin and fragments as
per SDS-PAGE (Figure 6.2A, lane 10) and chromogenic assay yielded a specific activity
of 528 U per mg.
γ-γ crosslinking of FI by FXIIIa
γ-γ crosslinking of rFI by rFXIIIa was analyzed by SDS-PAGE as previously
described.49 γ-chain dimers begin forming within a couple of seconds when rFI and
rFXIII were activated by pdFIIa (Figure 4.2A) and rFIIa (Figure 4.2B) as seen by the
disappearance of the monomer and appearance of the dimer. The α-chain monomer is
also disappearing for both rFI samples and by 5 minutes, most of the rFI α-chain
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monomer has disappeared resulting in smearing at the top of the lanes. γ-γ dimers were
not observed in the rFI sample treated with pdFIIa (Figure 4.2A, lane 8) or rFIIa (Figure
4.2B, lane 8).

A
1

B
2

188

3

4

5

6

7

8

9

1

10

2

3

4

5

6

7

8

9

10

188

98

γ-γ

98

62

α

62

49

β
γ

49

38

38

28

28

γ-γ
α
β
γ

Figure 4.2. Formation of fibrin γ-chain crosslinks as analyzed by reducing SDS-PAGE. SDS-PAGE
gels under reducing conditions. Formation of fibrin γ-chain cross-links was analyzed for clots created with
components used to optimize the LFS: rFI, rFXIII and pdFIIa (A) or rFIIa (B). Lane 1: a molecular
weight marker. Lane 2: rFI prior to incubation with rFXIII and FIIa. Lanes 3 through 7: rFI, rFXIII and
FIIa incubated for 2 seconds, 5, 15, 30 and 60 minutes. Lane 8: rFI incubated with FIIa for 60 minutes.
Lane 9: rFXIII sample prior to incubation with rFI and FIIa. Lane 10: FIIa sample prior to incubation with
rFXIII and rFI.

Thromboelastography (TEG) analysis of fibrin clot formation
The effect of increasing FI concentration was analyzed by TEG. While rFXIIIa
(0.35 mg/ml) and pdFIIa (52.8 U/ml) were held constant, rFI was increased from zero to
15 mg/ml (Figure 4.3). As expected, rFXIIIa treated with pdFIIa did not yield any
change in viscosity. Increase in rFI concentration did not greatly affect time to clot
initiation (R) which ranged from 16.67 ± 2.89 seconds for 6 and 12 mg/ml and 21.67 ±
2.89 mg/ml for 3 mg/ml rFI. Clotting kinetics were also relatively consistent for 6 (K =
51.67 ± 2.89, α = 79.83 ± 1.5), 9 (K = 50.00 ± 0, α = 81.90 ± 0.56), 12 (K = 50.00 ± 0, α
= 82.50 ± 0.69) and 15 mg/ml (K = 50.00 ± 0, α = 83.10 ± 0.50). Maximum clot strength
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increased significantly with the increase in FI concentration (p < 0.001). At 0, 3, 6, 9, 12,
and 15 mg/ml, clot strengths increased: 0 ± 0, 1,355.9 ± 556.4, 4,610.8 ± 127.9, 9,856.0 ±
1,093.0, 19,946.8 ± 2,343.3 and 25,283.2 ± 3,861.9 dynes/sec.
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Figure 4.3. Effect of increasing rFI concentration on clot parameters by thromboelastography.
Thromboelastographic data was collected on solutions containing constant concentrations of pdFIIa (52.8
U/ml) and rFXIIIa (0.35 mg/ml) with varying concentrations of rFI of 0, 3, 6, 9, 12 and 15 mg/ml. Data
were expressed as mean +/- standard deviation.

Clotting strength and kinetics of various tri-component mixtures of rFI and pdFI
(from Enzyme Research and Baxter- Tisseel®), rFXIIIa and pdFIIa at different
concentrations were evaluated by thromboelastography.

The first experiment added

variable concentrations of pdFIIa (0, 0.03, 0.05, 0.10, 0.15, 0.20, and 0.25 mg/ml) while
maintaining constant concentrations of rFI or pdFI (8.56 mg/ml) and rFXIII (0.35).
Increasing pdFIIa significantly sped clot initiation time (R) and time to clot firmness (K)
and increased clot strength (MA) for both rFI and pdFI (p < 0.001 for all) (Figure 4.4).
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At the highest pdFIIa level, time to clot initiation was equivalent for all three FI: 10.0 ± 0
seconds.
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Figure 4.4. FIIa dependent maximal clot strength (MA) and clot initiation time (R) with constant FI
and rFXIIIa. Thromboelastographic data was collected on solutions containing constant concentrations of
pdFI or rFI (8.56 mg/ml) and rFXIIIa (0.35 mg/ml, 2,408 U/ml, stoichiometric molar ratio (rFXIIIa/FI) =
0.17) with varying concentrations of added pdFIIa of 0, 0.03, 0.05, 0.10, 0.15, 0.20 and 0.25 mg/ml
(stoichiometric molar ratios: 0, 0.03, 0.06, 0.13, 0.19, 0.26 and 0.32). At the various levels of pdFIIa, pdFI
from Enzyme Research result in stronger clot strengths (red, R2 = 0.82) than pdFI (Tisseel®) from Baxter
(green, R2 = 0.83). rFI yields clot strengths lower than both pdFI samples with low pdFIIa levels but
exceeds strengths of pdFI (Tisseel®) at high levels of pdFIIa (blue, R2 = 0.96). The addition of increasing
units of pdFIIa resulted in faster clot initiation times for pdFI from Enzyme Research (orange, R2 = 0.91),
pdFI from Baxter (gray, R2 = 0.91) and rFI (pale blue, R2 = 0.91). Data were expressed as mean +/standard deviation.

The second experiment added variable concentrations of rFXIII (0, 0.03, 0.13,
0.23, 0.28, 0.35 and 0.42 mg/ml) while maintaining constant concentrations of rFI or
pdFI (8.56 mg/ml) and pdFIIa (52.8 U/ml). Increasing rFXIIIa did not greatly alter the
clot initiation time (R); however, it did significantly increase clot strength (MA) for rFI
(p < 0.001) and both pdFI samples (Tisseel p , Enzyme Research p < 0.001) (Figure 4.5).
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At the highest level of rFXIIIa, pdFI from Tisseel® yielded the lowest clot strength
(4,367.3 ± 761.8 dynes/sec), pdFI (Enzyme Research Laboratories) yielded the highest
(12,347.5 ±1,429.5 dynes/sec) and rFI fell between (6,904.8 ± 566.2 dynes/sec). Times
to clot initiation were similar for the three FI samples.
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Figure 4.5. rFXIIIa dependent maximal clot strength (MA) and clot initiation time (R) with constant
FI and pdFIIa concentrations. Thromboelastographic data was collected on solutions containing constant
concentrations of plasma-derived or recombinant fibrinogen (8.56 mg/ml) and pdFIIa (0.10 mg/ml,
stoichiometric molar ratio (FIIa/FI) = 0.13) with varying concentrations of added rFXIIIa of 0, 0.03, 0.13,
0.23, 0.28, 0.35 and 0.42 mg/ml (stoichiometric molar ratios: 0, 0.01, 0.07, 0.12, 0.14 and 0.17). At the
various levels of rFXIIIa, pdFI from Enzyme Research yielded almost two-fold greater clot strengths (red,
R2 = 0.97) than pdFI (Tisseel®) from Baxter (green, R2 = 0.74). rFI yielded clot strengths lower than both
pdFI samples with low rFXIIIa exceeds strengths of pdFI (Tisseel®) at high levels of rFXIIIa (blue, R2 =
0.96). The addition of rFXIIIa to resulted in minimal changes in clot initiation times for pdFI from Enzyme
Research (orange, R2 = 0.98), pdFI from Baxter (gray, R2 = 0.61) and rFI (pale blue, R2 = 0.82). Data were
expressed as mean +/- standard deviation.

Increasing the concentration of rFXIIIa (Figure 4.5) and FIIa (Figure 4.4) both yielded
asymptotic approaches to maximal clot strength for rFI and both FI samples. Ratios of
rFXIIIa (0.16, 0.039 mg rFXIIIa per mg FI) and FIIa (0.18, 11.7 U FIIa per mg FI) with
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respect to fibrinogen, located at the asymptote for clot strength, were selected for the
remaining experiments.
The optimal level of calcium was also determined by maintaining rFI at 15 mg/ml
and rFXIIIa and pdFIIa molar ratios to FI at 0.16 and 0.18, respectively. Calcium was
added at 0, 3, 6, 9, 11, 12 and 15 mM. Calcium concentration did not alter time to clot
initiation (R) or coagulation time (K); however, maximum clot strength was dependent
on calcium. At 0 mM CaCl2, clot strength was 3,399 dynes/sec. Maximum clot strength
was not significantly different for CaCl2 at 3 mM or greater (p = 0.876) (Figure 4.6).
Further experiments used 12 mM CaCl2.
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Figure 4.6. CaCl2 dependent maximal clot strength (MA) with constant rFI, rFXIIIa and pdFIIa
concentrations. Thromboelastographic data was collected on solutions containing constant concentrations
of rFI (15 mg/ml), rFXIIIa (0.59 mg/ml, stoichiometric molar ratio (FXIIIa/FI) = 0.16) and pdFIIa (0.33
mg/ml, stoichiometric molar ratio (FIIa/FI) = 0.18) with varying concentrations of CaCl2 of 0, 3, 6, 9, 11,
12, and 15 mM. Data were expressed as mean +/- standard deviation.

Once the optimal ratio was established, experiments were also performed to
identify whether the ratios were optimal at higher FI concentrations and whether an
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increase in rFXIIIa helped in the presence of higher rFI. The first experiment maintained
stoichiometric molar ratios of rFXIIIa/rFI (0.16) and pdFIIa/rFI (0.18) while increasing
rFI concentrations (9, 12, 12.5 and 15 mg/ml). Increasing FI resulted in an increase in
clot strength (p = 0.017); however, 15 mg/ml was not significantly greater than that of
12.5 mg/ml (p = 0.262) (Figure 4.7). Time to clot initiation was not affected.
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Figure 4.7. Effect of increasing rFI while maintaining stoichiometric molar ratios of rFXIIIa/rFI and
pdFIIa/rFI of 0.16 and 0.18, respectively. Thromboelastographic data was collected on solutions
containing increasing concentrations of rFI (9, 12, 12.5 and 15 mg/ml) while maintaining stoichiometric
molar ratios of rFXIIIa/rFI and pdFIIa/rFI at 0.16 and 0.18, respectively. Data were expressed as mean +/standard deviation.

To determine whether the rFXIIIa/rFI ratio of 0.16 was optimal at a higher rFI
concentration (12.5 mg/ml), experiments were performed that maintained rFI and FIIa
(FIIa/FI = 0.18) while increasing rFXIIIa/FI (0.16, 0.18 and 0.20). Increasing the ratio of
rFXIII/rFI did not alter clot strength (p = 0.292), kinetics (p < 0.001) or time to clot
initiation (p < 0.001) (Figure 4.8).
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Figure 4.8. Effect of increasing rFXIIIa concentration. Thromboelastographic data was collected on
solutions containing constant concentrations of rFI (12.5 mg/ml) and pdFIIa (stoichiometric molar ratio
(FIIa/FI) = 0.18) with varying stoichiometric molar ratios of rFXIIIa of 0.16, 0.18 and 0.2. Data were
expressed as mean +/- standard deviation.

Thromboelastographic properties of clots made by tri-component mixtures of rFI,
rFXIII and pdFIIa were compared to the average values (N = 22) of clots made by fresh
citrated human whole blood (Figure 4.9). Clots consisting of 8.6 mg/ml rFI, 0.35 mg/ml
rFXIIIa and 52.8 U/ml pdFIIa had maximum clot strengths 3.5 ± 0.2 -fold greater (11,550
± 560 dyne/sec) than clots formed by NHB alone (3,330 ± 810 dyne/sec). Clot onset (R)
and time to clot firmness (K) were also much faster for this tri-component mixture (R =
12 ± 3 seconds, K = 50 ± 0 seconds) than NHB (R = 412 ± 68 seconds, K = 375 ± 136
seconds). A tri-component mixture that replaced 8.6 mg/ml rFI with 8.6 mg/ml FI
(Tisseel®, Baxter) and contained equivalent amounts of rFXIIIa and pdFIIa yielded
slower clot onset time and time to clot firmness (R = 22 ± 6 seconds, K = 60 ± 17
seconds) and significantly lower clot strength (4,367 ± 762 dyne/sec) than the rFI
version.

124
80
rFI (8.6 mg/ml) + rFXIII (0.35 mg/ml) + pdFIIa (52.8 U/ml)
70

Clot Strength (mm)

60
50

pdFI (8.6 mg/ml) + rFXIII (0.35 mg/ml) + pdFIIa (52.8 U/ml)

40
30
Normal Human Whole Blood

20
10
0
0

200

400

600

800
1000
1200
1400
1600
1800
Time (sec)
Figure 4.9. Thromboelastographic properties of NHB and tri-component mixtures of rFI, pdFIIa
and rFXIIIa. Clots consisting of 8.6 mg/ml plasma-derived fibrinogen from a commercial LFS, 0.35
mg/ml rFXIII and 52.8 U/ml pdFIIa (black) have maximal clot strengths 18% greater than the average
maximal strength of clots from whole blood of 22 normal donors (red). Replacing the plasma-derived
fibrinogen with recombinant fibrinogen (blue) yielded clot strengths 67% greater than blood and 41%
greater than that of the fibrinogen from the commercially available LFS. Data were expressed as mean +/standard deviation.

Finally, the optimal fully-recombinant LFS was compared to a commercially
available pdLFS (Tisseel,® Baxter) used as intended. The fibrin sealant and thrombin
portions of Tisseel® were mixed in equal portions yielding a pdLFS containing between
67 and 106 mg/ml pdFI and 400 to 625 U/ml pdFIIa and 36 to 44 mM CaCl2. These
results were compared to clotting parameters obtained with combining rFI (15 mg/ml),
rFXIII (0.59 mg/ml, rFXIII/rFI = 0.16), rFIIa (0.33 U/ml, rFIIa/rFI = 0.18) and 12 mM
CaCl2 (Figure 4.10). The time to clot initiation (R) was slightly slower for the optimized
rLFS (10.0 ± 0 seconds) than Tisseel® (8.3 ± 2.89 seconds) (p = 0.374); however, the
time to clot firmness (K) were equivalent (50.0 ± 0 seconds). Maximum clot strengths
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were similar at 24,424.9 ± 3,821.9 and 26,374.6 ± 6,242.6 dynes/sec, respectively (p =
0.728).
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Figure 4.10. Thromboelastographic properties of the optimized tri-component rLFS and a pdLFS
(Tisseel®). Clots consisting of 15 mg/ml rFI, 0.59 mg/ml (4,095 U/ml) rFXIIIa and 0.33 mg/ml (176.7
U/ml) rFIIa (FXIIIa/FI = 0.16, FIIa/FI = 0.18) (blue) have faster clot kinetics and equivalent maximal clot
strengths as a pdLFS (Tisseel®) as prepared by its manufacturer’s instructions (red). Tisseel contains 33.5
to 53 mg/ml pdFI and 200 to 312.5 U/ml pdFIIa. Data were expressed as mean +/- standard deviation.

Clot lysis by thromboelastography
Plasminolysis of clots formed by rFI- and pdFI-based LFS were examined by
TEG. Plasmin did not greatly affect the initiation of clot onset but altered clot strength
greatly for both pdFI and rFI (Table 4.1). Addition of 8.4 and 84 U/ml plasmin to
Tisseel® results in no alteration in clotting kinetics and no lysis. Addition of 8.4 or 17
U/ml of plasmin to pdFI-based clots, resulted in a 62% and 57% decreases in maximal
clot strength (from 10,334.0 ± 3,599.3 to 3,914.1 ± 691.1 and 4,423.1 ± 450.0 dynes/sec,
respectively) with a 0 and 1.9% lysis 60 minutes after maximal clot strength was reached.
Increasing plasmin to 84 U/ml resulted in a 77% decrease (2,388.2 ± 476.1 dynes/sec)
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from the untreated sample with 8.2% lysis. Strength of rFI-based clots decreased 49%,
41%, and 92% with the addition of 8.4, 17, and 84 U/ml (from 5,632.3 ± 1,151.4 to
2,896.6 ± 729.8, 3,315.6 ± 1,682.3 and 474.4 ± 105.5 dynes/sec, respectively) with
subsequent lysis of 31.4%, 59.7% and 94.1% 60 minutes after maximal clot strength was
reached. Addition of 842 mU/ml resulted in no clot formation.
Table 4.1. Effects of plasmin on clotting parameters of Tisseel®, pdFI- and rFI-based clots by TEG.
Zero to 842 mU/ml of plasmin were added to solutions containing pdFI- (Tisseel and Enzyme Research)
and rFI-based LFS components. Values listed are means ± standard deviation.
Time to Clot
Maximal Clot
Sample
Lysis (%)
Initiation (sec)
Strength (dynes/sec)
0 mU/ml plasmin
8.3 ± 2.9
26,374.6 ± 6,242.6
0±0
Tisseel®

8.4 mU/ml plasmin

10.0 ± 0

19,381.7 ± 1,185.9

0±0

84 mU/ml plasmin

10.0 ± 0

23,486.9 ± 1,771.9

0±0

0 mU/ml plasmin

10.0 ± 0

10,334.0 ± 3,599.3

0±0

8.4 mU/ml plasmin

13.3 ± 2.9

3,914.1 ± 691.5

0±0

17 mU/ml plasmin

11.7 ± 2.9

4,423.1 ± 450.0

1.9 ± 1.8

84 mU/ml plasmin

15.0 ± 0

2,388.2 ± 476.1

8.2 ± 7.7

0 mU/ml plasmin

10.0 ± 0

5,632.3 ± 1,151.4

0±0

8.4 mU/ml plasmin

10.0 ± 0

2,896.6 ± 729.8

31.4 ± 4.8

17 mU/ml plasmin

10.0 ± 0

3,315.6 ± 1,683.2

59.7 ± 7.9

84 mU/ml plasmin

15.0 ± 3.2

474.4 ± 105.5

94.1 ± 3.6

842 mU/ml plasmin

No clot

No clot

No clot

pdFI-based LFS

rFI-based LFS

Discussion
The objective of the research presented in this chapter was to optimize the
components of and identify the importance of FXIII in a LFS. Fibrinogen is the key
factor that provides FS their adhesive6, 14, 50 and hemostatic abilities and tensile strength.14
All research concurs regarding the import of fibrinogen in FS. Our data supported earlier

127
findings that increases in fibrinogen result in stronger clots;23 however, we observed
diminishing returns while increasing FI concentration. Increasing FI from 3 to 6 mg/ml
resulted in a 2.4-fold increase in maximal clot strength; however, increasing from 12 to
15 mg/ml did not yield significantly different maximum clot strengths (p = 0.110). Thus,
the extremely high FI levels in many FS, like Tisseel® which contains up to 53 mg/ml,
may not be necessary unless the protein’s preparation lowers FI clotability.
Thrombin is also a key factor in FS.

Previous research found that FIIa

significantly increases the rate of fibrin formation14, 23, 51 and also plays a role in tensile
strength.11, 14 The ratio of FI to FIIa is important.52 Our results support these findings.
The increase of FIIa sped clot formation and kinetics and also significantly increased
maximum clot strength (Figure 4.4); however, excess FIIa can deleteriously affect
clotting. Researchers found that if FIIa is too high, inhomogeneous clots are formed.52
We found that high levels of thrombin could reduce maximum clot strength (data not
shown) probably due to the rapid increase in viscosity lowering the diffusion of FXIII
required to create a strong clot; however, more research needs to be conducted to clarify
this phenomenon.
The import of FXIII is debated. Some researchers found that the ratio of FI to
FXIII was important52 while others did not see differences when FXIII was added to
FS.11, 53 Biochemical studies indicate that α-α and γ-γ crosslinking by FXIIIa increases
clot strength 3.5-fold;18 therefore, FXIII should be included in FS if clot strength is
desired.

Researchers found that the rate of fibrin crosslinking was faster in FS

containing more FXIII46 and thereby increased the clot’s resistance to fibrinolysis.46, 54
In addition, research found that FXIII was critical in FS for fibroblast migration.12 In

128
challenging situations where blood flow was not easily disrupted requiring FS to clot
and adhere to tissue quickly, sealants that included FXIII had significantly better results
than those without FXIII.46
Most FS on the market contain FI and FIIa in similar amounts; however, FXIII
content ranges.46 The ratio of FXIII to FI in human plasma is approximately 0.4 U/mg;
however, some commercial products contain no FXIII or 0.1 U/mg except for Beriplast
P which contains approximately 0.44 to 0.89 U/mg.46 Dickneite et al. found that a
FXIII to FI ratio of 0.78 U/mg (70 U/ml FXIII) resulted in a slightly greater tensile
strength than concentrations above or below this range.46 They concluded that the
addition of FXIII hastens crosslinking and increases clot strength.46 Their research
suggested 40 to 80 U/ml (0.44 to 0.89 U/mg) FXIII concentration in FS.46
We added multiple levels of rFXIIIa to our LFS and found even our lowest
addition of 23.13 U rFXIIIa per mg FI (208 U/ml) yielded a significantly higher
maximal clot strength than rLFS without rFXIIIa (Figure 4.5). This lowest treatment is
almost 24-fold greater than the highest levels added to commercial FS. Our optimal
rLFS contains 274 U rFXIIIa per mg FI (2,464 U/ml) which is 308-fold greater than
commercial FS. Previous research has not added FXIII to the levels that we have
because this requires a production source that can create abundant amounts of rFXIIIa.
Thromboelastography indicates that the addition of FXIII prolongs fibrinolysis,54
reduces time to clot initiation and increases clotting kinetics and viscoelastic strength. 55,
56

While our results supported the increase in clot strength, kinetics and time to clot

initiation were not greatly affected.
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Byrne et al. varied FS components FI (23 to 58 g/l), FXIII (1 to 12.5 U/ml,
FXIII/FI ratio: 0.16 to 0.24) and FIIa (50 to 1000 U/ml) to identify the optimal mixture.
This research found that FS with 39 mg/ml FI, no added FXIII and 200 to 600 U/ml FIIa
yielded the best viscoelastic properties.53 Higher FI and FIIa concentrations inhibited
wound healing and lower levels were not effective sealants.11, 53 Our optimal FI and FIIa
levels are significantly lower than the published optimal mixture and commercially
available products.
Our optimal LFS contains 9 mg/ml FI, 0.36 mg/ml FXIIIa (FXIIIa/FI molar ratio
of 0.16), 105.6 U/ml FIIa (FIIa/FI molar ratio of 0.18) and 12 mM CaCl2. While 15
mg/ml rFI yielded slightly higher clot strength, it was not statistically significant (Figure
4.3); therefore, we selected 9 mg/ml rFI for our optimal rLFS. The optimal ratio of
FXIIIa to FI (0.16) was selected to provide the highest viscoelastic strength (Figure 4.4
and 4.8). The optimal ratio of FIIa to FI (0.18) was selected to provide the fastest
initiation of clot formation and clotting kinetics. rFI concentrations were selected to
provide the necessary clot strength while minimizing material use. 12 mM CaCl2 was
selected to ensure that when applied to a wound an ample amount of the required
component was available to both exogenous and endogenous proteins.

Our results

indicate that rLFS is unaffected by increases in calcium concentration greater than 3 mM
(slightly above physiological levels of ~2 mM) which contradicts previous research that
indicated that reducing calcium below 10 mM resulted in reduction in viscoelastic
strength.11 Fibrin clots made with rFI, rFXIII and FIIa yielded 5.0-fold greater shear
elastic modulus strength than clots formed from NHB alone. The clotting kinetics and
viscoelastic strength of our optimized LFS was equivalent to those of a commercially
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available LFS; however, it uses approximately 75% less fibrinogen and thrombin. Initial
preclinical testing indicates that this optimal rLFS is effective as a sealant alone and in
combination with a dressing on multiple liver and femoral arteriotomy models.
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Chapter 5
Ex vivo Evaluation of the Liquid Fibrin Sealant Components
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Abstract
Commercial scale biosynthesis has been demonstrated for recombinant fibrinogen
(rFI) in the milk of transgenic cows, thrombin (FIIa) by mammalian cell culture and
Factor XIII by cell culture (rFXIII). These recent developments will enable the use of
therapeutics that require abundant production schemes that could not previously be met
by plasma sources. One possible use for these three proteins is as components in a
recombinant liquid fibrin sealant (rLFS). The function of fibrin sealants is based on
complicated interactions between other pro- and anticoagulant proteins, blood cells and
vessel surface under flow and viscosity conditions; therefore, our optimized rLFS and its
components needed to be tested ex vivo.

Each individual component and all

combinations of the LFS components were dosed into citrated normal human blood
(NHB) and its respective platelet rich (PRP) and platelet poor plasma (PPP) fractions to
analyze its effects on blood coagulation. Thromboelastographic analysis showed:


rFI at near-hyperfibrinogenemic levels can increase clot strength when dosed into
NHB, PRP and PPP. rFI alone or with rFXIII increases time to clot initiation
when added to PRP or PPP.



FIIa in combination with other components or alone significantly decreases the
time to clot initiation for NHB, PRP and PPP. The addition of FIIa alone or with
rFXIII to NHB, PRP or PPP significantly reduces clot strength; however, addition
of rFI reverses the loss in clot strength.



rFXIII alone or in combination with rFI increases clot strength when added to
PPP but not when added to NHB and PRP indicating that blood-borne platelets
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play a large role by providing FXIII. When added to NHB, rFXIII speeds time to
clot initiation by a median of 24%.
With regard to therapeutic uses, both rFI and rFXIIIa have advantages. rFI dosed in
NHB alone did not significantly alter time to clot initiation or coagulation time but did
increase clot strength. Consequently, rFI may be useful for infusion therapy following
haemodilution. rFXIIIa reduced time to clot initiation slightly but did not significantly
change clot strength or kinetics; therefore, it may be an effective infusion therapy for
FXIII deficiency. The research presented in this chapter is the first detailed evaluation of
the effects of haemodilution on PRP and PPP coagulation parameters. In addition, it is
also the first report of detailed in vitro effects of doping FI, FXIIIa and FIIa into NHB,
PRP and PPP.
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Introduction
Commercial scale biosynthesis has been demonstrated for recombinant fibrinogen
(rFI) in the milk of transgenic cows, thrombin (FIIa) by mammalian cell culture and
Factor XIII by cell culture (rFXIII). These recent developments will enable the use of
therapeutics that require abundant production schemes that could not previously be met
by plasma sources. One possible use for these three proteins is as components in a
recombinant liquid fibrin sealant (rLFS). Fibrin sealants (FS) mimic natural clotting
mechanisms thereby providing similar functions as endogenous plasma components such
as creating hemostatic clots1 and providing a scaffold for cellular infiltration needed to
regenerate tissue.1,

2

FS, which contain fibrinogen (FI), thrombin (FIIa) and calcium

chloride and occasionally Factor XIII (FXIII), reproduce the final stage of the clotting
cascade to aid hemostasis. FIIa catalyzes the conversion of FI to soluble fibrin monomer
and FXIII to activated FXIII (FXIIIa).3-6 FXIIIa then catalyzes the formation of the
crosslinked, insoluble fibrin clot that is melded with the platelet-based, primary
hemostatic plug.5, 7-9 FS function is based on complicated interactions between other proand anticoagulant proteins, blood cells and vessel surface under flow and viscosity
conditions;10 therefore, our optimized rLFS and its components should be tested ex vivo.
Very little research has been performed on the effects of LFS components on
hemostasis in ex vivo situations. Thromboelastographic (TEG) analysis of blood samples
taken after rFXIII administration showed increased clot strength and decreased
fibrinolysis with lesser effects on the speed of clot formation.11 Detailed analysis of the
impact of rFI dosing into blood (in vitro or in vivo) on clotting kinetics and viscoelastic
strength requires gram amounts of rFI and thus has not been reported to date. The
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objective of the research presented in this chapter was to evaluate our optimized rFI,
rFXIIIa and rLFS ex vivo. In particular, rFI was evaluated as a replacement therapy
following near exsanguination by examining the interaction of rFI with endogenous
proteins. Each component of the rLFS was added individually and in combination with
the others to normal human blood (NHB) and platelet rich (PRP) and platelet poor plasma
(PPP) to evaluate interactions between exogenous and endogenous proteins and cellular
components. The research presented in this chapter is the first detailed evaluation of the
effects of haemodilution on PRP and PPP coagulation parameters. In addition, this is the
first report of detailed testing of kinetics and viscoelastic strength of clots formed by
endogenous and individual and combined exogenous components of a LFS.

Materials and Methods
Materials
Purified, plasma-derived prothrombin was bought from Enzyme Research
Laboratories (South Bend, IN). Recombinant thrombin (Recothrom®) was purchased
from Zymogenetics. Purified recombinant fibrinogen, expressed in the milk of transgenic
Swiss Brown cows, was obtained from Pharming Group NV (Leiden, Netherlands).
Materials for the thromboelastograph were purchased from Haemoscope (Niles, IL).
Unless otherwise specified, reagents were purchased from Sigma (St. Louis, MO).
Vector construction, expression and purification of FXIIIA in Pichia pastoris
The human Ultimate ORF clone containing the human coagulation factor
FXIIIA1 cDNA in the pENTRTM221 vector was purchased from Invitrogen (Carlsbad
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CA). The following primers were used to obtain FXIIIa gene to subclone in pPICZA
intracellular

Pichia

expression

vector.

(Forward,

5'-

CCAATTGATGCATCATCATCATCATCATTCAGAAACTTCCAGGACCGC-3';
Reverse, 5'-GCGGCCGCTCACATGGAAGGTCGTCTTTGAATC-3').

The forward

primer introduced a methionine and 6 histidine amino acids at the N-terminus of mature
FXIIIa peptide. The PCR product was digested with MfeI and NotI and subcloned into
pPICZA which was digested with the same enzymes. The DNA sequence of the FXIIIA
was confirmed by sequencing the insert fragment. One of the confirming plasmid
pPICZAFXIIIa was linearized with PmeI and transformed into P. pastoris X-33 host
strain and copy number of the clones was determined as described.12 Varying copy
number clones were screened in shake flask culture to confirm intracellular production of
FXIIIa protein. The highest producing clone was scaled up to 5 L bench scale. A fedbatch fermentation protocol was followed to optimize FXIIIa production as described by
Zhang et al., (2007).13 At the end of fermentation process the cells were separated by
centrifugation (6,000g) and pellet was stored at -80oC.
Frozen cell paste was processed in 300 gram batches. Cells were lysed in three
sets of 100 gram batches. 100 grams of cell paste was resuspended in 100 ml of cold
lysis buffer (50 mM Tris-HCL, 10 mM MgSO4, 1 mM EDTA, 10 mM potassium acetate,
1 mM DTT (DL-Dithiothreitol), 2 mM PMSF (phenylmethanesulphonylfluoride) in
methanol, pH 9.5). 100 ml (250 g) of 0.5 mm glass beads (Biospec, Bartlesville, OK)
were added and the cells. Surrounded by an ice bath, cells were lysed using a BeadBeater
Blender (Biospec, Bartlesville, OK) with twenty 20 second on/off cycles. The cell lysate
mixture was then centrifuged to remove cellular debris. The lysate from 300 grams of
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cell paste was combined and purified using the HisBind Purification Kit (EMD
Chemicals, Inc., San Diego, CA) with 40 ml of resin slurry. Following purification,
rFXIII was dialyzed in 10 mM Tris-HCl, 0.1 mM EDTA, 60 µM polysorbate-20, pH 8.0
in snake-like dialysis membranes and the protein samples were filter-sterilized and
concentrated using the Amicon tubes (Millipore, Billerica, MA). The purity of the
sample was tested by SDS-PAGE (NuPAGE 12% Bis-Tris) (Invitrogen, Carlsbad, CA)
and immunoblot. The concentration of rFXIII was determined by standard Bicinconic
Acid (BCA) methods.
FIIa preparation
Frozen, plasma-derived human prothrombin (Enzyme Research Laboratories,
South Bend, IN), was thawed at 37oC. Plasma-derived thrombin (Enzyme Research
Laboratories, South Bend, IN) was added at a 1/10 mass to mass thrombin/prothrombin
ratio. 0.35 grams of sodium citrate per milliliter of solution was added (Lanchantin
1965). This solution was incubated at 37oC on a rotating mixer for five hours. Sodium
citrate was removed using PD-10 desalting columns (GE Healthcare, Giles, United
Kingdom).

Activation of prothrombin to thrombin was confirmed by reducing and

nonreducing SDS-PAGE (12% Bis-Tris NuPAGE) (Invitrogen, Carlsbad, CA) stained
with Colloidal Blue (Invitrogen, Carlsbad, CA). The concentration of the thrombin
solution was determined by standard Bicinconic Acid (BCA) methods. The specific
activity was determined by aPTT analysis.
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Human blood sampling and processing
Fresh, normal whole human blood (NHB) from 20 healthy, medication-free
individuals, collected in tubes containing 3.2% citrate, was obtained from Research
Blood Components (Brighton, MA). Each individual NHB sample was divided in thirds.
The NHB sample remained unprocessed while the other two were processed into plateletrich plasma (PRP) and platelet-poor plasma (PPP). PRP was prepared by centrifuging
NHB at 160xg for 8 minutes at 22oC. NHB was centrifuged at 2300xg for 15 minutes at
22oC to obtain PPP. All blood fractions were used within 36 hours of being drawn and
were stored at 0oC until analyzed at which time the samples were warmed to 37oC.
Thromboelastography analysis of fibrin clot formation
TEG analysis was conducted on individual fresh, citrated NHB, and respectively
derived PRP and PPP samples from 20 individuals. Aliquots of each NHB, PRP and PPP
sample were dosed with purified rFI, rFXIII and/or pdFIIa alone or combination. All
blood fractions were diluted to 1.3x to provide volume for addition of the biologics.
Control samples were performed to determine the affects of diluting NHB, PRP and PPP
on time to clot initiation (R), coagulation time (K, time to reach clot firmness of 20 mm)
and maximal clot strength (MA) as evaluated by TEG. Each NHB and respective plasma
samples (429.72 µl) were transferred to single-use TEG cups that had been enlarged by
boring with a 0.406 inch bit (650 µl final volume). Combinations of solutions containing
rFI (1.42 mg, 2.32 mg/ml rFI in cup), rFXIII (0.11 mg, 0.18 mg/ml rFXIIIa in cup,
rFXIII/rFI molar ratio = 0.16), FIIa (0.08 mg, 0.13 mg/ml FIIa in cup, FIIa/rFI molar
ratio = 0.25), and CaCl2 (11 mM) were added to the TEG cups. Ringer’s solution was
used to normalize mixture volumes.
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The TEG Analytical Software (version 4.2.2, Haemoscope, Niles, IL) collected
the time to clot initiation (R), the time to achieve a clot firmness of 20mm (K) and the
maximal clot strength (MA) for blood products collected from 20 donors. Samples were
run until program termination to collect percent lysis 60 minutes after reaching maximum
clot strength (LY60) on blood products from 3 of the 20 donors. Data was exported from
the TEG Analytical Software to Microsoft Excel for analysis. ANOVA and two tail T
test (equal variance) analyses were performed to identify statistical significance between
treatment groups of raw data. An α of 0.05 was used for all statistical analyses. The
percent change of TEG values resulting from treatment with biologics was normalized
relative to the averaged respective sample (N = 20) treated with Ringer’s solution alone.
The instrument was calibrated each day of use. All tests described above include
three replicate samples in each treatment group. All NHB and respective plasma samples
were tested within 36 hours of the blood draw of each individual donor.
NHB, PRP and PPP samples from 20 donors were tested untreated and treated
with rFI alone, rFI and FIIa together, rFI and rFXIIIa together, rFI, rFXIIIa and FIIa
together. NHB, PRP and PPP samples from 10 donors were tested when treated with
FIIa alone, FXIIIa alone and FIIa and FXIIIa in combination.

Results
rFXIIIa and pdFIIa characterization
SDS-PAGE and N-terminal sequencing indicated that the purified protein from
the yeast was rFXIIIa rather than rFXIII. These and immunoblots indicated rFXIIIa had
a purity of greater than 98% (data not shown). The Pefakit® Factor XIII Incorporation
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Assay (Pentapharm, CT) yielded a specific activity of almost 7,000 U/mg for rFXIIIa.
The pdFIIa prepared by citrate activation was comprised of α-thrombin and fragments as
per SDS-PAGE (Figure 5.2A, lane 10) and chromogenic assay yielded a specific activity
of 528 U per mg.
Donor data
Blood was collected from 20 healthy, drug-free donors from 15 men and 5 women
with a mean age of 29 (median: 26, maximum: 50, minimum: 20). 11 of the 20 were
White, 7 Black, 1 Asian and 1 Hispanic.
TEG analysis of haemodilution
All blood fractions were diluted 1.3x so that 30% of the TEG cup volume was
available for addition of the biologics. The effect of dilution by Ringer’s solution on
NHB, PRP and PPP was evaluated by thromboelastography for time to clot initiation (R),
coagulation time (time to reach clot firmness of 20 mm, K) and maximal clot strength
(MA). Dilution resulted in statistically significant changes in time to clot initiation for
PRP and PPP when diluted with Ringer’s solution (p = 0.011 and 0.014) but not for NHB
(p = 0.087). Coagulation time was statistically different for NHB (p = 0.002) but not for
PRP and PPP (p = 0.626 and 0.132). Maximal clot strength was statistically different for
PPP (p = 0.026) but not for NHB and PRP (p = 0.288 and 0.245).
Although not statistically significant, in general, diluting with Ringer’s solution
reduced R, K and MA for NHB (Figure 5.1). Percent change in R was reduced in 17 of
the 23 NHB samples ranging from a 38% reduction to almost 10% increase (Figure
5.1A). Similarly, coagulation time (K) was reduced in 19 of 22 with a range from a 52%
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reduction to an 8% increase (Figure 5.1B). 14 of the 23 NHB samples also had reduced
clot strength when diluted with Ringer’s solution ranging from a 22% reduction to a 22%
increase (Figure 5.1C).
As with NHB, dilution of PRP with Ringer’s solution tended to reduce R, K and
MA (Figure 5.2). When diluted with Ringer’s solution, PRP was reduced in all 22 cases
ranging from a just over 2% to a 33% reduction (Figure 5.2A). 15 of 22 diluted PRP
samples had reduced coagulation time but ranged from a 47% reduction to 54% increase
(Figure 5.2B). Percent changes in clot strength for diluted PRP ranged from a 23%
reduction to 13% increase; however, 20 of 22 PRP samples had reductions in clot
strength (Figure 5.2C).
Like NHB and PRP, R and MA were reduced when PPP was diluted with
Ringer’s solution; however, coagulation time tended to increase (Figure 5.3). All but 2 of
the 22 PPP samples had reduced clot initiation time (R) when diluted with Ringer’s
solution. Percent change in R ranged from a 41% reduction to a 3% increase (Figure
5.3A). All 22 PPP samples had a reduction in clot strength from 14% to 35% when
diluted (Figure 5.3C). Coagulation time of diluted PPP was the only measured parameter
that showed primarily an increase after dilution (Figure 5.3B). The six PPP samples with
zero percent change in K were samples that never reached 20 mm clot strength either
before or after dilution. Four of the 22 samples (Donors R, X, Z and AA) reached 20 mm
clot strength before dilution but not after. Only two samples showed a reduction in K
when diluted. Percent changes of K ranged from a 34% reduction to a 539% increase.
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Figure 5.1. Percent change in time to clot initiation (R), clot coagulation time (K) and maximal clot
strength (MA) when normal human blood (NHB) is diluted 30% with Ringer’s solution. The bars
represent average values and the brackets represent the standard deviation. N = 23 for R and MA, 22 for K.
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Figure 5.2. Percent change in time to clot initiation (R), clot coagulation time (K) and maximal clot
strength (MA) when platelet rich plasma (PRP) is diluted 30% with Ringer’s solution. The bars
represent average values and the brackets represent the standard deviation. N = 22.
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Figure 5.3. Percent change in time to clot initiation (R), clot coagulation time (K) and maximal clot
strength (MA) when platelet poor plasma (PPP) is diluted 30% with Ringer’s solution. The bars
represent average values and the brackets represent the standard deviation. N = 22.
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The three blood products, NHB, PRP and PPP, diluted by 30% were statistically
compared. R, K and MA results for NHB, PRP and PPP were compared by t test if
significant differences were identified by ANOVA (Table 5.1). With respect to clot
initiation time, NHB was not statistically different form PRP or PPP; however, PRP and
PPP were significantly different from each other. NHB, PRP and PPP were statistically
different from each other with respect to both K and MA. These findings indicate that
platelets and cellular components contribute to coagulation parameters.

Table 5.1. p values from t test comparisons of normal human blood (NHB), platelet rich plasma
(PRP) and platelet poor plasma (PPP) on time to clot initiation (R), time to reach clot firmness of
20 mm (K) and maximal clot strength (MA).
Time to clot initiation Coagulation time
Maximum clot
Clotting Parameter
(R)
(K)
strength (MA)
NHB vs. PRP
0.572
< 0.001*
< 0.001*
NHB vs. PPP
0.062
< 0.001*
< 0.001*
PRP vs. PPP
0.014*
< 0.001*
< 0.001*
* statistical significance based on α = 0.05

TEG analysis of protein doping into NHB, PRP and PPP
rFI (final concentration: 2.32 mg/ml), rFXIII (final concentration: 0.18 mg/ml),
and/or FIIa (final concentration: 0.13 mg/ml, 52.9 U/ml) were dosed into purchased
citrated, NHB and its respective PRP and PPP. Time to clot initiation (R), coagulation
time (time to reach clot firmness of 20 mm, K) and maximal clot strength (MA) were
evaluated by thromboelastograph (TEG). ANOVA analysis indicates that dosing NHB,
PRP and PPP with proteins do result in statistically significant changes in clotting
parameters (Table 5.2).

t test analyses were performed to identify which proteins

significantly altered clotting parameters. The percent change of TEG values resulting
from treatment with biologics were normalized relative to the averaged respective sample
(N = 20) treated with Ringer’s solution alone.
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Table 5.2. p values from ANOVA analyses on time to clot initiation (R), time to reach clot
firmness of 20 mm (K) and maximal clot strength (MA) due to treatment with biologics.
Normal Human
Platelet Rich
Platelet Poor
Clotting Parameter
Blood
Plasma
Plasma
Time to clot initiation (R)
< 0.0001
< 0.0001
< 0.0001
Coagulation time (K)
< 0.0001
< 0.0001
0.0001
Maximum Clot Strength (MA)
< 0.0001
< 0.0001
< 0.0001
* statistical significance based on α = 0.05

TEG analysis of time to clot initiation
ANOVA analyses indicated that protein treatment significantly altered R for
NHB, PRP and PPP (Table 5.2). t test analyses indicated that dosing any protein into
PRP or PPP and all but rFI alone or rFI in combination with rFXIIIa results in a
significant change in time to clot initiation (Table 5.3).

Table 5.3. p values from t test analyses on time to clot initiation (R) comparing diluted normal
human blood (NHB), platelet rich plasma (PRP) and platelet poor plasma (PPP) to samples
containing biologics.
Normal Human
Platelet Rich
Platelet Poor
Diluted sample vs.:
Blood
Plasma
Plasma
rFI dosed sample
0.101
< 0.001*
< 0.001*
rFXIIIa dosed sample
0.003*
0.010*
0.001*
FIIa dosed sample
< 0.001*
< 0.001*
< 0.001*
rFI + FIIa dosed sample
< 0.001*
< 0.001*
< 0.001*
rFXIIIa + FIIa dosed sample
< 0.001*
< 0.001*
< 0.001*
rFI + rFXIIIa dosed sample
0.950
0.001*
< 0.001*
rFI + rFXIIIa + FIIa dosed sample
< 0.001*
< 0.001*
< 0.001*
* statistical significance based on α = 0.05

Percent changes in R indicate that FIIa dominates clot speed (Figure 5.4). When
examining percent changes, the addition of rFI alone increased clot initiation by 8%,
30%, and 39% for NHB, PRP and PPP, respectively. Individual sample values ranged
from a 42% increase to a 13% decrease in time to clot initiation for NHB, 14% to 49%
increase for PRP and 15% to 72% increase for PPP. The average standard deviations for
each sample were 10, 5 and 8 for NHB, PRP and PPP, respectively.
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The addition of rFXIII alone decreased R by 24%, 12%, and 13% for NHB, PRP
and PPP, respectively. Individual sample values ranged from 2% to 40% decrease in time
to clot initiation for NHB, 30% increase to 38% decrease in R for PRP and 2% increase
to 21% decrease for PPP. The average standard deviations for each sample were 6, 4 and
6 for NHB, PRP and PPP, respectively.
Clot initiation time (R) was affected predominantly by FIIa which added alone
decreased median clot initiation times by 74%, 91% and 91% for NHB, PRP and PPP,
respectively. Individual sample values ranged from 68% to 83% decrease in time to clot
initiation for NHB, 87% to 93% decrease for PRP and 67% to 95% decrease for PPP. The
average standard deviations for each sample were 7, 5 and 5 for NHB, PRP and PPP,
respectively.
When FIIa is added with rFI, time to clot initiation decrease by 86%, 95% and
96% for NHB, PRP and PPP, respectively. The average standard deviations for each
sample were 2, 3 and 5 for NHB, PRP and PPP, respectively. Individual sample values
ranged from 82% to 92% decrease in time to clot initiation for NHB, 91% to 96%
decrease for PRP and 91% to 97% decrease for PPP. The average standard deviations for
each sample were 6, 5 and 6 for NHB, PRP and PPP, respectively.
When FIIa is added with rFXIII, time to clot initiation decrease by 81%, 93% and
94% for NHB, PRP and PPP, respectively. Individual sample values ranged from 76% to
88% decrease in time to clot initiation for NHB, 87% to 95% decrease for PRP and 81%
to 96% decrease for PPP. The average standard deviations for each sample were 5, 4 and
4 for NHB, PRP and PPP, respectively.
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The addition of rFI with rFXIII did not affect the time to clot initiation for NHB
but increased it for PRP and PPP by 33% and 25%, respectively. Individual sample
values ranged from a 13% increase to 22% decrease in time to clot initiation for NHB,
14% to 72% increase for PRP and 11% to 49% increase for PPP. The average standard
deviations for each sample were 8, 6 and 4 for NHB, PRP and PPP, respectively.
Addition of rFI, rFXIII and FIIa decreased clot initiation time by 88%, 94% and
96% for NHB, PRP and PPP, respectively. Individual sample values ranged from 82% to
92% decrease in time to clot initiation for NHB, 92% to 96% increase for PRP and 94%
to 97% increase for PPP. The average standard deviations for each individual sample
were 4, 5 and 6 for NHB, PRP and PPP, respectively.
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Figure 5.4. Percent change in time to clot initiation (R) with the addition of recombinant fibrinogen
(rFI), plasma-derived thrombin (pdFIIa) and/or recombinant FXIIIa (rFXIIIa) to normal human
blood (NHB), platelet rich plasma (PRP) and platelet poor plasma (PPP). The bars represent median
values and the brackets represent the highest and lowest values for the 20 subjects.
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TEG analysis of coagulation time
ANOVA analyses indicated that protein treatment significantly altered K for
NHB, PRP and PPP (Table 5.2). t test analyses indicated that dosing rFI alone, FIIa
alone, rFI and FIIa together, rFXIIIa and FIIa together, and rFI, rFXIIIa and FIIa together
significantly changes maximal clot strength (Table 5.4). K of PRP was significantly
altered with the addition of FIIa alone and rFXIIIa and FIIa in combination. K of PPP
was significantly altered with the addition of rFI alone, rFI with rFXIIIa, and rFI with
rFXIIIa, and rFI.

Table 5.4. p values from t test analyses on coagulation time (K) comparing diluted normal human
blood (NHB), platelet rich plasma (PRP) and platelet poor plasma (PPP) to samples containing
biologics.
Normal Human
Platelet Rich
Platelet Poor
Diluted sample vs.:
Blood
Plasma
Plasma
rFI dosed sample
0.004*
0.954
0.025*
rFXIIIa dosed sample
0.568
0.137
0.077
FIIa dosed sample
< 0.001*
0.003*
rFI + FIIa dosed sample
0.002*
0.064
0.370
rFXIIIa + FIIa dosed sample
< 0.001*
0.036*
rFI + rFXIIIa dosed sample
0.318
0.790
< 0.001*
rFI + rFXIIIa + FIIa dosed sample
0.012*
0.117
0.016*
* statistical significance based on α = 0.05, FIIa and rFXIIIa + FIIa dosed samples never achieved 20
mm clot strength.

Percent changes in K indicate that FIIa dominates coagulation time (Figure 5.5).
Coagulation time (K) was reduced 24% and 54% for NHB and PPP, respectively, and
increased 14% for PRP when rFI was added. Individual sample values ranged from a 1%
increase to a 48% decrease in K time for NHB, a 60% increase and 21% decrease for
PRP and 0% to 70% decrease for PPP.
When rFXIIIa was added, the K value was increased 5% for NHB and reduced
24% and 70% for PRP and PPP, respectively. Individual sample values ranged from a
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52% increase to a 32% decrease in coagulation time for NHB, 0% to 43% decrease for
PRP and 0% to 91% decrease for PPP.
When FIIa was added, coagulation time 111%, 125% and 0% for NHB, PRP and
PPP, respectively. Individual sample values ranged from 48% to 165% increase in
coagulation time for NHB, 59% to 269% increase for PRP and 0% to 199% increase for
PPP. When FIIa was added with rFI, coagulation time increased by 35%, 46% and 0%
for NHB, PRP and PPP, respectively. Individual sample values ranged from a 13%
decrease and 72% increase in K value for NHB, a 126% increase to a 14% decrease for
PRP and a 199% increase to 61% decrease for PPP. When FIIa is added with rFXIII,
coagulation time increased by 90%, 64% and 0% for NHB, PRP and PPP, respectively.
Individual sample values ranged from 62% to 233% increase in K for NHB, 30% to
144% increase for PRP and 0% to 199% increase for PPP.
The addition of rFI with rFXIII decreased NHB and PPP by 16% and 82%,
respectively, and increased PRP by 17%. Individual sample values ranged from a 44%
increase to 43% decrease in K for NHB, a 78% increase to 62% decrease in K for PRP,
and 37% to 94% decrease for PPP.
Addition of rFI, rFXIII and FIIa increased coagulation time for NHB and PPP by
30% and 39%, respectively, and a 57% decrease for PPP. Individual sample values
ranged from a 5% decrease to a 61% increase in K for NHB, a 29% decrease to a 113%
increase in K for PRP and a 83% decrease to a 8% increase in K for PPP.

155
300
250

NHB
PRP

200

PPP

% Change in K

150
100
50
0
-50
-100
rFI

rFXIIIa

rFIIa

rFI + FIIa

rFXIIIa +
FIIa

rFI +
rFXIIIa

rFI +
rFXIIIa +
FIIa

Figure 5.5. Percent change in coagulation time (K) with the addition of recombinant fibrinogen
(rFI), plasma-derived thrombin (pdFIIa) and/or recombinant FXIIIa (rFXIIIa) to normal human
blood (NHB), platelet rich plasma (PRP) and platelet poor plasma (PPP). The bars represent median
values and the brackets represent the highest and lowest values for the 20 subjects.

TEG analysis of maximal clot strength
ANOVA analyses indicated that protein treatment significantly altered MA for
NHB, PRP and PPP (Table 5.2). t test analyses indicated that dosing rFI alone, rFXIIIa
alone, FIIa alone, rFXIIIa and FIIa together, and rFI and rFXIIIa together significantly
changes maximal clot strength (Table 5.5). MA of PRP was significantly altered with the
addition of FIIa alone and rFXIIIa and FIIa in combination. MA of PPP was significantly
altered with the addition of FIIa alone, FIIa together with rFI or rFXIIIa, and rFI in
combination with rFXIIIa.
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Table 5.5. p values from t test analyses on maximal clot strength (MA) comparing diluted normal
human blood (NHB), platelet rich plasma (PRP) and platelet poor plasma (PPP) to samples
containing biologics.
Normal Human
Platelet Rich
Platelet Poor
Diluted sample vs.:
Blood
Plasma
Plasma
rFI dosed sample
< 0.001*
0.935
0.802
rFXIIIa dosed sample
0.028*
0.212
0.852
FIIa dosed sample
< 0.001*
0.002*
< 0.001*
rFI + FIIa dosed sample
0.850
0.125
0.027*
rFXIIIa + FIIa dosed sample
< 0.001*
0.004*
< 0.001*
rFI + rFXIIIa dosed sample
0.047*
0.817
0.039*
rFI + rFXIIIa + FIIa dosed sample
0.647
0.452
0.881
* statistical significance based on α = 0.05

rFI dominated the changes in clot strength as can be observed with percent change
in MA (Figure 5.6). When added alone, rFI increased median clot strength by 27%, 6%
and 26% for NHB, PRP and PPP, respectively. The individual sample values ranged
from a 19% to 51% increase in clot strength for NHB, a 14% increase to 20% decrease
for PRP and 5% to 103% increase in strength for PPP. The average standard deviations
for each sample were 2, 2 and 1 for NHB, PRP and PPP, respectively.
rFXIII added alone did not greatly affect clot strength of NHB or PRP but
increased strength of PPP clots by a median of 48%. The individual sample values ranged
from a 6% increase to 57% decrease in clot strength for NHB, a 6% increase to 16%
decrease for PRP and 17% to 95% increase for PPP. The average standard deviations for
each sample were 3, 3 and 1 for NHB, PRP and PPP, respectively.
When FIIa was added alone to NHB, PRP and PPP, median clot strength for each
sample decreased by 30%, 26%, 51%, respectively. The individual sample values ranged
from 23% to 38% for NHB, 18% to 38% for PRP and 46% to 64% for PPP. The average
standard deviations for each sample were 2, 2 and 1 for NHB, PRP and PPP, respectively.
When rFI was added with FIIa, rFI reversed the effects of FIIa resulting in clot
strengths similar to NHB, PRP and PPP alone. Median clot strengths were increased
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11% and 29% for NHB and PPP and decreased 3% for PRP. Individual sample values
ranged from a 5% decrease to a 25% increase in clot strength for NHB, a 31% decrease to
5% increase for PRP and 18% decrease to 65% increase for PPP. The average standard
deviations for each sample were 2, 2 and 1 for NHB, PRP and PPP, respectively.
When FIIa was combined with rFXIII to NHB, PRP and PPP, there were similar
decreases in median clot strength of 32%, 19%, 39%, respectively. The individual sample
values ranged from 25% to 47% for NHB, 13% to 33% for PRP and 17% to 57% for
PPP. The average standard deviations for each sample were 2, 3 and 1 for NHB, PRP and
PPP, respectively.
When added in combination with rFXIII, rFI increased median clot strength for
NHB, PRP and PPP by 18%, 5% and 63%, respectively. The individual sample values
ranged from 3% to 36% increase in clot strength for NHB, a 23% increase to 10%
decrease for PRP and 5% to 161% for increase in strength for PPP. The average standard
deviations for each sample were 3, 3 and 2 for NHB, PRP and PPP, respectively.
The addition of rFI, rFXIII and FIIa did not change PRP clot strength but
increased median clot strengths of NHB and PPP by 6% and 61%, respectively.
Individual sample values ranged from a 5% decrease to a 29% increase in clot strength
for NHB, a 6% decrease to 14% increase for PRP and a 12% to 22% increase for PPP.
The average standard deviations for each sample were 3, 4 and 2 for NHB, PRP and PPP,
respectively.
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Figure 5.6. Percent change in maximal clot strength (MA) with the addition of recombinant
fibrinogen (rFI), plasma-derived thrombin (pdFIIa) and/or recombinant FXIIIa (rFXIIIa) to
normal human blood (NHB), platelet rich plasma (PRP) and platelet poor plasma (PPP). The
bars represent median values and the brackets represent the highest and lowest values for the 20
subjects.

TEG analysis of lysis
The percent lysis 60 minutes after achieving maximal clot strength was measured
by TEG (Figure 5.7). Undiluted NHB was lysed by 3.7% 60 minutes after achieving
maximal clot strength with a range of 0% to 4.9%. Undiluted PRP was lysed by 6%
ranging from 2.8% to 10.4%. Undiluted PPP was lysed by 0% ranging from 0% to 1%.
Diluted NHB, PRP and PPP were lysed by 1.7%, 11.1% and 0%, respectively. The
individual sample values ranged from 0.5% to 8.2% for NHB, 8.8% to 13.1% for PRP
and 0% to 0.1% for PPP.
When rFI was added, NHB and PRP were lysed by 3.7% and 9.6%, respectively
with ranges of 0.9% to 3.9% for NHB and 9.5% to 12.7% for PRP. When rFI and FIIa
were added, NHB and PRP were lysed by 0% and 4.1%, respectively with ranges of 0%
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to 5.2% for NHB and 0.3% to 6.5% for PRP. When rFI was in combination with rFXIIIa,
NHB and PRP were lysed by 1.4% and 2.0%, respectively with ranges of 0.6% to 2.1%
for NHB and 0% to 3.9% for PRP. When rFI, rFXIIIa and FIIa were added, NHB and
PRP were lysed by 0% and 6.6%, respectively with no lysis for NHB and a range of 1.7%
to 8.5% for PRP. PPP had no detectable lysis when rFI, rFXIIIa and/or FIIa were added.
ANOVA analyses indicated that treatment with proteins alone or in combination
did not significantly alter lysis in NHB and PPP (p = 0.620 and 0.533); however, there
were significant changes in PRP (p = 0.025). t test analyses indicated that PRP samples
dosed with rFI with FIIa or rFI with rFXIIIa significantly increased the percent lysis (p =
0.028 and 0.025, respectively).
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Figure 5.7. Percent lysis 60 minutes after reaching maximum clot strength of undiluted or diluted
normal human blood (NHB), platelet rich plasma (PRP) and platelet poor plasma (PPP) alone or
with the addition of recombinant fibrinogen (rFI), plasma-derived thrombin (pdFIIa) and/or
recombinant FXIIIa (rFXIIIa). The bars represent median values and the brackets represent the highest
and lowest values for 3 subjects. Samples with no detectable lysis are marked (*). Statistical significance
is identified by ‡. P values were 0.028 for rFI + pdFIIa and 0.025 for rFI + rFXIIIa.

Discussion
The data presented in this chapter indicate that time to clot initiation (R) and
maximal clot strength (MA) were not significantly altered by 30% haemodilution but
coagulation time (K) was significantly reduced for NHB. These findings partially
support previous research which showed that 29% dilution of citrated human blood with
lactated Ringer’s solution did not significantly alter time to clot initiation (R),
coagulation time (K) and maximal clot strength (MA) as measured by TEG.14 Both of
these studies contradict findings that NHB diluted 33% with lactated Ringer’s solution
had significantly faster activated clot times but slightly slower clotting rates. 15 This is
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the first report of a detailed analysis of results of dilution of PRP and PPP on clotting
parameters.

Dilution with Ringer’s solution significantly reduced the time to clot

initiation for PRP and PPP and maximum clot strength for PPP.
Coagulation time (K) was significantly altered by haemodilution in NHB only.
Time to clot initiation (R) was significantly reduced for PRP and PPP and although it was
not statistically significant, 17 of the 22 NHB samples showed reduced times to clot
initiation (R). Dilution of NHB reduces the concentration of fibrinogen15, 16 and other
plasma proteins and also decreases platelet16 and other cellular components in the blood.
By reducing cellular components, the viscosity of blood should decrease thereby easing
the diffusion of coagulation proteins to the clotting site. However, both PRP and PPP are
free of red blood cells but neither are significantly different than NHB with regard to time
to clot initiation. Consequently, cellular components may not interfere greatly with
initiation of clots. Rather, the dilution of plasma proteins may play a greater role. While
the reduction in fibrinogen would hinder clotting, dilution also lowers the concentrations
of anticoagulant proteins which may interfere with the initiation and rate of clot
formation. With respect to viscoelastic strength, dilution with Ringer’s solution resulted
in a significant reduction in PPP only. This indicates that platelets play an important role
in creating clot strength. This could be due to their inclusion in the clot by providing
surfaces for the fibrin clot but is also certainly related to their release of FXIII which
crosslinks the fibrin clot creating viscoelastic strength. Platelets dispersed throughout the
clot probably hasten17 and further stabilize the clot18 by releasing additional FXIII.
Activated platelets play an essential role in the formation of the primary hemostatic plug
and clot strength1, 7, 9, 19-21 because they supply both dimeric FXIII and the majority of
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FIIa to the wound surface9, 21, 22 Research indicates that FXIII in the platelets is necessary
to obtain optimal crosslinking.23
This study examines the effects of added rFI, rFXIIIa and pdFIIa on fibrin clot
formation in NHB, PRP or PPP ex vivo. The fibrinogen concentration was increased by
50% in each sample to near hyperfibrinogenemic levels. rFXIIIa and pdFIIa were
dosed at optimal LFS concentrations determined in the research in the previous chapter.
Thrombin played the most dominant role in altering time to clot initiation.
Addition of pdFIIa alone or in combination with one or both of the other proteins to
NHB, PRP and PPP resulted in significant reductions in clot initiation times (Figure
5.4).

The coagulation cascade culminates in the activation of large amounts of

prothrombin to thrombin which is responsible for activating both endogenous and
exogenous fibrinogen into fibrin and FXIII into FXIIIa. The lag observed from the start
of the test and the formation of a clot is related to the rate limiting activation of
prothrombin to thrombin. By adding this key enzyme in the active form, the limiting
step is removed resulting in near instantaneous clot formation. rFXIIIa added alone did
not greatly affect time to clot initiation; whereas rFI alone or with rFXIIIa slowed time
to clot initiation time in PRP and PPP but not NHB.
FIIa alone or in combination with rFXIIIa significantly prolonged coagulation
time for NHB and PRP. rFXIIIa addition without FIIa resulted in slight decreases in
coagulation time for PPP but not for NHB or PRP. This indicates that platelets provide
enough FXIII to maintain normal coagulation kinetics and the absence of FXIII reduces
the rate of formation of a crosslinked fibrin clot.
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The addition of FIIa alone or with rFXIII to NHB, PRP or PPP significantly
reduced clot strength; however, addition of rFI reversed the loss. FIIa addition results in
fast initiation of clot formation resulting in a rapid increase in viscosity which reduces
diffusivity of FXIIIa required to crosslink the fibrin aggregations creating a stronger clot.
rFI added alone to yield near-hyperfibrinogenemic levels increased clot strength when
dosed into NHB and PPP. However, when rFI was added in combination with rFXIIIa it
only increased clot strength for PPP but not when added to NHB and PRP indicating that
blood-borne platelets play a large role by providing FXIII.
The addition of any of the biologics alone or in combination with any of the
others did not significantly alter clot lysis for NHB or PPP.

Lysis of PRP was

significantly reduced with the addition of rFI in combination with pdFIIa or rFXIIIa. The
addition of excess rFXIIIa in combination with rFI reduces lysis compared to rFI added
alone because it ensures ample crosslinking of endogenous and exogenous fibrin(ogen).
The addition of pdFIIa seems to interfere with fibrinolysis components located in plasma.
These results suggest that rFI and rFXIII in combination with FIIa can be
combined to create a LFS with equivalent or better kinetic and viscoelastic properties as
currently available products. With regard to therapeutic uses, both rFI and rFXIIIa have
advantages. rFI dosed in NHB alone did not significantly alter time to clot initiation or
coagulation time but did increase clot strength. Consequently, rFI may be useful for
infusion therapy following haemodilution. rFXIIIa reduced time to clot initiation slightly
but did not significantly change clot strength or kinetics; therefore, it may be an effective
infusion therapy for FXIII deficiency.
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Chapter 6
Preliminary in vivo Testing of the Optimized Liquid Fibrin Sealant
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Abstract
The research presented in this chapter evaluates the optimal liquid fibrin sealant
(LFS) consisting of recombinant human fibrinogen (rFI) and recombinant Factor XIII
(rFXIIIa) in vivo in multiple injury models. The rLFS was evaluated for its effectiveness
in aiding hemostasis alone and in presence of a dressing as assessed in femoral
arteriotomy and multiple liver models in swine. A 4 mm femoral arteriotomy model
described previously was used to evaluate the ability of rLFS to aid in hemostasis when
exposed to arterial pressure and blood flow. Three liver injury models were also used to
test the rLFS:

small wedge-shaped resections and Grade V X-shaped stelate liver

lacerations and liver lobe resections. This is the first report of the use of a fullyrecombinant LFS used alone or in combination with a bioresorbable dressing. We also
designed and tested a prototype airbrush-based spray device for LFS application and
compared it to a pressurized air canister and the typical dual syringe applicator. Stelate
liver lacerations, major lobe resections and some of the larger wedge resections included
extensive tissue and vascular damage; however, our optimal LFS successfully achieved
hemostasis in a significant number of the wounds. LFS applied without the assistance of
a dressing was able to stop bleeding of oozing wounds or those with small vessels;
however, a scaffold was needed when wounds contained large vasculature. Although the
results presented in this chapter are promising, more research needs to be conducted to
develop the best LFS application device and dressing that optimizes hemostatic results
but is not dependent on the experience of the applicator.
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Introduction
Trauma deaths are a result of hemorrhage in 37% of civilians1 and 47% military
personnel2 and are the primary cause of death for individuals under 44 years of age.3
For the past 2000 years, the same techniques have been used to stop hemorrhage:
packing with gauze, direct pressure and tourniquet.4 This method is inadequate for
treating severe hemorrhage.

The Department of Defense Combat Casualty Care

Research Program is focused on developing more effective options for treating
hemorrhage5 and especially desires a hemostatic dressing.5
Fibrin sealants (FS), also known as fibrin glues, are viewed as the best tissue
sealant6 because they are biocompatible,7-9 biodegradable9 and safe7 and are not linked
to excessive inflammation, immune responses or necrosis.8,

9

Because they mimic

natural clotting mechanisms, FS provide similar functions as endogenous components
such as creating hemostatic clots10 and providing a scaffold for cellular infiltration
needed to regenerate tissue10, 11 and dissolve the clot.10 FS, which contain fibrinogen
(FI), thrombin (FIIa) and calcium chloride and occasionally Factor XIII (FXIII),
reproduce the final stage of the clotting cascade to aid hemostasis. FIIa catalyzes the
conversion of FI to soluble fibrin monomer and FXIII to activated FXIII (FXIIIa).12-15
FXIIIa then catalyzes the formation of the cross-linked, insoluble fibrin clot that is
melded with the platelet-based, primary hemostatic plug.14, 16-18 In addition to binding
other fibrin molecules and creating the fibrin clot, fibrin adheres the clot to the wound
by binding to collagen exposed at the site of tissue injury in addition to platelets,
endothelial and other cells.7
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To aid in hemostasis, FS can be used alone or in combination with a dressing to
stop blood oozing which cannot be stopped by suturing.19 FS are typically applied by a
needle and syringe sequentially or simultaneously in a dual-syringe delivery device.7, 20
Devices have also been designed to deliver FS in aerosol form.7 While FS have proved
useful in innumerable surgical procedures, they have their weakness. When applied to
wounds with large vascular damage, FS can be diluted or swept away from the injury.21
The use of a scaffold to provide mechanical support and a matrix on which to clot can
aid hemostasis by FS. The composition of the dressing is important and the optimal FSbandage will include a bioresorbable material that does not require a subsequent
operation for its removal which may cause hemorrhage in an already over-taxed system.
Dressings consisting of dry, lyophilized FI and FIIa on different backings (gauze,22
silicone,4,

23

and Vicryl21,

24

) were evaluated in femoral arteriotomy,22,

injury4 and Grade V liver injury21 models.

23, 25

ballistic

Under normal, hypothermic and

coagulopathic conditions, these bandages were significantly better than control
dressings with respect to minimizing blood loss4,

22, 23, 25

and maintaining blood

pressure.4, 22 A liquid fibrin sealant (LFS) has also been tested in combination with a
dressing. A resorbable polyglycolide felt dressing in combination with a commercial
LFS successfully sealed air leaks following pulmonary surgery.26
FS function is based on complicated interactions between other pro- and
anticoagulant proteins, blood cells and vessel surface under flow and viscosity
conditions;19 therefore, our optimized rLFS must be tested in vivo. Femoral arterial and
liver injury models in swine are frequently used to evaluate FS efficacy. Both femoral
and liver injuries mimic severe wounds that result in hemorrhagic death. The liver
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provides a hemostatic challenge because the parenchymal tissue is highly vascularized 19
and the vessel is unable to be constricted.27 Most hemorrhage requiring reoperation28 and
death from abdominal organ injury is due to liver injury.29 Liver injuries that expose
significant vascularity and extensive parenchymal tissue damage is considered a “Grade
V” 30 and 50 to 90% result in death.21 To date, these injuries are best treated by packing
with gauze and closing the abdomen; however, another operative procedure is required to
remove the gauze.31-33 Consequently, a liver injury model is an excellent test of FS.
While there is some research on FS use in liver, there is need for control trials testing FS
in liver injury models that compare FS and compression results.34
The objective of the research presented in this chapter was to evaluate our
optimized rLFS in vivo in multiple injury models. The rLFS was evaluated for its
adherence to injured tissue and its effectiveness in aiding hemostasis alone and in
presence of a bioresorbable dressing as assessed in femoral arteriotomy and multiple
liver models in swine. A 4 mm femoral arteriotomy model described previously23 was
used to evaluate the ability of rLFS to aid in hemostasis when exposed to arterial
pressure and blood flow. Three liver injury models were also used to test the rLFS:
small wedge-shaped resections and Grade V X-shaped stelate liver lacerations and large
lobe resections. This is the first report of the use of a fully-recombinant LFS used alone
or in combination with a bioresorbable dressing.

We also designed and tested a

prototype airbrush-based spray device for LFS application and compared it to a
pressurized air canister and the typical dual syringe applicator.
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Materials and Methods
Materials
Purified, plasma-derived prothrombin was bought from Enzyme Research
Laboratories (South Bend, IN). Recombinant thrombin (Recothrom®) was purchased
from Zymogenetics. Purified recombinant fibrinogen, expressed in the milk of transgenic
Swiss Brown cows, was obtained from Pharming Group NV (Leiden, Netherlands).
Materials for the thromboelastograph were purchased from Haemoscope (Niles, IL).
Unless otherwise specified, reagents were purchased from Sigma (St. Louis, MO).
Vector construction, expression and purification of FXIIIA in Pichia pastoris
The human Ultimate ORF clone containing the human coagulation factor
FXIIIA1 cDNA in the pENTRTM221 vector was purchased from Invitrogen (Carlsbad
CA). The following primers were used to obtain FXIIIa gene to subclone in pPICZA
intracellular

Pichia

expression

vector.

(Forward,

5'-

CCAATTGATGCATCATCATCATCATCATTCAGAAACTTCCAGGACCGC-3';
Reverse, 5'-GCGGCCGCTCACATGGAAGGTCGTCTTTGAATC-3').

The forward

primer introduced a methionine and 6 histidine amino acids at the N-terminus of mature
FXIIIa peptide. The PCR product was digested with MfeI and NotI and subcloned into
pPICZA which was digested with the same enzymes. The DNA sequence of the FXIIIA
was confirmed by sequencing the insert fragment. One of the confirming plasmid
pPICZAFXIIIa was linearized with PmeI and transformed into P. pastoris X-33 host
strain and copy number of the clones was determined as described.35 Varying copy
number clones were screened in shake flask culture to confirm intracellular production of
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FXIIIa protein. The highest producing clone was scaled up to 5 L bench scale. A fedbatch fermentation protocol was followed to optimize FXIIIa production as described by
Zhang et al., (2007).36 At the end of fermentation process the cells were separated by
centrifugation (6,000g) and pellet was stored at -80oC.
Frozen cell paste was processed in 300 gram batches. Cells were lysed in three
sets of 100 gram batches. 100 grams of cell paste was resuspended in 100 mL of cold
lysis buffer (50 mM Tris-HCL, 10 mM MgSO4, 1 mM EDTA, 10 mM potassium acetate,
1 mM DTT (DL-Dithiothreitol), 2 mM PMSF (phenylmethanesulphonylfluoride) in
methanol, pH 9.5). 100 ml (250 g) of 0.5 mm glass beads (Biospec, Bartlesville, OK)
were added and the cells. Surrounded by an ice bath, cells were lysed using a BeadBeater
Blender (Biospec, Bartlesville, OK) with twenty 20 second on/off cycles. The cell lysate
mixture was then centrifuged to remove cellular debris. The lysate from 300 grams of
cell paste was combined and purified using the HisBind Purification Kit (EMD
Chemicals, Inc.,San Diego, CA) with 40 mL of resin slurry. Following purification,
rFXIII was dialyzed in 10 mM Tris-HCl, 0.1 mM EDTA, 60 µM polysorbate-20, pH 8.0
in snake-like dialysis membranes and the protein samples were filter-sterilized and
concentrated using the Amicon tubes (Millipore, Billerica, MA). The purity of the
sample was tested by SDS-PAGE (NuPAGE 12% Bis-Tris) (Invitrogen, Carlsbad, CA)
and immunoblot. The concentration of rFXIII was determined by standard Bicinconic
Acid (BCA) methods.
FIIa preparation
Frozen, plasma-derived human prothrombin (Enzyme Research Laboratories,
South Bend, IN), was thawed at 37oC. Plasma-derived thrombin (Enzyme Research
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Laboratories, South Bend, IN) was added at a 1/10 mass to mass thrombin/prothrombin
ratio. 0.35 grams of sodium citrate per milliliter of solution was added (Lanchantin
1965). This solution was incubated at 37oC on a rotating mixer for five hours. Sodium
citrate was removed using PD-10 desalting columns (GE Healthcare, Giles, United
Kingdom).

Activation of prothrombin to thrombin was confirmed by reducing and

nonreducing SDS-PAGE (12% Bis-Tris NuPAGE) (Invitrogen, Carlsbad, CA) stained
with Colloidal Blue (Invitrogen, Carlsbad, CA). The concentration of the thrombin
solution was determined by standard Bicinconic Acid (BCA) methods. The specific
activity was determined by aPTT analysis.
Experimental dressings
Nanofiberous and macrofiberous made from a racemic poly(D,L-lactide)
(PDLLA) was obtained from LNK Chemsolutions. The production process and treatment
of the bandage are proprietary knowledge of LNK. The nanofiberous PDLLA has fiber
diameters of approximately 100 nm and is produced as a 100 µm thick sheet. 8-ply
bandages were created to yield better handling ability by stacking eight 100 µm layers.
The smooth and hydrophobic unmodified PDLLA was evaluated. It was also tested after
coating with a proprietary treatment to create a hydrophilic dressing.

Both the

hydrophobic and hydrophilic dressings were modified by adding macropores and
corrugations to assist its hemostatic capability by allowing blood inflow. Macropores
were created by punching several sets of holes using a bed of nails device (Figure 6.1).
Corrugations were also created by wetting the bandage with water until damp and heating
it between two plates at approximately 32oC for 10 minutes to several hours (Figure 6.2).
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In many of the experiments, these 8-ply modified bandages were stacked in layers with
the corrugations laid perpendicular to each other (Figure 6.3).
.
A

B

Distance between nails = 6 mm

C

D

E

Figure 6.1. Device and method for perforating the PDLLA dressing. This bed of nails (A) was used to
create macropores in the PDLLA. PDLLA was laid on a thin stainless steel plate containing holes
matching the bed of nails (B) and the bed of nails was firmly pressed so that the nails transversed the
PDLLA and embedded in a layer of styrofoam below the plate (C). After creating the first set of holes (D),
the PDLLA was removed, placed back on the plate and the bed of nails carefully aligned to create another
set of macropores. This device was used three times on each bandage creating a well perforated bandage
(E).
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B

C

D

Figure 6.2. Plates and method employed to corrugate PDLLA. Two stainless steel plates were
designed with peak heights of 1.5 mm and a 3 mm distance between peaks (A, B). These plates were
heated to approximately 32oC and PDLLA dampened with deionized water was placed between the plates
(C). The PDLLA was incubated between the heated plates for 10 minutes to several hours to create
corrugations (D).

Figure 6.3. Final PDLLA bandage format. The perforated, corrugated PDLLA was layered so that the
corrugations were perpendicular to those in adjacent layers.

LFS application devices
The LFS was tested alone in two liver injury models and with the aid of a scaffold
(gauze or PDLLA) in a femoral arteriotomy and massive liver resection. LFS was
applied to the wounds or the dressing by numerous methods (Figure 6.4). LFS was
applied to the wedges by a dual-syringe system made in the operating room (Figure 6.4A)
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and spray device predecessor to UNL’s device (not shown). LFS was applied to the
stelate liver lacerations by Tisseel’s Duploject® system (Figure 6.4B) and the PTI spray
device (Figure 6.4C). LFS was applied to dressings by pipette or UNL’s airbrush-based
spray device (Figure 6.4D and E).
A

C

B

D

E

Figure 6.4. LFS application device used during in vivo experiments. LFS was applied by two syringes
taped together with needles bent towards each other (A), Tisseel’s® duploject system (B), PTI’s spray
device (C), frontal (D) and top (E) views of UNL’s airbrush-based spray device.

A spray device was designed to deliver the rLFS in two atomized components at
finely-adjustable flow rates over a narrow focus area.

The device consists of two

modified artist-grade airbrushes (single-action, external mix, Paasche airbrushes), a main
pressure regulator and two fine control pressure regulators.

The airbrushes were

modified from delivering liquid by suction to a pressurized flow allowing the use of
lower air flow. Both regulators pressurizing the solutions to each airbrush was set at 15
psi. Each spray device is equipped with adjustable nibs which control the spray pattern,
flow rate and the amount of material delivered. The airbrushes were coupled together
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and a single trigger bar created to synchronize spraying. The pressure adjustment module
consists of a main pressure regulator that adjusts the air pressure from house air which is
coupled to two fine control pressure regulators that modulate the air flow and pressure
into each airbrush.
Animals
This research used crossbred commercial (domestic) swine obtained from UNL
Agricultural Research and Development Center (Mead, NE). All procedures performed
during this research were approved by the Institutional Animal Care and Use Committee
of the Omaha VA Hospital. All animals were treated according to the Guide for the Care
and Use of Laboratory Animals (National Institutes of Health publication 86-23, revised
1996).
TEG evaluation of blood samples throughout surgery
Multiple blood samples were drawn throughout surgery. Samples were drawn
before surgery, after surgery and between procedures that resulted in significant blood
loss. One to two milliliters of blood were drawn into tubes containing 3.2% sodium
citrate and stored on ice until testing by thromboelastography (TEG) which occurred
within five hours. 340 µl of each sample was loaded into a single-use TEG cup followed
by 20 µl of 200 mM CaCl2 (final concentration: 11.11 mM) to start the reaction. The
TEG Analytical Software (version 4.2.2, Haemoscope, Niles, IL) collected the time to
clot initiation (R), the time to achieve a clot firmness of 20mm (K) and the maximal clot
strength (MA) for 30 minutes. Data was exported from the TEG Analytical Software to
Microsoft Excel for analysis. t tests with an α of 0.05 were used to compare pre- and
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post-surgical clotting parameters for statistical significance. The percent change of TEG
values from the initial and final blood samples for each pig were calculated.

The

instrument was calibrated each day of use. All tests included three replicate samples in
each treatment group.
In vivo evaluation of rLFS
In vivo experiments on the rLFS were performed on 44 male pigs three months of
age and a mean weight of 32.1 ± 2.2 kg (range:

27.2 and 38.6 kg).

Pigs were

anesthetized by inhalation through an endotracheal tube. Under general anesthesia, a
catheter was inserted into the right carotid artery and jugular vein of each swine for blood
pressure monitoring and administration of fluid and medication. Animals were included
in results only if their systolic blood pressures were greater than 100 mmHg. Depending
on the planned experiments, the liver and/or the femoral arteries were exposed. The
femoral artery injury model consisted of a 4 mm hole. A midline laparotomy was
performed and the liver pulled up through the incision. Liver injuries included small
wedge-shaped excisions, X-shaped stelate liver lacerations and large liver lobe resections.
A Pringle maneuver was used on the stelate liver lacerations and several of the large liver
resections to minimize blood loss. After creating the injury, the planned treatment was
applied. The LFS was tested alone or in combination with the PDLLA dressing which
was also evaluated alone and with various modifications. rLFS was tested alone on
wedge-shaped liver resections and stelate liver wounds. rLFS combined with the PDLLA
dressings was evaluated on femoral arteriotomy injuries and large liver lobe resections.
Each swine underwent multiple procedures and were euthanized at the end of testing.
ANOVA and two tail t test (equal variance) analyses were performed to identify
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statistical significance between treatment groups of raw data. An α of 0.05 was used for
all statistical analyses.
rLFS on hepatic wedge resections
For the small, wedge-shaped liver resections, a cauterization tool was utilized to
draw the triangular wedge resections with a base of 1 cm and increasing heights of 0.5,
1.0, 1.5, 2.0, 2.5 and 3.0 cm (Figure 6.5). Each wedge was resected with scissors. rLFS
(9 mg/ml rFI, 0.36 mg/ml rFXIII (2,463 U/ml, rFXIIIa/FI = 0.16), 105.6 U/ml rFIIa
(FIIa/FI = 0.18), 12 mM CaCl2) was applied by spray device or by two 3 ml syringes
taped together with needles bent together to mix the solution approximately 2 cm from
the tips. The rLFS was separated into two reservoirs: rFI/rFXIII into one and rFIIa/CaCl2
in the other and applied at an approximate flow rate of 0.4 ml/sec. A total of 18 mg rFI,
0.72 mg rFXIIIa and 211.2 U rFIIa was applied to each wedge.

Hemostasis was

subsequently evaluated and given a score: 1 indicated complete hemostasis; 2 for mostly
hemostatic with minor oozing; 3 for partially hemostatic with prominent oozing and 4 for
minimal effect and complete failure. Ringer’s solution was applied as a control.
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Figure 6.5. Wedges marked on a liver lobe by a cauterization tool.
Wedges with a base of 1.0 cm and increasing heights of 0.5 to 3.0 cm
marked on a liver lobe by a cauterization tool for testing rLFS.

rLFS on hepatic stelate laceration
Grade V stelate liver lacerations were created by making one or two overlapping
X-shaped wounds using a home-made device (Figure 6.6) with an arm length of ~38 cm
and X-shaped blades ~8 cm in length. The injuries were treated in five pigs with rLFS
(7.1 mg/ml rFI, 0.25 mg/ml rFXIII (1,735 U/ml, rFXIIIa/FI = 0.16), 84.64 U/ml rFIIa
(FIIa/FI = 0.18), 12 mM CaCl2). The solution was applied by Tisseel’s Duploject® twosyringe system (Figure 6.4B). A total of 6 ml were used to treat four pigs and 10 ml to
treat the other pig. With this system, the rLFS was applied over 30 seconds to several
minutes.
The rLFS was also applied by Propulsion Technology, Inc.’s (PTI) delivery
device (Figure 6.4C) in three pigs. The device separates the rLFS into two reservoirs
(rFI/ CaCl2 and rFXIIIa/rFIIa/CaCl2) and utilizes air pressure for delivery. This system
applied 60 ml of rLFS (9 mg/ml rFI, 0.36 mg/ml rFXIII (2,463 U/ml, rFXIIIa/FI = 0.16),

182
105.6 U/ml rFIIa (FIIa/FI = 0.18), 12 mM CaCl2) in approximately 3 to 30 seconds.
Each stelate liver laceration was treated with 540 mg rFI, 21.6 mg rFXIIIa and 6,336 U
rFIIa. Hemostasis was subsequently evaluated.
In one pig, LFS (10.2 mg/ml rFI, 0.40 mg/ml rFXIII (2,791 U/ml, rFXIIIa/FI =
0.16), 119.7 U/ml rFIIa (FIIa/FI = 0.18), 12 mM CaCl2) was applied by the initial spray
device designed by LNK Chemsolutions. 5 ml LFS was applied intermittently over a
couple of minutes. The laceration was treated with 51 mg rFI, 2 mg rFXIIIa and 598.5 U
rFIIa. Hemostasis was subsequently evaluated.

A

B

Figure 6.6. Device used to create stelate liver laceration. Home-made, stainless steel device designed
with ~38 cm arms (A) and sharp X-shaped blades (B) to create a ~8 cm x ~8cm wound.

rLFS dressing on femoral arteriotomy model
rLFS coated nanofiberous and microfiberous PDLLA was evaluated in a femoral
arteriotomy model. After exposing both femoral arteries, blood flow through the artery
was controlled by applying vessel loops or arterial clamps proximal and distal from the
site of injury. While blood flow was occluded, a femoral arteriotomy was created with a
4 mm aortic punch. The test dressing was carefully laid over the wound and the blood
was allowed to flow through the artery. Manual pressure was held on the bandage for
four to five minutes. The success of a dressing was evaluated by the level of hemostasis
(complete hemostasis, oozing or uncontrolled flow) and adherence to the artery.
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Bandages constructed of hydrophobic unaltered PDLLA nanofibers (typically 4
cm x 4 cm, 8-ply) were tested dry, wet with Ringer’s solution or wet with rLFS (0.44
mg/cm2 per ply rFI, 0.02 mg/cm2 per ply rFXIIIa (rFXIIIa/rFI = 0.16), 5.07 U/cm2 per
ply FIIa (FIIa/rFI = 0.18), 12 mM CaCl2). PDLLA coated with Ringer’s solution and
FIIa (9.32 mg/cm2 pdFIIa, 7 mM CaCl2) were also evaluated. Hydrophilic, modified
PDLLA dressings were also tested alone and coated with rLFS at the same levels.
Microfiberous PDLLA bandages (3 cm x 3 cm with a depth of 1 cm) were coated with
rFI, rFXIII and pdFIIa (3.87 mg/cm2 rFI, 0.15 mg/cm2 rFXIII, 0.09 mg/cm2 pdFIIa, 7
mM CaCl2) or Ringers solution alone or with pdFIIa (0.09 mg/cm2 pdFIIa, 7 mM CaCl2).
Liquids were applied to the dressings by pipette.
rLFS dressing on hepatic resections
The LFS was tested on hepatic resections of multiple sizes. Small resections
excised the tip of the lobe exposing a parenchymal area of 5-7 cm by 2 cm. Excisions of
medium resections exposed an area of 10-12 cm by 3 cm. Large resections exposed an
area of 15-17 cm by 5-6 cm (25-33% of the liver mass). After removal of the lobe by
scissors, blood flow was limited by manual pressure or a Pringle maneuver. Dressings
were applied to the exposed tissue and held by manual pressure for three minutes. When
released, the success was evaluated by the level of hemostasis (1 indicated complete
hemostasis; 2 for mostly hemostatic with minor oozing; 3 for partially hemostatic with
prominent oozing and 4 for minimal effect and complete failure).
Bandages constructed of hydrophilic, PDLLA nanofibers modified with
macropores, corrugations and roughing of the wound-side (typically 5 cm x 5 cm, 8-ply)
were tested dry, wet with Ringer’s solution or wet with approximately 0.43 mg/cm2 per
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ply rFI, 0.02 mg/cm2 per ply rFXIIIa (rFXIIIa/rFI = 0.16), 5.07 U/cm2 per ply FIIa
(FIIa/rFI = 0.18), 12 mM CaCl2. rLFS was applied to the PDLLA by pipette or by
UNL’s spray device (Figure 6.4D and E). After being coated with rLFS, the bandages
were placed on the wound within 2 to 4 seconds and a small amount of blood was
allowed to flow through the macropores and infiltrate the bandage. A series of 5 cm x 5
cm bandages were coated and applied to the wound. Small resections typically required
three or four bandages. Medium and large bandages typically needed five to seven
coated dressings. Therefore, small resections used approximately 33 mg rFI, 1.3 mg
rFXIIIa and 380 U rFIIa. Medium and large resections used approximately 78 mg rFI, 3
mg rFXIIIa and 887 U rFIIa.

Results
Evaluation of swine clotting factors
Blood samples for each swine were drawn before, during and after surgical
procedures and evaluated within five hours by thromboelastography (TEG). This was
used to identify pigs with abnormal clotting parameters and to monitor changes in
endogenous coagulation parameters throughout the surgery due to blood loss or
haemodilution (Table 6.1). t tests indicated that average pre- and post-surgical clotting
parameters were not significantly different for time to clot initiation (p = 0.242),
coagulation time (p = 0.319) or maximum clot strength (p = 0.185). Consequently, all
procedures on each swine can typically be included; however, this was determined for
each individual swine. A representative TEG tracing is shown (Figure 6.7). Even after
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significant blood loss, few post-surgical TEG results differed significantly from initial
samples.

Table 6.1. Average time to clot initiation (R), coagulation time (K) and maximum amplitude of presurgical and post-surgical blood samples and the subsequent percent change. Data presented as
average ± standard deviation, N = 35 for pre-surigical, 33 for post-surgical and % change.
Time to Clot
Coagulation Time
Maximum Amplitude
Initiation (sec)
(sec)
(mm)
Pre-surgical blood sample
328.71 ± 93.03
100.98 ± 28.58
67.92 ± 4.82
Post-surgical blood samples
362.60 ± 140.31
109.32 ± 39.36
65.48 ± 9.58
% Change
0.12 ± 0.32
0.13 ± 0.36
-0.04 ± 0.14
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Figure 6.7. Representative TEG tracings of blood samples from a pig before, during and at the
conclusion of the surgery. Thromboelastographic comparison of clotting parameters of presurgical
blood samples from five swine (A); and comparisons of bloods drawn from the same swine throughout
the surgical procedure (B).
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LFS on hepatic wedge resections
The optimized rLFS was applied to wedge resections of the liver with a base of
1.0 cm and heights from 0.5 to 3.0 cm. Wedge resections were performed on 16 pigs and
rLFS was applied by spray device (Figure 6.8) on 9 pigs and the two-syringe system
(Figure 6.9) on the remaining 7 pigs.

B

A

C

Figure 6.8. Wedge resection treated with rLFS applied by spray-device. Triangular-shaped wedges
with bases of 1.0 cm and 0.5 to 3.0 cm heights were resected (A) resulting in profuse bleeding (B) which
was treated with rLFS applied by a spray-device (C). This application resulted in complete hemostasis.

A

B

C

Figure 6.9. Wedge resection treated with rLFS applied by double barrel syringe. Triangular-shaped
wedges with bases of 1.0 cm and 0.5 to 3.0 cm heights were resected resulting in profuse bleeding (A)
which was treated with rLFS applied by a spray-device (B). The rLFS created a solid, white clot (C). This
application resulted in complete hemostasis.

The two application techniques yielded similar results.

ANOVA indicates that

hemostatic results obtained at different depths are statistically different (p < 0.001).
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Complete hemostasis was achieved most frequently in the smaller wedges (Figure 6.10,
Table 6.2). 82% of the 0.5 cm height wedge cuts were completely hemostatic while the
remaining two cuts were mostly hemostatic. 64% of the 1.0 cm height resections were
mostly hemostatic with the other 5 being completely hemostatic. At a depth of 1.5 cm,
27% were completely hemostatic, 45% mostly hemostatic, 18% less hemostatic and 9%
failed. At 2.0 cm, 9% were completely hemostatic, 45% were mostly hemostatic and
45% were less hemostatic. 9% were mostly hemostatic while 91% of 2.5 cm depths
resulted in minimal hemostasis. At a depth of 3.0 cm, 75% were minimally hemostatic
with the remaining 25% resulting in no hemostasis.

Frequency of Hemostasis Score

10
Complete Hemostasis
Mostly hemostatic, minor oozing
Less hemostatic, prominent oozing
Minimal effect/failure

8

6

4

2

0
0.5

1.0

1.5
2.0
Excision Depth (cm)

2.5

3.0

Figure 6.10. Frequency of hemostasis scores at each excision depth. The frequency of complete
hemostasis (green), mostly hemostatic (blue), less hemostatic (yellow) and minimal effect (red) is shown at
each excision depth.

189
Table 6.2. Average hemostasis scores for excision depths.
Data presented as average ± standard deviation.
Depth (cm)
N
Hemostasis Score
0.5
11
1.18 ± 0.40
1.0
14
1.64 ± 0.50
1.5
11
2.09 ± 0.94
2.0
11
2.36 ± 0.67
2.5
10
2.90 ± 0.32
3.0
8
3.25 ± 0.46

The approximate areas of the parenchymal tissue were estimated at each depth
and volume of LFS needed to create hemostasis estimated (Table 6.3). This data was
used to calculate the approximate volume of LFS needed per cm2 of tissue injury. At
wedge depths of 0.5, 1.0 and 1.5 cm, 5.0, 3.8 and 2.8 ml LFS per cm2 is needed to
typically yield complete hemostasis, respectively. Consequently, the average volume of
LFS needed is 3.88 ± 1.09 ml/cm2 using 34.9 mg/cm2 rFI, 1.4 mg/cm2 rFXIIIa and 409.7
U/cm2 rFIIa. These values are true for wedges with a depth of 1.5 cm or less. Unlike the
smaller wedges, the larger wounds contained large blood vessels up to 1 cm in diameter
(Figure 6.11) that interfered with hemostasis. The LFS was unable to stop bleeding of
large vessels. LFS formed a clot over the large vessels; however, the LFS was unable to
adhere to the parenchymal tissue surrounding the vessel most likely due to the pressure of
the blood pouring out of the vessel. This resulted in significant bleeding from under the
clotted layer of LFS.

Table 6.3. Estimated areas of the wound created by the wedge excisions.
Approximate
LFS needed
Estimated LFS
Depth
Estimated
Thickness
for hemostasis
(ml) per cm2
2
(cm)
Area (cm )
(cm)
(ml)
needed
0.5
0.3
0.12
0.6
5
1.0
0.4
0.37
1.4
3.78
1.5
0.5
0.71
2.0
2.8
2.0
0.6
1.14
> 2.0
2.5
0.7
1.68
> 2.0
3.0
0.8
2.31
> 2.0
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Figure 6.11. Sizeable vessel transected in larger wedge resections. The
wedges with depths of 2.5 an 3.0 cm typically had sizeable vasculature at the
apex of the wedge up to 1 cm in diameter.

rLFS on hepatic stelate laceration
The optimal LFS was tested on grade V stelate liver lacerations in nine pigs
(Figure 6.12). The average hemostasis score was calculated based on the number of Xshaped wounds (Table 6.3). One X-shaped wound had an average hemostasis score of
1.50 ± 0.55. Two X-shaped wounds had an average hemostasis score of 1.67 ± 0.58.
One X-shaped wound was created in the five pigs treated with LFS applied by Tisseel’s
Duploject® system. Three of the five resulted in complete hemostasis. The last two were
mostly hemostatic with minor oozing that was subsequently stopped by packing with
gauze and pressure. Two overlapping X-shaped wounds were created in two of the three
stelate lacerations treated by PTI’s application device. The last pig had only one Xshaped wound created.

After the four to five minute hold, all three were mostly

hemostatic with minor oozing that was stopped by gauze and pressure. The one pig
treated with LFS applied by LNK’s spray device had two overlapping X-shaped wounds
that was completely hemostatic.
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Figure 6.12. Grade 5 stelate liver injury treated with LFS. Stelate liver laceration before (A) and after
(B) treatment with 7.05 mg/ml rFI, 0.28 mg/ml rFXIII, 0.16 mg/ml pdFIIa (84.5 U/ml), 6 mM CaCl 2
applied by Duploject system (see Figure 6.5).
Table 6.3. Average hemostasis scores for number X-shaped
wounds. Data presented as average ± standard deviation.
# X-shaped
N
Hemostasis Score
Wounds
1
6
1.50 ± 0.55
2
3
1.67 ± 0.58

rLFS dressing on femoral arteriotomy model
Numerous versions of the PDLLA bandage and gauze were tested alone, wet with
Ringer’s solution and coated in various components of LFS on a 4 mm femoral
arteriotomy (Figure 6.13) in 13 pigs. Two forms of PDLLA were tested: nanofiberous
(Figure 6.13B) and microfiberous (Figure 6.13C). The nanofiberous PDLLA was tested
in its original smooth, hydrophobic form (Figure 6.13B) and in a hydrophilic, modified
form (Figure 6.3). Only 14.7% of nanofiberous PDLLA were hemostatic (Figure 6.13D);
however, 60% of treatments with the microfiberous PDLLA were hemostatic (Figure
6.13E, Table 6.4). Four of the five successful nanofiberous PDLLA dressings were
coated with all of the components of the LFS and were modified with corrugations;
however, a majority of those treatments failed. A significantly larger percentage of the
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microfiberous PDLLA dressings were successful and the best results were observed when
treated with rFXIIIa and FIIa and with all components of the LFS.

A

C

B

D

E

Figure 6.13. 4 mm arteriotomy treated with bandages soaked in LFS. A 4 mm hole was made in the
femoral artery (A) and treated with bandages constructed of PDLLA nanofibers (B) and microfibers (C).
Nanofiberous bandages (4 cm x 4 cm, 8-ply) were coated with rFI, rFXIII and pdFIIa (0.44 mg/cm2 per ply
rFI, 0.02 mg/cm2 per ply rFXIII, 0.004 mg/cm2 per ply pdFIIa, 7 mM CaCl2) (D). Microfiberous bandages
(3 cm x 3 cm with a depth of 1 cm) were coated with rFI, rFXIII and pdFIIa (3.87 mg/cm2 rFI, 0.15
mg/cm2 rFXIII, 0.09 mg/cm2 pdFIIa, 7 mM CaCl2) (E).
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Table 6.4. Hemostatic results of PDLLA treated with
applied to femoral arteriotomies.
PDLLA
Modifications
form
Microfiberous
None
Microfiberous
None
Microfiberous
None
Microfiberous
None
Microfiberous
None
Nanofiberous
None
Nanofiberous
None
Nanofiberous
None
Nanofiberous
None
Nanofiberous
None
Nanofiberous
corrugation
Nanofiberous
corrugation
Nanofiberous
macropores, corrugation
Nanofiberous macropores, corrugation, surface roughing
Nanofiberous macropores, corrugation, surface roughing
Nanofiberous macropores, corrugation, surface roughing

Ringer’s or various components of LFS
Treatment

N

None
Ringer’s
FIIa
rFXIIIa + FIIa
rFI + rFXIIIa + FIIa
Ringer’s
FIIa
rFXIIIa
rFXIIIa + FIIa
rFI + rFXIIIa + FIIa
rFXIII + FIIa
rFI + rFXIIIa + FIIa
None
None
rFI
rFI + rFXIIIa + FIIa

10
11
4
1
4
7
1
1
2
4
4
4
1
1
2
7

%
hemostatic
50
64
50
100
75
0
0
0
0
0
0
50
0
0
50
29

rLFS dressing on hepatic resections
Three large hepatic resections were made, covered with gauze and sprayed with
LFS (Figure 6.14). All three were completely hemostatic. Three small, one medium and
35 large resections were treated with PDLLA alone or coated with LFS (Table 6.5).
Once the lobe was resected, 5 cm x 5 cm dressings coated with LFS were applied one by
one to the wound surface.

53.3% of the LFS coated dressings were completely

hemostatic (Figure 6.15) while 43.3% were mostly hemostatic and the remaining 3.3%
were less hemostatic.

Some applications successfully adhered to the entire wound

surface and were not affected by the large vessels (Figure 6.15C); however, pockets
frequently formed over the largest vessels apparently due to the pressure from the blood
flow. The cases that were not completely hemostatic oozed from under the dressing
apparently from these large vessels. These had less adhesion then those resulting in
complete hemostasis. The method of application of the LFS to the PDLLA did not
appear to affect the success.
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A

B

C

Figure 6.14. Treatment of large hepatic resection with gauze coated with rLFS. A fatal injury was
created by removing an ~12 cm long section (A) which was covered with gauze (B) and then rLFS (C).
Table 6.5. Hemostatic results of PDLLA treated with LFS applied to hepatic resections. All bandages
were modified by adding macropores, corrugations and roughing the surface.
PDLLA
Size of
Completely
Mostly
Less
Hydrophobicity N
Failed
form
Resection
Hemostatic Hemostatic Hemostatic
Nanofiberous
Small
Hydrophobic
1
1
0
0
0
Nanofiberous
Small
Hydrophilic
2
2
0
0
0
Nanofiberous Medium
Hydrophobic
1
1
0
0
0
Nanofiberous
Large
Hydrophobic
1
1
0
0
0
Nanofiberous
Large
Hydrophilic
30
16
13
1
0

195
A

B

C

D

E

Figure 6.15. Treatment of a large hepatic resection with nanofiberous PDLLA coated with rLFS.
The planned resection, consisting of ~25% of the liver mass, was marked by a cauterization tool (A).
Following removal, 5 cm x 5 cm nanofiberous PDLLA dressings coated with rLFS were applied to the
wound and held for 3 minutes under pressure. When the pressure was removed, the wound was hemostatic
(B) despite the presence of large vasculature as visualized in the removed portion of the liver (C). After the
surgery, the bandage was removed and the level of adherence evaluated. The adherence was strong enough
to lift the liver by the bandage (D). Clot is clearly visible on the surface of the dressing (E).

Dry PDLLA without LFS was also applied to three liver resections resulting in
complete hemostasis in one and minor oozing in another. Although these results are
similar to that achieved with LFS coated PDLLA, the dressings alone were not as
adhered to the wound as those treated with LFS. We also applied larger (10 cm x 5 cm)
rather than multiple small dressings coated with LFS; however, both attempts resulted in
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minimal hemostasis. The large bandages tended to have creases and were difficult to lay
flat on the wound resulting in tunneling of blood under the dressing. Consequently, the
dressings failed to adhere to the tissue.

Discussion
Our optimal LFS was tested alone and in combination with a PDLLA dressing on
multiple injury models. The LFS was effective in stopping bleeding in wedge resections
with shallow depths but failed in deeper cuts.

Depths of 2.0 or more centimeters

typically had large vasculature at the apex of the wedge (Figure 6.11).

The LFS

successfully formed a clot over the large vessels; however, the LFS was unable to adhere
to the parenchymal tissue surrounding the vessel most likely due to the pressure of the
blood pouring out of the vessel. This resulted in significant bleeding from under the
clotted layer of LFS. Consequently, LFS can effectively treat oozing tissue and wounds
containing small vasculature; however, requires a scaffold when large vessels are present.
Research indicates that the fibrinogen in FS is critical for adhesion and the best
results are attained at 40 to 70 mg/ml;8 however, we achieved good hemostasis with 9
mg/ml as seen in the stelate liver laceration model (Figure 6.12). All of the grade V
stelate lacerations resulted in complete hemostasis or only slight oozing which was
subsequently stopped by pressure and gauze.

Although all of the treatments were

considered successful, the best results were achieved with the minimal amount of sealant
implying that application is the key. Three of the five resulting in complete hemostasis
were treated with 6 ml LFS and the one with two X-shaped wounds that ended in
complete hemostasis was treated with 5 ml LFS. Three of the four treatments resulting in
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slight oozing were treated with 60 ml of LFS. Hence, the Duploject® and spray device
applicators were significantly better than PTI’s device which mixed large volumes of FS
in a nozzle.
Application with the spray device appears to lower the amount of LFS required to
achieve hemostasis. This is probably true because the device focuses the application to a
targeted area, judiciously supplies the proteins, and better mixes the two components of
the LFS. The spray device was designed for possible uses such as:
1. treating wounds not containing major blood vessels;
2. coating the PDLLA dressing with LFS immediately prior to application;
3. applying LFS to the top of a wound already covered with PDLLA;
4. precoating the wound prior to mesh application.
The spray device has two chambers that keep the rFI/rFXIIIa solution separate from the
rFIIa solution until application and can administer as little as 0.5 ml volumes of LFS. Its
efficiency is a result of the spray pattern which focuses the spray to a 1 to 3 cm diameter
target area without spurious atomization and thoroughly mixes the clotting factors for
immediate clot formation.
Our bioengineering paradigm for bandage design focuses on the use of a
resorbable mesh to efficiently deliver expensive clotting factors. The use of a dressing in
combination with the LFS shifts the burden of the mechanical stabilization of the wound
surface to the mesh. Hence, the dressing material withstands the pressure from blood
flow while exogenous and endogenous clotting factors need only adhere the dressing to
the wound.

Macropores, corrugations and roughing of the surface of the PDLLA
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dressing were performed in an attempt to enlist endogenous factors in the blood as
additional support for the LFS by allowing it to intercolate into the bandage material.
The modifications to the PDLLA are designed to mimic the ability of surgical
cotton gauze to intercolate endogenous blood to gain adhesion.

This was done by

imparting a corrugated and perforated structure to the PDLLA nanofibrous mesh which
resulted in the necessary macroporous interstitial space for sufficient blood clot
intercolation to achieve adhesion. This was done without increasing the mass of PDLLA
mesh. Cotton gauze macroporosity arises from microfilamentous structure and not only
has the deficiency of not being resorbable, but has a material mass that is not affordable
when translated directly to a PDLLA microfibrous equivalent.
A dressing consisting of dry, lyophilized FI and FIIa on a different backings was
evaluated in a femoral arteriotomy (6 mg/cm2 pdFI, 50 U/cm2 pdFIIa),22 ballistic injury
(10.29 mg/cm2 pdFI, 28.57 U/cm2 pdFIIa, 2.5 mg/cm2)4 and Grade V liver injury (15
mg/cm2 pdFI, 37.5 U/cm2 pdFIIa, 117 µg/cm2)21 models. Under normal, hypothermic
and coagulopathic conditions, this bandage was significantly better than gauze with
respect to minimizing blood loss and maintaining blood pressure.4,

22

We have

significantly reduced the protein levels on the PDLLA making the dressing more
economically feasible. Compared to the grade V liver injury, our LFS contains 97%
less FI (0.43 mg/cm2) and 90% less FIIa (5.07 U/cm2). Despite significantly reducing
the protein content, our LFS successfully aided hemostasis in grade V liver injuries.
Jackson et al. coated a silicone backing with a lyophilized FS which proved
significantly more successful in creating hemostasis than the control dressing in a 4 mm
femoral arteriotomy model in pigs. Five of six wounds resulted in complete hemostasis
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in 15 minutes compared to none of the controls after 60 minutes.23 Our LFS coated
dressing failed to achieve this success. The modified nanofiberous PDLLA succeeded
in only 29% of the treatments; however, the microfiberous PDLLA successfully
resulted in hemostasis in 75% of treatments. These results were achieved after a five
minute hold compared to the 15 minutes in the previous study. We believe our low
success rate is due to the limited cross-sectional area for adhesion of bandage. This was
supported by our success in achieving hemostasis in large liver resections.
Our success rate significantly increased when treating larger surface areas with
LFS coated nanofiberous PDLLA despite the existence of vessels up to 1 cm in
diameter.

53.3% of treatments were completely hemostatic and 43.3% mostly

hemostatic after a 3 minute hold; however, if pressure was held for 15 minutes, many of
the mostly hemostatic results may have been upgraded. The success appeared to be
highly dependent on the application technique in large liver laceration. The best results
were achieved when a slight amount of blood was allowed to flow through the bandage
and pressure was held over the entire length of the wound to ensure adhesion especially
around the large blood vessels. Practice typically resulted in better results. When
pressure was not held directly over the wound, pockets of blood would form under the
bandage. These pockets were frequently hemostatic; however, they typically resulted in
lower adhesion of the bandage to the wound. The treatments that continued to ooze
were frequently linked to the lifting of the bandage by the blood flow from a major
vessel.
Our aim is to create a FS dressing that works under various conditions by
untrained personnel; therefore, more work needs to be done to lessen the effect of
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application technique. Despite the unreliable performance, 97% of the applications
yielded complete or mostly hemostatic results on a lethal injury. Those rated as mostly
hemostatic were rendered completely hemostatic by applying pressure and gauze or a
second application of LFS coated PDLLA. One application of LFS coated PDLLA on a
large resection resulted in complete hemostasis without holding pressure.
Previous research indicates that efficacy of FS depend on the surgical situation
and the method and speed of application is critical for success.37 Our research supports
these conclusions. While our LFS alone could successfully achieve hemostasis in some
wounds, it required a scaffold in wounds with major vasculature. Our LFS coated
dressings were extremely successful in treating grade V hepatic resections; however, was
less effective when treating 4 mm femoral arteriotomies. As previously described, the
application technique significantly affects results and once the PDLLA is coated with the
mixed solutions it must be applied quickly before the LFS clots. Our future objective is
to minimize these limitations.
Like the LFS, the PDLLA bandage is early in its design stage. The dressing was
designed to provide a strong matrix so that for larger wounds the bandage provides the
necessary strength to withstand blood pressure while the LFS stops bleeding through the
pores of the bandage and glues the bandage to the wound. It was also designed to
encourage tissue regeneration with respect to cell migration and proliferation. Details
regarding the design of the bandage including manufacturing process, fiber features, pore
sizes and pre-treatments of the material to make it more hydrophilic are proprietary
knowledge of LNK Chemsolutions. The degradation rate of the matrix after implantation
has not yet been determined; however, it is estimated to be removed within 30 to 60 days.
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Future studies will include detailed evaluation of (1) the interaction of the LFS and
bandage fibers at the molecular level; (2) the degradation/dissolution rate of the bandage
material in vivo and effects of byproducts which are anticipated as being minimal; and (3)
the rate of remodeling of tissue on the LFS/PDLLA matrix.
The research presented in this chapter is the first report of the use of a fullyrecombinant LFS used alone or in combination with a bioresorbable dressing. We also
designed and tested a prototype airbrush-based spray device for LFS application and
compared it to a pressurized air canister and the typical dual syringe applicator. Stelate
liver lacerations, major lobe resections and some of the larger wedge resections included
extensive tissue and vascular damage; however, our optimal LFS successfully achieved
hemostasis in a significant number of the wounds. LFS applied without the assistance of
a dressing was able to stop bleeding of oozing wounds or those with small vessels;
however, a scaffold was needed when wounds contained large vasculature. Although the
results presented in this chapter are promising, more research needs to be conducted to
develop the best LFS application device and dressing that optimizes hemostatic results
but is not dependent on the experience of the applicator.
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Abstract
Recombinant factor VIII (rFVIII) therapy for Hemophilia A has proven to be safe
and efficacious. However, rFVIII is produced by mammalian cell culture at low levels
similar to blood plasma which cannot satisfy the future global demand for prophylactic
and other optimal therapies. The milk of transgenic livestock may be the most cost
effective and prodigious production vehicle for achieving that future goal. Prior to this
study, FVIII expressed in mouse, rabbit, and pig milks was largely inactive. For the first
time, we report the expression of a bioengineered FVIII together with von Willebrand
Factor (vWF) in milk (FVIII-tg). FVIII-tg was produced by the mammary gland at >600fold higher activity levels than human plasma and >450-fold higher than reported for cell
culture.

FVIII-tg had biological activity similar to commercial rFVIII and showed

similar binding avidity to plasma-derived vWF which is a prerequisite for stability when
in circulation. The intravenous infusion of immunopurified FVIII-tg rendered normal
hemostasis to hemophilia A mice in response to tail transection. Importantly, this work in
transgenic mice serves as a basis for the translational development of rFVIII produced by
transgenic pigs.
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Introduction
Hemophilia A is an X-linked, inherited disorder of blood coagulation primarily
caused by deficiency or dysfunction of factor VIII (FVIII) that affects approximately one
in every 5,000-10,000 males.1-3 Currently, hemophilic patients are treated with
intravenous infusion of highly purified FVIII concentrates derived from donor human
plasma or a variety of recombinantly-derived FVIII (rFVIII) produced by animal cells
such as Chinese hamster ovary (CHO) cells in large scale bioreactors.4-6 Aggressive
prophylactic FVIII replacement therapy reduces hemarthroses7 and this has become the
standard of care for the management of pediatric patients with severe hemophilia and is
now also showing benefits in adult patients.

However, to achieve this level of

prophylactic replacement therapy requires greater than $100,000 USD per patient per
year.8 Despite the clear benefits of prophylactic therapy in this population, 80% of the
world hemophilia population does not receive adequate access to replacement therapy.
Many factors contribute to this, but a lack of abundance and associated costs of current
production of plasma-derived FVIII and rFVIII concentrates, preclude the application of
universal prophylactic treatment of hemophilia A in even the most economically
developed countries and routine access in developing countries.1, 4, 5
The commercial manufacturing of FVIII from blood plasma and rFVIII from
animal cell culture are both greatly and similarly inefficient. This is primarily due to
limitations in the biosynthetic pathway of rFVIII which have been well detailed in
mammalian expression systems.9-11 This pathway is inhibited at transcription,12-14 posttranslational modification and translocation from the endoplasmic reticulum to the Golgi
apparatus.9,

15

While wild-type (WT)-FVIII is expressed in animal cell culture at <1
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unit/ml, the co-expression of von Willebrand Factor (vWF) greatly stabilizes and
increases the accumulation of secreted WT-FVIII activity and is commercially used to
produce rFVIII. Alternatively, we and others have previously reported on the ability of
the mammary gland to express rFVIII in the milk of transgenic mice,16 rabbits,17,

18

sheep19 and pigs20 (Table 7.1). Using milk avails the mammary gland’s high cell density
of about 109 epithelial cells per ml of luminal volume relative to the much lower 5 x 106
animal cells per ml of the classical bioreactor 21. However, while WT-FVIII was made in
milk at 600-fold greater concentration than blood plasma or animal cell culture, the
specific activity of the rFVIII was very low at about 2 to 10% of expected.16,

17, 20

Analysis suggests that the markedly reduced specific activity was a consequence of the
instability of rFVIII expressed in milk, especially in the absence of vWF.

Table 7.1. A comparison of expression levels and activity of WT-FVIII made in plasma,
cell culture and milk of transgenic animals.
WT-FVIII
Activity Level
Specific Activity
Source*
Concentration
(IU/ml)
(IU/mg)
(μg/ml)
3
Human plasma
0.2
1
5,000
COS-1 in cell culture10
Dual vWF/FVIII transfected CHO
cell culture

0.026

0.125

4,800

N/A

1.3979

>4,00022

Milk of Transgenic Mice16
50.21
13.41
267
Milk of Transgenic Rabbits17
117
0.521
4.5
Milk of Transgenic Pigs20
2.66
0.62
233
Milk of Transgenic Sheep19
0.006
N/A
N/A
* The highest expression levels of WT-FVIII reported from references provided. N/A: not available.

As a fundamental precursor to large-scale production in transgenic livestock, we
show for the first time that fully biologically active, single chain rFVIII can be secreted
into the milk of transgenic mice while at >450-fold activity levels than previously
reported with WT-FVIII in animal cell culture. First, we utilized a novel bioengineered
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form of rFVIII with demonstrated high secretion efficiency (226/N6) yielding >10-fold
improved expression over B domain-deleted FVIII and WT-FVIII.15. This particular
form of rFVIII is expressed in mammalian cells as a single chain molecule with high
efficiency due to improved mRNA expression, improved ER-Golgi transport, and
reduced cellular ER stress.23 Secondly, we further enhanced the stability of FVIII within
the milk environment by co-expression of vWF and alpha-1 antitrypsin (AAT). This is
the first report of FVIII and vWF coexpression in transgenic animals.

Materials and Methods
DNA constructs
The WAP7FVIII 226/N6 construct was assembled by altering the Kpn I site of
pUCWAP624 by the addition of linkers that introduced a Sal I site immediately
downstream of the 4.1 kbp WAP (whey acidic protein) promoter and in front of 1.7 kbp
of mouse WAP 3’ UTR that contains the coding of the polyadenylation signal to produce
pUCWAP7. The sequence for 226/N6 was removed by restriction enzyme digest using
Sal I and Xho I from pMT2226/N6 described previously.15 This fragment was introduced
into the Sal I site of pUCWAP7 and ligated. The resulting plasmid, pUCWAP7FVIII226/N6, was digested with Not I to release the expression construct (WAP7FVIII226/N6) that was separated by agarose gel electrophoresis.
The plasmid pUCWAP6vWF containing the WAP6vWF expression construct was
a gift from Dr. Henryk Lubon, (American Red Cross, Rockville, MD). This plasmid
contained the cDNA for vWF placed between the 4.1 kbp WAP promoter and the 1.7 kbp
3’UTR. Removal of the WAP6vWF expression construct was achieved by digesting the
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plasmid with Not I and Sfi I followed by agarose gel electrophoresis. The plasmid
designated PPL456 containing the BLG (beta lactoglobulin) driven AAT construct was a
kind gift from Dr. David Ayares (Revivicor, Blacksburg, Virginia). This construct has
been previously described in detail.25

The expression construct (BLG-AAT) was

removed from plasmid elements by digest with restriction enzymes Not I and Sal I
followed by agarose gel electrophoresis.

All released fragments were purified by

extraction prior to microinjection using a Nucleospin Extract kit (Clonetech Laboratories,
Inc. Palo Alto, CA).
Generation and identification of transgenic mice
Transgenic mice were generated by pronuclear microinjection of purified DNA
constructs through the Transgenic Core facility at the University of Michigan. Briefly,
purified DNA was microinjected into fertilized eggs obtained by mating (C57BL/6 x
SJL)F1 or C57BL/6 female mice with (C57BL/6 x SJL)F1 male mice.

Pronuclear

microinjection was performed as previously described.26 PCR primer pairs were: for
WAP7FVIII-226/N6,
(ccttggcttagcgatgttga);

WAPS2
for

WAP6vWF,

(ctgtgtggccaagaaggaagtttg)/FVIIIA2
WAP150

(gctctctctgtgtggccaag)/vWFA1

(ttccttctgcacaaagggtc); for AAT construct, BLG-S1 (ctggctctgacctgtccttg)/AATa1
(atcgtgagtgtcagccttgg).
Southern analysis was performed on select mice to confirm PCR results and
evaluate transgene ratio and copy number. Mouse DNA (10 μg) was digested with EcoRI
and Hind III and subjected to agarose gel electrophoresis. Probes were produced by
biotin incorporation via PCR using the KPL Detector DNA biotinylation kit (KPL, Inc.
Gaithersburg, Maryland).

PCR primers are as follows:

for WAP, WAPprobeS1
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(gcatgctcacactcaacagg)/ WAPprobeA1 (taagagtgtggaggcgcttg); for AAT, same primers
as for PCR, BLG-S1/AAT-A1. Size of each probe is approximately 500 bp. Blocking
and detection was performed per manufacturer’s instructions using a KPL Detector AP
chemiluminescent blotting kit followed by exposure to film.
Mouse milk collection and preparation
Milk collection was done as previously described26. Briefly, naturally lactating
females were separated from their pups for a period of 1 to 3 hours, then anesthetized
with 0.2 to 0.4 ml of Avertin given IP. After becoming anesthetized, animals were then
given 2 IU of oxytocin IM in the hind leg. After 30 seconds each gland was massaged to
express milk then milk was collected into a 1.5 ml microcentrifuge tube by vacuum
aspiration through a small heat-polished glass capillary tube. Samples were stored at 70oC.
Factor VIII Biochemical Analysis
Samples were thawed at 37 0C, immediately placed on ice, diluted 1:10 using PBS
buffer and centrifuged at 10,000 rpm for 10 minutes. The upper lipid layer was removed
and the supernatant analyzed. FVIII ELISA was purchased from Affinity Biologicals Inc.
(Ancaster, ON, Canada). FVIII deficient plasmas and FACT (normal human pooled
plasma) were purchased from George King Bio-Medical Inc. (Overland Park, Kansas).
FVIII activity was measured by 1) one-stage aPTT clotting assay on an MLA Electra 750
fibrinometer by reconstitution of human FVIII-deficient plasma or 2) by modified twostage assay utilizing the COAMATIC Factor VIII (Chromogenix, Milano, Italy)
according to the manufacturer’s instructions. The ELISA activity assay standard curves
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assumed a FVIII concentration of 200 ng/mL antigen (1 IU/mL) of activity. The ELISA
assays on milk samples were sensitive to 0.02 μg FVIII/ml. Chromogenic FVIII activity
measurements were sensitive to 0.05 IU/ml in milk.
Immunoaffinity chromatography purification of FVIII from transgenic mouse milk
Supernatant of pretreated milk samples were pooled and passed through a 0.2 um
filter. After incubating transgenic mouse milk (diluted to 50 ml with TBS) with F8conjugated sepharose beads overnight, the sample and beads were packed into a 50
ml/1.5 cm diameter column. The purification procedure was carried out according to the
protocol described previously.27 226/N6-CHO protein was purified from stablytransfected Chinese hamster ovary (CHO) cell lines as described previously.15
Western Blots
Nonreduced and reduced samples were evaluated by sodium dodecyl sulfate
polyacrylamide (SDS-PAGE) gel electrophoresis on 4-12% NuPage® Bis-Tris gels
(Invitrogen Carlsbad, CA). Blots were probed for FVIII with a sheep anti-human FVIII
polyclonal antibody (USBiological, F0016-10, Swampscott, MA) primary antibody and a
donkey anti-sheep IgG peroxidase conjugate secondary antibody (Sigma, A3415, St.
Louis, MO). Blots were probed for vWF with a goat anti-human vWF peroxidase
conjugated polyclonal antibody (USBiological, V2700-04B, Swampscott, MA). Blots
were probed for AAT with a rabbit anti-human α1-antitrypsin polyclonal antibody
(USBiological, A2298-27H, Swampscott, MA) primary antibody and a goat anti-rabbit
IgG peroxidase conjugate secondary antibody (Sigma, A9169, St. Louis, MO).
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FVIII-vWF binding ELISA
Immulon 4HBX plates (Fisher Scientific, Pittsburgh, PA) were coated with antiFVIII antibody (F8C-EIA-C, Affinity Biologicals) overnight at 40C diluted 1:100 in 0.05
M sodium carbonate/bicarbonate, pH 9.6. Protein samples were diluted in TBST (50 mM
Tris-HCl, pH 7.6, 150 mM NaCl, 0.05% Tween 20), 3% BSA, 1% FVIII-deficient
human plasma(George King Bio-Medical) in 1.5 mL microcentrifuge tubes, and
incubated for 2 hours at 370C. Wells were washed with TBST containing 10mM CaCl2
four times. Samples were loaded into wells and incubated for 2 hours. Wells were washed
four times, and anti-vWF antibody conjugated with HRP (p0266, Dako, Carpenteria, CA)
was diluted 1:1000 with TBST, and incubated for 2 hours at 370C or overnight at 40C.
After four washes with TBST with 10mM CaCl2, O-phenylenediamine dihydrochloride
substrate (SIGMAFAST OPD, Sigma) was added and the reaction was stopped by 2.5 M
H2SO4. Absorbance was read at 490 nm.
In vivo tail clip assay in the hemophilia A mouse
Hemophilia A mice (exon 16 knockout)28 were subjected to a tail clip bleeding
assay. Mice of at least 10 weeks age were injected with purified FVIII proteins 226/N6-tg
or 226/N6-CHO-FVIII.

C57BL/6 and hemophilia A mice littermates were used as

controls for injection with lactated Ringer’s solution. Mice were injected with 80IU/kg
body weight of the FVIII proteins in 100 μl lactated Ringer’s solution via tail vein.
Ketamine 85 mg/kg with xylazine 5 mg/kg was injected IP to induce anesthesia. After 5
minutes, the tails of mice were cut 1.5 mm from tail tips. The tails were then immediately
submerged into 14 ml conical tubes filled with saline at 370C. Blood from the tail was
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collected 10 minutes. Weights of the tubes at time 0 and 10 minutes were measured and
the difference used to quantify blood lost. Mice were euthanized after the procedure.

Results
Identification and expansion of transgenic lineages
The aim of this study was to characterize the properties of single chain rFVIII
made in the milk of the highest expressing lineages prior to trialing in transgenic pigs. In
particular, we have assessed the secretion limitations, biological activity and stability of
226/N6 in milk. We focused our lineage expansion on a single trigenic and two bigenic
lineages which expressed 226/N6-tg at 100-fold higher levels than other lineages: bigenic
for 226/N6 and AAT (875 and 406) and trigenic for 226/N6, AAT and vWF (415).
Transgenic mouse lineages were detected by Southern analysis after screening DNA
isolated from tail biopsy using PCR. Figure 7.1A shows the schematics for the three
constructs used: WAP7FVIII-226/N6, WAP6vWF, and BLG-AAT. The PCR 5’ and 3’
oligonucleotide primer sites and restriction endonuclease cleavage sites used for Southern
analysis are indicated. Most mono-, bi- and trigenic lineages contained multiple copies
of the FVIII, and/or VWF, and/or AAT transgenes, respectively.

A typical Southern

Blot used to simultaneously detect and ascertain the copy number of the WAP7FVIII226/N6 and WAPvWF transgenes is shown in Figure 7.1B. The probe DNA was derived
from the mouse WAP promoter and was designed to detect not only the FVIII and vWF
transgenes but also the endogenous WAP gene as an internal standard present at two
copies per mouse genome. For example, band sizes were present in the DNA of trigenic
415 mice (Lane 3) corresponding to 10 copies of the 2.4 kbp WAP72FVIII-226/N6, and 3
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copies of the 4.5 kbp WAP6vWF relative to the 7.2 kbp endogenous WAP gene. The
presence of the BLG-AAT transgene was confirmed by the use of the BLG-AAT cross
junction probe (separate Southern analysis, data not shown).

All lineages studied

contained greater than one copy of BLG-AAT transgene per genome. The estimated copy
numbers for the highest 226/N6-tg expressers of bigenic mouse lineages were: 2 and 4
copies of WAP7FVIII-226/N6 for Line 406 (Lane 1) and Line 875 (Lane 3), respectively
and >1 copy for BLG-AAT. In each lineage, the BLG-AAT transgene was likely cointegrated into the same chromosomal loci along with WAP7FVIII-226/N6 as evidenced
by the Mendelian co-transmission of both transgenes through F1 and F2 generations that
were made by out breeding with wild-type mice (data not shown).
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Figure 7.1. Transgene construction schematics and Southern analysis for 226/N6, vWF, and AAT.
(A) Schematics for transgenic constructs WAP7FVIII-226/N6, WAP6vWF and BLG-AAT are presented.
Restriction sites (vertical arrows) used for Southern analysis and oligomeric DNA primer binding
hybridization sites (horizontal lines and arrows) used for PCR detection of the transgenes are shown. (B)
Isolated genomic mouse DNA from three highest 226/N6 expressing lineages was digested with
EcoRI/Hind III and probed with a WAP promoter probe. Expected fragments sizes are: WAP7FVIII226/N6: 2.4 kbp; WAP6vWF: 4.5 kbp; and endogenous mouse WAP gene: 7.2 kbp. Sample loading is as
follows: M = molecular weight marker, lane 1-4, 406 mouse (bigenic for 226/N6 and AAT), 415 mouse
(trigenic for 226/N6, vWF and AAT), 875 mouse (bigenic for 226/N6 and AAT) and non-transgenic
control. Reference DNAs: column V = 50 copies/genome WAP6vWF, column F = 50 copies of
WAP7FVIII 226/N6 and column A = 50 copies of BLG-AAT. Molecular weight markers are listed on the
left and restriction digest product band designation is on the right: band eWAP = endogenous mouse WAP
gene; vWF = WAP6vWF; FVIII = WAP7FVIII-226/N6.
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Coexpression of 226/N6-tg, vWF-tg and AAT-tg in trigenic mouse milk
We used comparative Western blot analysis of SDS-PAGE under non- and
reducing conditions to determine the extent of complexation and underlying proteolysis,
respectively. Reducing conditions disrupt both FVIII-vWF complexes and the disulfide
bridges linking vWF subunits. Reduced Western blots probed with anti-human FVIII
polyclonal antibody are shown in Figure 7.2A. Commercial rFVIII (Recombinate, Baxter,
Deerfield, IL) (Lane 2) shows typical heterogeneity due to proteolytic fragmentation of
the B domain resulting in variably sized heavy chains of M r 120 to 180 kDa. In contrast,
plasma-derived FVIII-vWF complex (CSL Behring, King of Prussia, PA) (Lane 3) shows
less FVIII proteolysis and has a predominant species of Mr 280 kDa. A sample pool from
milks collected on different days from the highest expressing trigenic mouse lineage
(415; Lane 4) shows a predominant species at Mr 190 kDa and lesser species at about Mr
140 kDa. The theoretical molecular weight of 226/N6 is about 190 kDa. Samples from
the highest expressing bigenic 226/N6-tg:AAT-tg mice showed a similar profile to Lane
4 (data not shown). The non-transgenic mouse milk pool (Lane 5) shows no signal.
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Figure 7.2. 226/N6-tg is complexed with vWF-tg in transgenic mouse milk. Assessment of vWF
binding by analyzing (A) reduced anti-FVIII, (B) reduced anti-vWF, (C) non-reduced anti-FVIII,
and (D) non-reduced anti-vWF Western Blots. All blots contain a molecular weight marker (lane 1),
Commercial rFVIII (lane 2), commercial pd-FVIII:vWF concentrate (lane 3), 226/N6-tg mouse milk (lane
4), non-transgenic mouse milk (lane 5). A non-reduced anti-FVIII Western Blot was performed to analyze
nonspecific binding of mouse milk proteins to 226/N6-tg and immunopurified 226/N6-CHO (E): molecular
weight marker (lane 1), 226/N6-CHO (lane 2), non-transgenic mouse milk (lane 3), 226/N6-CHO added to
non-transgenic mouse milk (lane 4), and 226/N6-tg:vWF-tg trigenic mouse milk (lane 5).
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Anti-vWF

Western

analysis

under

reducing

conditions

is

shown

in

Figure 7.2B. No vWF signal is observed in the rFVIII and non-transgenic mouse milk
pool (Lanes 2 and 5, respectively). The reference plasma-derived FVIII-vWF concentrate
shows a sharp, single band signal at about Mr 270 kDa (Lane 3) consistent with all VWF
species existing as monomeric units that are disassociated from FVIII under reducing
conditions. The trigenic milk pool sample shows a similarly strong band at about Mr 270
kDa (Lane 4). The approximate stoichiometric ratio of 226/N6-tg to vWF-tg subunits in
the milk of trigenic lineage 415, as evidenced by Western blot, was estimated to be about
1:1. This in turn was further corroborated by FVIII (Table 7.2) and vWF ELISA (data not
shown) quantitation.

Table 7.2. ELISA, 2-stage activity assay, and specific activity data on mono-, bi- and trigenic mice.
226/N6
Activity
Specific
226/N6 Source
Mouse ID
Concentration
Level
Activity
(μg/ml)
(IU/ml)
(IU/mg)
Monogenic mice: 226/N6
1960-1702
0.144
0.621
4,313
1926-1742
0.093
0.121
1,301
46-1247
0.066
0.392
5,939
Bigenic mice: 226/N6-AAT
875-234
34
25
735
875-233
6.2
44
7,097
516-45
7.3
13
1,781
406-128-10
83
122
1,470
Trigenic mice: 226/N6-vWF-AAT
415-101-2
183
678
3,705
415-101-1-2
14.5
555
4,549

Presence of FVIII-vWF complexes in trigenic mouse milk.
This is the first report of vWF being co-expressed with FVIII in milk and also the
first study of vWF complexation with 226/N6. Based upon the stability introduced to
rFVIII by rvWF in cell culture,29 we sought a similar effect on FVIII in milk. We found
that native, plasma-derived FVIII:VWF complexes exist within monomeric and higher
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molecular weight vWF species under non-reducing, SDS-treatment conditions. Similar
to plasma-derived vWF, vWF-tg is expressed in milk as monomers and also higher
molecular weight species that likely represent multimers consisting of monomers linked
by disulfide bridges. For example, Western analysis for FVIII-VWF concentrate shows
FVIII and vWF band signals within a similar Mr range that are both >420 kDa (Figure
7.2, lanes 3 of Panels C and D, respectively) due to co-migration caused by the
complexes. Conversely, the reference commercial rFVIII that is devoid of vWF has a
similarly broad pattern as occurs under reducing conditions with an upper Mr limit less
than 280 kDa (Figure 7.2, Panel C, Lane 2). Congruently, rFVIII shows no signal for
vWF (Figure 7.2, Panel D, Lane 2). The trigenic mouse milk pool shows a predominant
band near Mr 420 kDa and another minor band at a much higher Mr (Figure 7.2, Panel
D, Lane 4) that is similar to the reference plasma-derived FVIII-vWF concentrate (Figure
7.2, Panel D, Lane 3).

This is consistent with a major population of 226/N6-tg

complexed with monomeric vWF-tg at Mr 450 kDa and a higher band due to complexing
with multimeric vWF-tg species. The high avidity of this complex is underscored by the
apparent absence of free 226/N6-tg under these conditions.
We did not observe nonspecific binding of milk proteins with 226/N6-tg in
transgenic milk or with 226/N6-CHO added to control mouse milk by using non-reduced
Western analysis (Figure 7.2, Panel E). Immunopurified 226/N6-CHO was made in CHO
cells without co-expression of vWF and it migrates as a single band at Mr 190 kDa (Lane
2). When incubated with non-transgenic mouse milk, 226/N6-CHO still consisted of a
single band at 190 kDa (Lane 4). This suggests that it does not form strong complexes
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with endogenous mouse milk proteins as does 226/N6-tg with coexpressed vWF (Lane
5).
Coexpression of AAT
The presence of serine proteases in milk such as plasmin and trypsin has been
well documented

39,40

. This BLG-AAT transgene was chosen because biologically active

rAAT has been previously and consistently produced at greater than 1000 μg/ml in the
milk of transgenic mice and sheep. Figure 7.3 shows the nonreduced, Western Blot
analysis of SDS-PAGE using detection by a polyclonal anti-AAT antibody. The AAT-tg
was expressed at much higher levels than either 226/N6-tg or vWF-tg and estimated to be
>1000 μg/ml.
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Figure 7.3. AAT is coexpressed in transgenic mouse milk. The non-reduced anti-AAT Western blot
contains a molecular weight marker (lane 1), 2 μg (lane 2) and 5 μg (lane 3) recombinant AAT, plasmaderived AAT (lane 4), transgenic mouse milk (lane 5), and non-transgenic mouse milk (lane 6). * - denotes
putative AAT-serine protease inhibitor covalent complex (SERPIN). The recombinant AAT (lanes 2 and 3)
and plasma-derived AAT references (Lane 4) as well as transgenic milk samples (Lane 5) have bands
present at about 54 kDa and >100 kDa. The putative AAT- SERPIN complexes indicate that the AAT was
biologically active.
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Quantitative analysis of rFVIII biological activity
Biochemical analysis of FVIII within the milk of mono-, bi- and trigenic mice is
presented in Table 7.2. Chromogenic FVIII activity and antigen as determined by a
FVIII-specific ELISA are shown. Milk was collected from F1 and F2 lineages during
three different days over a 17 day lactation. Three different F0 bigenic 226/N6-tg/vWF-tg
founders all expressed less than 0.02 μg/ml of FVIII by ELISA and so were not chosen
for expansion (data not shown).
One stage FVIII (aPTT) and two stage chromogenic activities were measured in
each of the expanded lineage specific milk pools. For aPTT coagulation measurements,
dilutions of milk of >1:200 were required to minimize nonlinear effects caused by milk
calcium and lipid. For those milks having greater than about 1 IU/ml, the aPTT and
chromogenic activities were comparable. Table 7.2 shows the highest chromogenic
activity and ELISA antigen values over the course of lactation within these milk samples
and their respective specific activities. The specific activities of commercial rFVIII
ranged from 1100 to 5000 IU/mg. The highest FVIII antigen and FVIII activity levels
occurred in the milk of one trigenic lineage (415), at 183 μg/ml and 678 IU/ml
respectively, yielding a specific activity of 3,705 IU/mg. In addition, high concentration
levels of 226/N6-tg activity and antigen were also measured in three of four 226/N6tg:AAT-tg bigenic lineages.
Notably, the range of 226/N6-tg specific activities was similar for all mouse milks
and expression levels. However, the lowest detectable levels of antigen and activities
occurred within monogenic 226/N6-tg mice: <0.15 μg/ml rFVIII antigen and <0.62
IU/ml activity. The maximum and mean specific activity levels present in milk were
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between 1,000 and 6,000 IU/mg for 226/N6-tg monogenic, 1,000 and 7,000 IU/mg for
bigenic 226/N6-tg:AAT-tg,

3700 and 4500 IU/mg in the trigenic 226/N6-tg:AAT-

tg:vWF-tg milks. Thus, the biochemical quality of 226/N6-tg was consistent in the milk
over a wide range of throughput by the mammary epithelia.
Immunopurification of rFVIII from trigenic mouse milk pools using an anti-A2
monoclonal immunosorbent (R8B12)30 resulted in a vWF-tg free product (data not
shown). The specific activity was 2838 IU/mg which compared favorably to 226/N6 that
was immunopurifed from CHO cells at 2892 IU/mg. Importantly, the specific activity of
226/N6-tg immunopurified from milk was consistent with that measured directly in the
trigenic mouse milk. ELISA detection of the binding of this vWF-free 226/N6-tg to
plasma-derived vWF (Figure 7.4) indicates that 226/N6-CHO, commercial rFVIII and
226/N6-tg have similar affinity to vWF.
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Figure 7.4. 226/N6-tg binds pd-vWF similarly to rFVIII. The relative affinity of plasma-derived vWF
for 226/N6-tg immunopurified from milk pools made from highest expressing trigenic mice (415),
commercial rFVIII, and 226/N6-CHO immunoaffinity purified protein were compared. Assessment of vWF
binding to various FVIII molecules by ELISA: commercial rFVIII (●), 226/N6-tg (■), 226/N6-CHO (▲).
Polynomial trend lines are shown for the reference rFVIII (solid line), 226/N6-tg (dashed line), 226/N6CHO (dotted line) with R2 values of 0.85, 0.89 and 0.97, respectively. The plasma-derived vWF was found
to similarly bind each of the FVIII species over a concentration range that approximates the linear FVIIIvWF binding curve.

In vivo tail clip assay in the hemophilia A mouse
Total blood loss in mg was observed for normal C57/BL mice and FVIII
knockout hemophilia A (HA) mice resulting from a terminal tail transection (Figure 7.5).
The HA mice were infused with either lactated Ringer’s, immunopurified 226/N6-CHO
or immunopurified 226/N6-tg. The 226/N6-CHO and 226/N6-tg proteins were each
infused at 80 IU/kg body weight. The normal C57/BL mice typically showed a cessation
of bleeding (4 of 4) at about 2 to 5 minutes (data not shown) with a total weight of blood
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loss over 10 minutes ranging from 80 to 175 mg. The HA mice infused with lactated
Ringer’s typically did not show a cessation of bleeding (10 of 12) with a total weight of
blood loss that ranged from 110 to 700 mg. The HA mice infused with 226/N6-CHO
showed a cessation of bleeding (5 of 5) typically at about 2 to 5 minutes with a total
weight of blood loss ranging from 50 to 225 mg. The HA mice infused with 226/N6-tg
showed a cessation of bleeding (5 of 6) typically at about 2 to 5 minutes with most mice
having a total weight of blood loss ranging from 50 to 225 mg. One HA mouse infused
with 226/N6-tg showed a total blood loss weight of 500 mg. An analysis of variance
indicated that the effect of treatment was significant (p < 0.001). Post hoc analysis
determined that only saline treated hemophilic A mice were significantly different from
control mice treated with saline (p = 0.002). An α of 0.05 was used as a significance
criterion for all statistics.
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Figure 7.5. Hemostatic efficacy in vivo of 226/N6-tg and 226/N6–CHO within the hemophilia A
mouse model. Total blood loss in mg was observed for normal C57/BL mice and FVIII knockout
hemophilia A (HA) mice resulting from a terminal tail transection. The HA mice were infused with either
lactated Ringer’s, immunopurified 226/N6-CHO or immunopurified 226/N6-tg. Bars represent the mean (n
≥ 4) and the error bars the standard deviation.

Discussion
By expressing rFVIII variant with high secretion efficiency in the milk of
transgenic mice, we have generated >450-fold higher levels of FVIII activity over that
reported for the animal cell culture expression of WT-FVIII. The highest reported levels
of FVIII made in animal cell culture have been those using co-expression of vWF to
stabilize the secreted FVIII (Table 7.1). To overcome the previously low expression of
FVIII activity in milk, our bioengineering strategy combined the advantages of the high
cell density of the mammary gland with high secretory efficiency, single chain stability of
226/N6, the stabilizing complexation of co-expressed vWF, and decreased milk-borne
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proteolysis through co-expression of AAT. In addition, the gene design of 226/N6 not
only imparted increased transcriptional efficiency but also benefited from decreased
transcriptional silencing provided by the co-integration of the highly active BLG-AAT
transgene. This is the first proof of principle that biologically active FVIII can be made
in milk at similarly high levels to that already demonstrated for other complex
coagulation proteins. While this study used mice, where typically only a few milk
samples spanning a 17 day lactation can be collected, it was a necessary step used to
assess the gross expression levels and general biochemical characteristics of the
recombinant protein before attempting to translate these concepts to livestock. Further
optimization of mammary expression of 226/N6 such as screening for lineages having
still higher expression levels due to more transcriptionally active chromosomal
integration sites is best done in a livestock species that is a candidate for commercial
production. Thus, the full delineation of our bioengineering effort to stabilize FVIII
activity by co-expression of VWF and AAT will be best assessed and realized in the
>100 liter per year lactations produced in animals such as pigs.
Our studies show that the single chain structure of 226/N6-tg retains its
procoagulant activity in milk where its specific activity is similar to commercial grade,
plasma-derived and recombinant FVIII (Table 7.2) in contrast to the proteolytically
fragmented, low activity WT-FVIII previously observed in the milk of mice,16 rabbits,17,
18

sheep19 and pigs20 (Table 7.1). The robustness of 226/N6-tg activity was reflected by

the similar specific activities of immunopurified and milk-borne 226/N6-tg as measured
by both one and two stage clotting assays. Importantly, the immunopurified 226/N6-tg
rendered normal hemostasis to FVIII knockout mice in response to a post-infusion, tail
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transection trauma challenge. In contrast to 226/N6, heterodimeric WT-FVIII has proven
to be unstable and therefore not suitable for production in milk. Importantly, our work
suggests that other FVIII variants that use covalent structure similar to 226/N6 which
stabilize the association of heavy and light chains15, 31, 32 may be appropriate candidates
for abundant production in the milk of transgenic livestock.
The co-expression of vWF in cell culture33 has been shown to stabilize the heavy
and light chains of WT-FVIII. Ours is the first report of FVIII co-expressed in milk along
with vWF. We have shown that essentially all of 226/N6-tg was strongly associated with
vWF-tg. The functionality of these complexes was reflected by the similarly high specific
coagulation activity measured by one and two stage assays. This activity indicates that
the vWF-tg is released upon thrombin cleavage of 226/N6 to form FVIIIa as occurs in
plasma-derived FVIII that is complexed by vWF.34, 35 In addition, 226/N6-tg was greater
than 90% separated from vWF-tg by immunopurification in a similar manner used to
purify plasma-derived FVIII from vWF (data not shown). The immunopurified 226/N6-tg
was subsequently shown to recombine in vitro with plasma-derived vWF in a similar way
as WT-FVIII. Importantly, complexation of FVIII with vWF is a prerequisite for stability
in circulation after infusion,9,

29, 36

The highest concentration of 226/N6-tg in milk

occurred with the presence of vWF-tg at an estimated 1:1 ratio of 226/N6-tg to vWF-tg
subunits. The native binding behavior of the 226/N6-tg with either vWF-tg or vWF
indirectly shows that the proper post-translational sulfation of tyrosine 1680 in the A3
domain of 226/N6 likely occurred, as it is required for complexation.37 The detailed
characterization of the post-translational modification of 226/N6-tg such as detection of
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sulfation and also its multiple sites of glycosylation will be done on material produced
from the milk of transgenic pigs.
While the FVIII activity levels reported here were very high, we believe that still
higher levels are possible in livestock. Mammary specific expression in transgenic mice
is typically more subject to transcriptional silencing than has been observed in transgenic
pigs. Transgene silencing and attenuation of mammary specific expression occurs in
>60% of mouse lineages38 and is thought to be primarily due to random transgene
insertion into transcriptionally dormant chromosomal locations.38 Using the same WAP
regulatory elements employed here for 226/N6-tg in mice, our past experiences with the
expression of other complex coagulation proteins such as human protein C typically
obtained levels of 500 to 1000 μg/ml in mice but 1000 to 5000 μg/ml in pigs. It is
noteworthy that the inclusion of the A1-A2 domain needed for FVIII functionality means
that some transcriptional limitations will be also inherent as is still present in the
bioengineered 226/N6 gene and not associated with the B domain.12-14 The consistently
very low rFVIII levels in monogenic 226/N6 or bigenic vWF:226/N6 mice were likely
due to the combination of FVIII transcriptional and chromosomal insertion transgene
silencing. It is also noted that co-expression of vWF and WT-FVIII in CHO cells does
not result in higher transcriptional efficiency for either protein. In contrast, we believe
that the high levels of FVIII and vWF expressed in bigenic 226/N6-AAT and trigenic
226/N6-vWF-AAT mice (Table 7.2) benefited from transcriptional rescue by cointegration of the BLG-AAT minigene. In a prior study, co-integration into the same
chromosomal site of the BLG-AAT with a BLG-human Factor IX transgene resulted in
increased expression in mouse milk.39, 40
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The AAT-tg was efficiently made at >1 g/l in the majority of the mouse milks
studied here.

This is consistent with its previously reported mammary specific

expression behavior in mice16 and sheep.41,

42

The presence of AAT antigen reactive

bands at about 90 to 100 kDa Mr is consistent with the formation of stable, AAT-serine
protease complexes reflecting the presence of serine proteases such as plasmin in milk
and the SERPIN-biological activity of the milk borne AAT. While it is not known exactly
how much protection from proteolysis36 and or metal chelation43 was provided to
226/N6-tg, the highest concentration of biological activity occurred in mice having both
by AAT-tg and/or vWF-tg. While we used co-microinjection of the three transgenes to
make trigenic mice, we will use somatic cell cloning to make trigenic pigs with special
attention to the preselection of cell lines having both equal stoichiometric and same site
co-integration and therefore more predictable expression efficiency for each of the
transgenes. The co-expression of other protease inhibitors more specific to plasmin such
as alpha-2 plasmin inhibitor is also another potential extension of this work.
Pigs are the most likely choice of transgenic livestock for future production of
FVIII because they combine the advantages of milk volume and hepatocyte-like posttranslational biochemistry such as glycosylation 67. While ruminants also provide ample
milk volume, their mammary biochemistry produces higher mannose, low sialic acid
glycoforms which may affect circulation residence times due to interactions with asialyo
receptors found in the human liver.67 Pigs have 100 days of lactation and produce 100 to
200 liters of milk per year.16,17,68 Hence, the number of pigs needed to meet the current
global FVIII demand is only about 400 if 226/N6 expression reported here in mice is
translated into the milk of sows (Table 7.3).The advantage of pig milk over other FVIII
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sources such as cell culture bioreactors and human plasma is evident in the greater than
two orders of magnitude reduction in source volume estimated to meet global FVIII
demand.16 In the case when infrastructure must be expanded to increase capacity, the
capital investment costs for classical cell culture become significant.

In contrast,

transgenic production yields high concentration of biopharmaceutical in milk which
reduces capital investment because adding additional pigs does not require significant
changes in expanding infrastructure.44 This will become important when developing
countries begin routine access to FVIII therapy including that needed for inhibitor
patients to facilitate immune tolerance strategies. It is noted that perhaps 25% or more of
FVIII used in most developed countries is consumed by inhibitor patients.45-47

Table 7.3. Potential volumes of source materials needed for current global
FVIII consumption.
Volume of Source Material
Source
(liters/year)
Plasma
27,400,000
Production Bioreactor Supernatant
13,700,000
Milk of Transgenic Pig
40,000
Potential volumes of source materials for Factor VIII required to meet the needs
for current global consumption.48 The estimated amount of FVIII in each source:
plasma (1 IU/ml); CHO cell bioreactor (2 IU/ml), and transgenic pig milk (678
IU/ml). A 20% purification yield for each source is assumed. The milk of 400
pigs (100 liters/year/pig) could supply the entire amount of FVIII currently needed
for global consumption.48

The safety and efficacy of transgenic milk derived products has crossed an
important threshold as the US FDA and EMEA has approved recombinant anti-thrombin
III made in goat milk (ATRYNR). The large scale processing renders the anti-thrombin
product to 99.99% purity. The high levels of FVIII biological activity reported here in
mouse milk bodes well for the development of transgenic livestock and an accompanying
purification process that will provide an abundant, cost effective source of FVIII. This
source would help to enable prophylactic intravenous therapy and also the development
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of alternative routes of administration including its use in longer lasting replacement
product designs. For example, using PEGylation5 to make longer lasting 226/N6-tg as
well as application to non-intravenous methods of delivery by intratracheal10 or oral5,11,12
administration will be facilitated by the abundance of FVIII provided by transgenic milk.
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Citrate activation of prothrombin
Chapter 2 was the first detailed analysis of the sequence of activation of
prothrombin by sodium citrate. Activation fragments were identified by N-terminal
sequencing. Unfortunately, this research was unable to answer several questions which
could be elucidated by the following:
1. FII activation in the absence of citrate: autocatalytic or reciprocal proenzyme
activation: Long-term incubation of FII results in activation despite inhibition of
FXa and FIIa. This proteolysis could be due to either autocatalytic activation,
reciprocal proenzyme activation (activation by FX) or by FXa which is
autoactivated. Purified plasma-derived material contains trace amounts of other
proteins; therefore, it is difficult to completely isolate individual proteins to
identify their roles in activation.1

Consequently, recombinant prothrombin

preparations are needed that do not have trace amounts of plasma proteins to test
certain hypotheses. Once purified, recombinant FII will be incubated alone and
with purified FX to test Teng and Seegers’2 theory that they coactivate.
2. Separate bands from citrate activation and analyze more thoroughly:

The

primary bands formed after citrate activation appear to be composed of thrombin,
α-thrombin and β-thrombin. These bands could be separated by size exclusion
chromatography and analyzed to ensure their identities and to determine more
accurate activity levels for each thrombin species.
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Recombinant factor XIIIa
Chapter 3 characterized rFXIIIa expressed in Pichia pastoris.

These results

indicate that rFXIIIa expressed in yeast closely mimic plasma-derived FXIII and may be
a good alternative for therapeutic uses; however, further research will further elucidate
the efficacy of rFXIIIa as a therapeutic:
1. Further evaluation of FXIIIa molecule: In this chapter, I propose that the rFXIIIa
molecule has an equivalent molecular weight as FXIII because of the addition of
the His-tag and myc epitope which is removed by incubation with thrombin.
These hypotheses could be confirmed by anti-His and/or anti-c-myc epitope
immunoblot analysis.
2. rFXIIIa as an infusion therapy: pdFXIII is used as an infusion therapy to treat
into individuals with FXIII deficiency.3 Yeast can produce ample amounts of
rFXIIIa for use in infusion therapies; however, the feasibility, efficacy, safety and
tolerability of rFXIIIa as an infusion therapy must be tested. FXIII can crosslink
substrates; however, FXIIIa crosslinks at a faster rate.4 Infusing the active form
may be detrimental and therefore needs to be evaluated.
a. rFXIIIa interaction with plasma proteins: If used as an infusion therapy,
rFXIIIa will need to be evaluated with regard to its interactions with the
plasma proteins. Deleterious effects with regard to being FXIIIa rather
than FXIII will need to be evaluated.
b. rFXIIIa ability to bind to fibrin’s αC-domain: Once activated, FXIIIa
binds to residues 241 to 476 in the αC-domain of fibrin5 which brings
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fibrin protofibrils into close proximity. This interaction is important for
rapid crosslinking thereby creating a strong clot resistant to lysis.
c. Pharmacokinetics: The time rFXIIIa lasts in circulation and the rate at
which it is utilized, metabolized, and removed needs to be evaluated.
Methods used to evaluate the rFXIII expressed in Saccharomyces
cerevisiae could be mimicked.6
d. Immune response: This yeast produced protein will need to be evaluated
for its immunogenicity. This will need to be tested in vivo.

Optimization of a liquid fibrin sealant
Chapter 4 identified the optimal ratio of components for a rLFS and identified
FXIIIa as an important factor in clot strength. The clotting kinetics and viscoelastic
strength of our optimized LFS was equivalent to those of a commercially available LFS;
however, it uses approximately 75% less fibrinogen and thrombin. While these results
are promising, more research needs to be performed to better characterize the clot that is
formed:
1. Examine clot structure created by optimal rLFS: The structure of the matrix
produced by a FS is altered by altering concentrations of any of the components
or the pH or temperature. Such changes can alter the function and adhesive
nature of the FS.7

In addition, the fiber diameter, porosity, branching and

permeability of a clot and fibrin(ogen)’s ability to bind platelets, endothelial cells,
smooth muscle cells and other cells play an important role in wound healing.8 For
example, high FIIa concentrations reduce “gelation time” which results in the
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production of small fiber diameters and pores.7 Research also indicates that the
rate of clot lysis is related to fiber diameter: thinner fibers lyse at a slower rate
than thicker fibers.9 Fiber diameter of clots created by rFI-based LFS should be
compared to those produced by pdFI-based LFS in vitro. Mullin et al. incubated
FI with FIIa, monitored protofibril formation and fibrinolysis by turbidity, and
evaluated fiber size by scanning electron microscopy (SEM).9 This research
optimized the speed and strength of the clot formed by our rLFS; however, we
have not yet analyzed the structure of the clot. Microscopy and other techniques
can be utilized to determine fibrin fiber thickness.10
2. Identify rheological properties: The rheological properties of clots created by our
rLFS should be evaluated with and without FXIII and compared to other
commercial FS as described previously.11
3. Model diffusion effects due to increases in thrombin: Increasing thrombin can
result in reductions in clot strength. This is probably due to an increase in
viscosity created by aggregation of fibrin which minimizes the diffusion of FXIII
need for crosslinking and creating a strong clot. This effect should be modeled.
4. Evaluate importance of extra FXIII activity in tissue adhesion: Marx and Mou12
found that the native transglutaminase activity in tissue (rat skin) is enough to
crosslink fibrin clots created by FS. The same methods described in this study
can be used to determine if the significantly greater FXIII activity
(approximately 36-fold higher) assists in adhesion to multiple tissues (not just
rat skin).
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5. rLFS affects on cell migration and proliferation and wound healing: In addition
to cessation of bleeding, the fibrin clot plays a key role in wound healing by
serving as a scaffold for and trapping growth factors and other ingredients
necessary for tissue regeneration.13, 14 The clot binds proteins and extracellular
matrix which directly contributes to wound healing15 and binds fibronectin
creating cellular adhesion.16-18

The fiber diameter, porosity, branching and

permeability of a fibrin clot is important for these functions.8 Fibrinolysis is also
controlled by fiber size and by binding plasminogen,19,
activator (tPA)19,

20

and α2-antiplasmin (A2AP).19,

21

20

tissue plasminogen

Interactions with these

molecules promote cell migration and encourage tissue regeneration.13

Several

studies can be performed to predict rLFS’ effect on wound healing:
a. Detailed analysis of clot porosity, fiber branching and permeability of
clot: Compare the porosity, branching and permeability of clots generated
by rFI to those created by pdFI so the effect on wound healing can be
predicted.
b. rFI-based clot retraction: Test the ability of a rFI-based clot to undergo
clot retraction which is necessary for wound healing.22
c. rLFS interaction with endothelial cells: Evaluate the ability of endothelial
cells to bind to and proliferate and migrate on rFI-based clots. Endothelial
cells infiltrate the clot and regenerate vascular tissue;8 therefore, the ability
of these cells to thrive on the recombinant fibrin clot is critical.
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In vivo testing of rLFS
Chapter 6 details the efficacy of our rLFS in initial in vivo models. Research on
specific uses and long-term use must be completed.
1. Long-term hemostasis, wound healing and LFS degradation: All of our in vivo
experiments have been nonsurvival; therefore, the ability of the rLFS with or
without the bandage to maintain hemostasis and allow functional tissue
regeneration without serious complications is unknown.

Kroez, Lang and

Dickneite23 evaluated immune response, wound healing and degradation kinetics
of a commercially available FS in a partial liver resection rabbit model. These
same methods could be used in our model. The thickness of the FS and tissue
regeneration is evaluated by histology. Antibody development to human proteins
were measured by ELISA.23 Survival studies on Grade V liver injuries could be
modeled after Holcomb et al.’s methods.24, 25
2. rLFS feasibility, tolerability, efficacy and safety for specific uses: Commercial
LFS’ are used in a variety of surgeries including cardiovascular,7,

26

vascular,27

thoracic,28, 29 plastic,7, 30 reconstructive,31 oncologic,32 ophthalmologic,32 dental,32
orthopedic,7,

32

hepatic33 and urologic surgeries,34,

and neurosurgery.7,

36, 37

35

microsurgical procedures7

We need to determine whether our rLFS can be used

successfully under the same circumstances in the pig model.
3. rLFS as a capable delivery vehicle: Previous research indicates that LFS’ can be
used as a delivery vehicle for fibroblasts;38 however, not all sealants can be
utilized in this manner.39

Determine whether our rLFS can be reliably and
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successfully used as a delivery vehicle for fibroblasts and other possible
drugs/factors.
4. Perfect spray delivery device: It is critical to develop a delivery device that is
convenient and easy to use for medical care personnel7 while applying the optimal
amount of each of the FS components. We have had difficulties in fitting off-theshelf spray devices to our needs. Our primary issue is finding a device that has
fine control over flow rates while aerosolizing the solutions. A device needs to be
designed that meets all of our needs.
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